Book

FINAL PROGRAM
FINAL PROGRAM
TABLE OF CONTENTS
CONFERENCE INFORMATION
Welcome Letter ...........................................................................................................................................................
Committees ....................................................................................................................................................................
About ISBD ......................................................................................................................................................................
General Information .................................................................................................................................................
Program at a Glance ................................................................................................................................................
Keynote Speakers ......................................................................................................................................................
Samuel Gershon Junior Investigator Award .........................................................................................
CME/CPD Accreditation ........................................................................................................................................
Interactive Application ...........................................................................................................................................
Information for Presenters ................................................................................................................................
Poster Overview ..........................................................................................................................................................
Venue Floor Plans .....................................................................................................................................................
04
06
08
09
12
20
21
22
25
27
30
31
SCIENTIFIC PROGRAM
Tuesday March 18, 2014 ........................................................................................................................................ 33
Wednesday March 19, 2014 ................................................................................................................................ 45
Thursday March 20, 2014 ..................................................................................................................................... 65
Friday March 21, 2014 ............................................................................................................................................ 87
Posters ............................................................................................................................................................................... 99
Index of Authors ....................................................................................................................................................... 131
RECOGNITION, ACKNOWLEDGEMENTS
AND INDUSTRY SUPPORT
Acknowledgements ...............................................................................................................................................
Industry Symposia Program ...........................................................................................................................
List of Exhibitors ......................................................................................................................................................
Exhibition Map ...........................................................................................................................................................
Exhibitor and Sponsor Profiles .....................................................................................................................
141
143
147
147
148
04
WELCOME LETTER
On behalf of the Scientific Program, Steering and Local Organizing Committees of
the 16th Annual Conference of the International Society for Bipolar Disorders (ISBD),
we would like to welcome you to Seoul for what has over the past 20 years become
the premier international conference on bipolar disorders.
The origin of the conference began in 1994 when Dr David Kupfer and Dr Ellen
Frank from the University of Pittsburgh organized the International Conference on
Bipolar Disorder (ICBD), the first international meeting entirely focused on bipolar
disorder. Since then, the ICBD had built its reputation as an excellent conference
for clinicians, researchers, patients and family members through its 9 biennual
conferences in Pittsburgh and the last one in Miami in 2013.
In 1999, together with Dr Samuel Gershon, also from Pittsburgh, Dr Kupfer
and Frank also founded the International Society for Bipolar Disorders (ISBD),
which since then organized 5 biennial meetings across the world, from Sydney
toEdinburgh, Delhi, Sao Paulo and Istanbul, which have gained recognition as the
representative international conference on bipolar disorders.
In 2013, the biennial ICBD and the biennial conference of the ISBD have merged
into the Annual Conference of the International Society for Bipolar Disorders, and
collectively we have now the 16th Annual Conference on Bipolar Disorders.
The Scientific Program Committee kept the traditions from both conferences,
which include Keynote Lectures, Concurrent Parallel Symposia, Rapid Oral
Communications, Poster sessions and Industry Sponsored Satellite Symposia.
In addition, we have continued the relatively new format of the last two meetings
(Istanbul and Miami) with Early Morning Brainstorming Sessions and PreConference Courses.
The programs include all aspects of clinical and research activities on bipolar
disorders, from diagnosis to treatment, from basic research to psychosocial
rehabilitation, from children to late life, to meet interests of all participants and to
enhance discussion. The core of the program, the concurrent parallel symposia, is
divided and designated into tracks (clinical manifestation, treatment, neurobiology,
imaging, cultural, and advocacy) to allow participants to follow all symposia
meeting their specific different interests.
05
ISBD has a tradition to work with patients and their families to overcome the burden
of bipolar disorder. This will be highlighted in the program on the last day, when
advocacy sessions and lessons from the West will enhance supportive activities in
the Asian regions which still suffer from strong stigma against bipolar disorder.
The meeting in Seoul was planned to promote bipolar disorders in Asia, and to
facilitate mutual understanding of the psychosocial environment surrounding
bipolar disorders between the East and the West. The Scientific Program
Committee worked with the Regional Organizing Committee to develop a Regional
Satellite Symposium and a Regional Poster Session to promote bipolar disorder
among Asian clinicians and researchers.
We hope all of you enjoy the diversity and inspiration of the program. Also, we
recommend that you explore the dynamic cultural diversities of Seoul and Korea
beyond Seoul, including sites that offer opportunities for breathtaking scenery as
well as quiet contemplation, that will extend your understanding of yin and yang,
harmony and balance, which is also essential for understanding of bipolar disorder.
Kyooseob Ha, MD, PhD
Willem Nolen, MD, PhD
VP for Education, ISBD

Chair, Scientific Program Committee
President, ISBD
Co-chair, Scientific Program Committee
06
COMMITTEES
CONFERENCE CHAIRS
Willem Nolen, MD, PhD
Chair, Steering Committee
Co-Chair, Scientific Program Committee
Kyooseob Ha, MD, PhD
Chair, Scientific Program Committee
Co-Chair, Steering Committee
Yeon Ho Joo, MD, PhD
Chair, Regional Organizing Committee
STEERING COMMITTEE
Willem Nolen, Chair, MD, PhD - The Netherlands
Kyooseob Ha, Co-Chair, MD, PhD - Korea
Michael Berk, MD - Australia
Yeon Ho Joo, MD, PhD - Korea
Manuel Sanchez de Carmona, MD - Mexico
Lakshmi Yatham, MBBS, FRCPC, MRCPsych - Canada
SCIENTIFIC PROGRAM COMMITTEE
Kyooseob Ha, Chair, MD, PhD - Korea
Willem Nolen, Co-Chair, MD, PhD - The Netherlands
Carlo Altamura, MD - Italy
Robert Belmaker, MD - Israel
Michael Berk, MD - Australia
Hyun Sang Cho, MD, PhD - Korea
Sophia Frangou, MD, PhD - USA
Mark Frye, MD - USA
Flavio Kapczinski, MD, PhD - Brazil
Tadafumi Kato, MD, PhD - Japan
Lars Vedel Kessing, MD, PhD, DMSc. - Denmark
David Kupfer, MD - USA
Beny Lafer, MD - Brazil
Carlos Lopez Jaramillo, MD - Colombia
Gin Malhi, MD - Australia
Andrew Nierenberg, MD - USA
Aysegul Ozerdem, MD, PhD - Turkey
Manuel Sanchez de Carmona, MD - Mexico
Lakshmi Yatham, MBBS, FRCPC, MRCPsych - Canada
L. Trevor Young, MD, PhD - Canada
07
REGIONAL ORGANIZING COMMITTEE

Yeon Ho Joo, Chair, MD, PhD - Korea
Yong Min Ahn, MD, PhD - Korea
Yuan-Hwa Chou, MD, PhD - Taiwan
B. Handoko Daeng, MD - Indonesia
Yiru Fang, MD, PhD - China
Tae Hyon Ha, PhD - Korea
Shigenobu Kanba, MD, PhD - Japan
Se Joo Kim, MD, PhD - Korea
Ong Hui Koh, MD - Malaysia
Heon-Jeong Lee, MD, PhD - Korea
M.S. Reddy, MD - India
Y.C. Janardhan Reddy, MD - India
Pichet Udomratn, MD - Thailand
Michael Ming - Cheuk Wong MB, BS, MRCPsych UK, FHKCPsych,
FHKAM Psychiatry - Hong Kong
Xin Yu, MD, PhD - China
ISBD EXECUTIVE COMMITTEE
Willem Nolen, MD, PhD - The Netherlands
President
Sophia Frangou, MD, PhD - USA
Vice-President, Governance
Andrew Nierenberg, MD - USA
Vice-President, Research
Kyooseob Ha, MD, PhD - South Korea
Vice-President, Education
Robert Belmaker, MD - Israel
Vice-President, Global Outreach
Manuel Snchez de Carmona, MD - Mexico
Secretary/Treasurer
08
ABOUT ISBD
HISTORY
Bipolar disorder is a severe and debilitating mental illness, which has only
recently started to receive the necessary attention from society, researchers,
practitioners, government, and private funding agencies. In response to the need
for further awareness, education, and research on this severe mental illness,
the International Society for Bipolar Disorders was created. The Society has as
its missions the promotion of awareness of this condition in society at large,
promotion of awareness and education about this condition among mental health
professionals, fostering research on all aspects of bipolar disorder, and promotion
of international collaboration in this area.
The International Society for Bipolar Disorders was launched at the 3rd
International Conference on Bipolar Disorders, in Pittsburgh, PA, June 17, 1999,
by David J. Kupfer, M.D., Founding President. Material distributed to all of the
delegates at the conference contained an invitation letter and an enrolment form.
The first issue (September, 1999) of Bipolar Disorders - An International Journal
of Psychiatry and Neurosciences, the official journal of the Society, contained a
similar enrolment form. The Journal was accepted into the Institute of Scientific
Indexing in 2000, was accepted into Medline and Index Medicus in 2001, and
received the impact factor of 5.221 in 2010, ranking it 10th out of 126 rated
psychiatric journals.
The Society is growing in membership with an elected board representing
17 countries. The ISBD is a major source for emerging research and clinical
data on bipolar disorders and is the only bipolar focused, research-oriented
Society working to bring this data to patients, families, and other mental health
professionals working on the front lines of bipolar care.
INTERNATIONAL SOCIETY FOR BIPOLAR DISORDERS

P.O. Box 7168
Pittsburgh, PA 15213
United States of America
Phone: (412) 802-6940
Fax: (412) 802-6941
www.isbd.org
09
GENERAL INFORMATION
CONFERENCE VENUE
COEX World Trade Center (North Entrance)
Samseong-Dong
Gangnam-gu
Seoul 135-731
www.coex.co.kr
REGISTRATION HOURS
The Registration Desks are situated in the Grand Ballroom Foyer
and will be open as follows:
Tuesday March 18, 2014
08:00 20:30
Wednesday March 19, 2014
06:30 19:00
Thursday March 20, 2014
06:30 18:30
Friday March 21, 2014
06:30 15:00
NAME BADGES
Upon registration, you will receive your name badge. You are kindly requested to
wear your name badge at all times during the Conference in order to have access
to the conference halls and exhibition area.
PRE-CONFERENCE COURSES
Pre-Conference Courses held on Tuesday March 18th require a ticket for entry.
To purchase a ticket please approach the registration desk. Kindly note that space
is limited and tickets will be sold on a first-come, first-served basis.
EXHIBITION OPENING HOURS
The exhibition will be open as follows:
09:00 20:30
08:00 18:30
08:00 18:30
INTERNET STATIONS
Free internet and email facilities will be available to all Conference participants in
the exhibition area during the exhibition opening hours only. Conference abstracts
will also be available for viewing from the stations. Please be considerate of fellow
participants when using these facilities.
10
WI-FI
Coex is a free Wi-Fi zone. Please be aware that public Wi-Fi capacity may have a
limited numberof simultaneous connections.
REFRESHMENTS
Self-served tea and coffee will be available in the Exhibition Area at the breaks
indicated in the Scientific Program. Lunch boxes will be served to the attendees of
the lunchtime industry symposia, in the session hall. Early morning brainstorming
sessions will also include light refreshments.
CME/CPD CERTIFICATE OF ATTENDANCE
CME/CPD Certificate of Attendance will be available for participants after the
Conference. Your certificate will be delivered electronically after completing the
educational evaluation and credit claiming procedure online via the link you will
receive following the Conference. The process will take 5-10 minutes. We thank
you for your feedback as it is an important part of the CME/CPD accreditation
process and helps improve future educational offerings.
For further information on how to obtain your CME Certificate of attendance,
please refer to the CME/CPD Accreditation pages in this Final Program.
CONFERENCE ABSTRACTS
ISBD 2014 Conference Abstracts will be published as an online supplement to
Bipolar Disorders: An International Journal of Psychiatry and Neurosciences.
To access the abstracts please visit: http://wileyonlinelibrary.com/journal/bdi
WELCOME RECEPTION
All registered participants are invited to join us for the Welcome Reception which
will take place in the Exhibition Area on Tuesday, March 18 at 19:30 - 20:30.
ISBD MEMBERSHIP MEETING
All ISBD members are invited to attend the ISBD Membership Meeting.
This meeting will take place on Wednesday, March 19, 18:00 19:00 in Hall F.
NOTICE BOARD/MESSAGES
Updates and notifications will be posted during the Conference on a notice board
in the Exhibition Area in the Grand Ballroom Foyer at the Conference venue.
Participants are also welcome to use this space to place messages for colleagues.
11
LIABILITY AND INSURANCE

The Conference Secretariat and Organizers cannot accept liability for personal
accidents or loss of or damage to private property of participants. Participants are
advised not to leave their personal belongings unattended in session halls and
throughout the Conference venue.
SAFETY AND SECURITY
Please do not leave any bags or suitcases unattended at any time, whether inside
or outside session halls.
SMOKING POLICY
This is a non-smoking event. Participants are kindly requested to refrain from
smoking in all public areas.
EMERGENCY TELEPHONE NUMBERS
119 - Fire, Emergency and Ambulance
112 - Police
CONFERENCE SECRETARIAT
1-3 Rue de Chantepoulet, PO Box 1726

CH-1211 Geneva 1
Switzerland
Tel: +41 22 908 0488
Fax: +41 22 906 9140
E-mail: isbd@kenes.com
Website: www.isbd2014.com
12
PROGRAM AT A GLANCE
Time
Hall A
Hall B
8:00
Hall C
Registration Opens
9:00
9:30
The 6th Conference of

the Asian Network of
Bipolar Disorder
East Asian
Bipolar Forum
Southeast Asia
and South Asia
Bipolar Forum
11:30
12:30
Lunch Break
13:00
The Korean
Academy of Child
and Adolescent
Psychiatry
Symposium
Lunch Break
The Korean
Academy of Child
and Adolescent
Psychiatry
Symposium
13:30
Experience from
Latin America
15:00
Coffee Break
Regional Poster Session (Poster Area)
15:30
(Continued)
Industry Symposium
(not included in main
event CME/CPD credit)
17:00
Opening &
Awards Ceremony
18:00
Keynote Lecture 1
Keynote Lecture 2
19:30
Welcome Reception
(Exhibition Area)
The 6th Conference of the Asian Network of Bipolar Disorder

The Korean Academy of Child and Adolescent Psychiatry Symposium
Pre-Conference Courses
13
Day 1 - Tuesday 18th March

Hall D
Hall E
Hall F
Poster Area
Registration Opens
State of the Art
in Diagnosing,
Assessing and
Treating Bipolar
Disorder: A Training
course to improve
your skills as a
bipolar expert
Lunch Break
State of the Art

in Diagnosing,
Assessing and
Treating Bipolar
Disorder: Continued
Proper use
of Mood
Stabilizers in
Long Term
Treatment
of Bipolar
Disorders
Treatment
of Bipolar
Disorders
During
Pregnancy and
Post-Partum
Regional
Poster Session
14
PROGRAM AT A GLANCE
Time
Hall A
Hall B
Hall C
Prescription Pattern
in the Treatment
of Bipolar Affective
Disorder: What the
Real World is Like
Bipolar Disorder
in Children and
Adolescents,
Compared with Adult
Bipolar Disorder
Molecular
Mechanisms of
Bipolar Disorder
7:00
8:30
10:00
Mid-Morning Break
10:30
Keynote Lecture 3
Keynote Lecture 4
12:00
Industry Symposium
13:30
What do we Know
About Lithiums
Role in Maintenance
Treatment of Bipolar
Disorder, 60 Years
After its Discovery?
15:00
Lunch Break
The Bipolar Prodrome: Can we

Identify At-Risk Individuals? An ISBD Task
Force Report
The Involvement
of Mitochondria in
Bipolar Disorder and
its Treatment
Afternoon Break
15:30
Clinical Guidelines
for Bipolar Disorder
Unique Features of
Bipolar Disorder in
Older Adults
An ISBD Task
Force Report
Diet, Exercise, and

Weight: Modifiable
Drivers of Disease
Severity and
Progression in People
with Mood Disorders?
17:00
18:00
18:30
Symposia Sessions
Brainstorming Sessions
15
Day 2 - Wednesday 19th March

Hall D
Hall F
Lithium Phobia:
Science or Superstition?
Clinical and Therapeutic

Peculiarities of Bipolar
Disorder in Late Life
Applications of Novel
Imaging Techniques to Gain
New Insights into Bipolar
Disorder
Rapid Communications I
Poster Area
Mid-Morning Break
Lunch Break
The Potential Clinical and

Therapeutic Relevance
of Imaging and Cognitive
Studies in Bipolar Disorder
Rapid Communications II
Afternoon Break
Crossing Borders in
Cognitive Assessment of
Bipolar Disorders
Poster Session I
ISBD Membership Meeting
Treatment Track I Clinical Manifestation

Neurobiology Track I Imaging Track I Cultural Track
Symposium Tracks:
16
PROGRAM AT A GLANCE
Hall A
Hall B
Hall C
7:00
8:30
New Psychosocial
Treatments for
Bipolar Disorder
The Challenge of
Designing Clinical
Trials An ISBD Task
Force Report
10:00
Neuroendocrine
Challenges and
Gender Differences in
Bipolar Disorder
An ISBD Task Force
Report
Mid-Morning Break
10:30
Keynote Lecture 5
Keynote Lecture 6
12:00
Industry Symposium
Lunch Break
13:30
New Medical Treatments Targeting

Cognitive Dysfuntion
in Bipolar Disorder
15:00
Afternoon Break
15:30
Investigations of
Bipolar Disorders
with the Forefront
Neurophysiologucal
Methods
Predictors and
Moderators of Psychosocial Treatment
Outcome for Bipolar
Depression
Suicide in Bipolar
Disorder;
An ISBD Task Force
Report
Metabolic Syndrome
and Bipolar Disorder
Glutamatergic System
in Bipolar Disorders:
From Etiology to
Treatment
17:00
Symposia Sessions
17
Day 3 - Thursday 20th March

Hall D
Hall F
How to Manage Bipolar

Disorder in Pregnancy and
Postpartum Disorder
Staging and Profiling

Bipolar Disorder: Conceptual
and Clinical Approaches
Structural, Functional and

Neuroreceptor imaging in
Affective Disorders
Socio-Cultural Challenges
in the Management of Bipolar Disorder
Poster Area
Mid-Morning Break
Lunch Break
Bipolar Disorder and

Neuroinflammation:
What Can we See?
Identifying Mood Disorder

and Correlates in Youth
from Different Cultures
Afternoon Break
Samuel Gershon Award

Winners
Cultural Issues and Bipolar

Disorder in China
Poster Session II

Neurobiology Track I Imaging Track I Cultural Track
Symposium Tracks:
18
PROGRAM AT A GLANCE
Time
Hall A
Hall B
The Future Care of Bipolar

Disorder: Trialogical Approaches
Bipolar Depression:
Phenomenology, Brain Imaging
and Predictors of Treatment
Response
7:00
8:30
10:00
Mid-Morning Break
10:30
Keynote Lecture 7
Keynote Lecture 8
12:00
Industry Symposium
Lunch Break
Self-management
in Bipolar Disorder
Different Aspects
of Mixed Depression
13:30
15:00
Adjourn
15:30
Symposia Sessions
19
Day 4 - Friday 21st March

Hall C
Hall D
Hall F
Transcranial Magnetic
Stigma as Perceived by
Stimulation Biomarker Patients with Bipolar Disorder.
and Therapeutic Stuides Cultural Differences between
The Netherlands and Japan
in Bipolar Disorder
Inflammatory Markers
and New Therapeutic
Challenge in Bipolar
Disorder
Rapid Communications III
Mid-Morning Break
Lunch Break
Genetic Studies on Bipolar Disorders
Korean Advocacy
Meeting
(In Korean)
Rapid Communications IV
Adjourn
Korean Advocacy
Meeting
(In Korean)

Neurobiology Track I Imaging Track I Cultural Track I Advocacy Track
Symposium Tracks:
20
KEYNOTE SPEAKERS
TUESDAY, MARCH 18
18:00 - 19:30
Hall A
The Role of Biomarkers in Clinical Practice: Lessons from Bipolar Disorder

L. Trevor Young, MD., PhD., Canada
The Neuroimaging Studies in Subjects at Ultra-High Risk for Psychosis
Jun Soo Kwon, M.D., Ph.D., South Korea
WEDNESDAY, MARCH 19
10:30 - 12:00
Hall A
Neurobiological Basis of Bipolar Disorder

Tadafumi Kato, MD., PhD., Japan
Early Intervention in Bipolar Disorder in a Moor Disorder Clinic
Lars Vedel Kessing, MD., PhD., DMSc., Denmark
THURSDAY, MARCH 20
10:30 - 12:00
Hall A
Novel Therapies: Translation, Validation and Implementation

Michael Berk, MD., Australia
Clinical Staging in Bipolar Disorder
Flavio Kapczinski, MD., PhD., Brazil
FRIDAY, MARCH 21
10:30 - 12:00
Psychoeducation and other psychological interventions:
Class effect or specific treatment modalities?
Francesc Colom, PsyD., MSc., PhD., Spain
Grassroots Advocacy; Hope, Resources, Support
Muffy Walker, USA
Hall A
21
SAMUEL GERSHON JUNIOR

INVESTIGATOR AWARD
The International Society for Bipolar Disorders (ISBD) recognizes the vital role
of developing the next generation of leaders in the field of bipolar disorders and
offers 4 awards for original research publication submissions. In order to promote
research interest in bipolar disorders in developing countries, two of the awards
are reserved for those from low and middle-income countries, as defined by the
2013 World Bank Classification. The awards are presented in conjunction with the
16th Annual Conference of the International Society for Bipolar Disorders) to be
held in Seoul, South Korea from 18-21 March 2014.
These awards are open to psychiatric trainees, postgraduate students, and junior
faculty up to and including the Assistant Professor rank from around the world,
independent of age, nationality, sex, or race.
THE 2014 SAMUEL GERSHON AWARD WINNERS
Cecilia Berlanga I Mexico
Fernando Goes I USA
Gislaine Reus I Brazil
Manpreet Kaur Singh I USA
These award winners will be presenting their research in a special session for
Samuel Gershon Award Winners.
Thursday, March 20 I 15:30 - 17:00 I Hall D
22
CME/CPD ACCREDITATION
COMMITMENT TO THE HIGHEST STANDARDS IN CME/CPD
Kenes is committed to being a valuable and knowledgeable partner in the design
and delivery of educationally strong, independent, transparent, and effective
CME/CPD programmes. Kenes is a proud member of the Good CME Practice Group
(gCMEp), a member organization contributing to improving health outcomes by:

Championing best practice in CME

Maintaining and improving standards
Mentoring and educating
Working in collaboration with critical stakeholders
Membership in the Good CME Practice Group illustrates the Kenes commitment
to high standards and knowledgeable partnership with its clients in the design and
delivery of educationally strong, independent, transparent, effective and financially
viable medical events.
EDUCATIONAL OBJECTIVES
After participating in this educational event, learners should be able to:

Address individual needs in compliance with their Continuous Professional

Development (CPD) plan
Evaluate the most important aspects of diagnosis and treatment of Bipolar
Disorders
Discuss new research outcomes related to Bipolar Disorders
Enhance the dialogue between psychiatrists and researchers as a means of
further developing individual expertise
Discuss how to optimize psychiatric care
Analyze the pros and cons of different treatments in psychiatric care related to
Bipolar Disorders
TARGET AUDIENCE
ISBD 2014 is the global meeting place for international scientists and clinicians
in the field of Psychiatry, especially Bipolar Disorders. Because of the diverse,
clinically focused educational offering, participants are able to tailor the
curriculum to meet the needs of international clinicians of all levels of experience.
23
ACCREDITATION STATEMENT AND CREDIT DESIGNATION

The Annual Conference of the International Society for Bipolar Disorders (ISBD) is
accredited by the European Accreditation Council for Continuing Medical Education
(EACCME) to provide the following CME activity for medical specialists.
The EACCME is an institution of the European Union of Medical Specialists (UEMS),
www.uems.net. Each medical specialist should claim only those hours of credit that
he/she actually spent in the educational activity.
AMERICAN MEDICAL ASSOCIATION (AMA)
Through an agreement between European Union of Medical Specialists
and the American Medical Association, physicians may convert EACCME
credits to an equivalent number of AMA PRA Category 1 Credit. Information
on the process to convert EACCME credit to AMA credit can be found at
www.ama-assn.org/go/internationalcme.
THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA
Live educational activities, occurring outside of Canada, recognized by the
UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning
Activities (Section 1) as defined by the Maintenance of Certification programme of
The Royal College of Physicians and Surgeons of Canada. For more information,
visit: www.royalcollege.ca
24
TO RECEIVE YOUR CME/CPD CERTIFICATE OF ATENDANCE

Your CME/CPD certificate will be available after the Conference. Your CME/
CPD certificate will be delivered electronically after completing the educational
evaluation and credit claiming procedure. The process will take 5-10 minutes.
We thank you for your feedback as it is an important part of the CME/CPD
accreditation process and helps improve future educational offerings.
BEFORE FRIDAY APRIL 18:

Follow the link in the email notification sent at the end of the event,
or visit the CME/CPD Accreditation page on the event website
Complete the anonymous online evaluation
You will be automatically directed to the credit claim system
Login with your unique User ID
(included in your registration package or on your badge)
Indicate the number of hours you attended
Your CME/CPD certificate will be automatically emailed to the address provided
Retain the certificate for your personal records
DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

In accordance with all CME/CPD accreditation criteria and standards for
commercial support, we are committed to ensuring balance, independence,
objectivity, and scientific rigor in its CME/CPD activities. Those in control of the
educational content disclose all relevant relationships (financial or other) with
any commercial interest that they or their spouse/partner have had within the
past 12 months. If an individual refuses to disclose, they are disqualified from
participating. Disclosure information is evaluated and conflicts of interest resolved.
Disclosure is made to participants prior to the activity. Participants are asked to
evaluate the objectivity and independence. Off-label or investigational use of a
therapeutic product is also disclosed.

Disclosure slide all speakers have been asked to present a disclosure slide
in their presentations
All submitters have been asked to complete Disclosure information on
submission of the abstracts
INDUSTRY SUPPORT DISCLOSURE

This event is supported, in part, by funding from industry. All support is managed in
strict accordance with CME/CPD accreditation criteria and standards for commercial
support. Appropriate acknowledgement of all supporting organizations is made in the
programme guide, on the event website, and with signage during the event. Disclosure
is made to participants prior to the activity. Industry support information is available on
page 142 and also on the Conference website at www.isbd2014.com
25
INFORMATION AT YOUR FINGERTIPS!

PAPERLESS SCIENTIFIC PROGRAM ON SMARTPHONES AND TABLETS
The ISBD Mobile websitetransforms smart phones and tablets
into dedicated tools for active meeting participation making
it easy for delegates to access the essential meeting content
and information they need meeting agendas, delegate lists,
posters, abstracts and faculty presentations. With the ISBD
Mobile web site delegates can search for the information they
need. For example, sessions and presentations can be searched
by day and time, venue location, topic and faculty.
http://isbd.meetingxpert.net
The paperless application is designed for cross platform access via laptop
and mobile devices such as Smartphones, iPhone, Android etc.
Access to the application is via your browser. Please contact our support at
support@meetingxpert.net for assistance.
SCHEDULER YOUR ITINERARY PLANNER
Scheduler is a new, smart application that helps you choose, plan and optimize
your conference itinerary allowing you to make the most out of your meeting. The
Scheduler makes it easy to select and prioritize the sessions you want to attend,
the presentations or posters you want to see, and the meetings with colleagues
youd like to arrange.
In preparation for the upcoming conference, the improved version of the itinerary
planner means each participant will receive a personal name and password via
a-mail. The scheduler allows you to browse sessions, presentations or search for
names and words in the title, author list or the body of the abstracts. By clicking
on the + icon, you can add them to your personal itinerary and by clicking on
you can remove them. Your schedule is saved automatically in MY ISBD. You will
also be able to add personal meetings on the calendar mode.
Once you have compiled your program, you can either import it into the calendar
on your personal device or export it as a PDF. The Scheduler can also be accessed
on your personal device via the conference mobile web site (view the short video
for instructions). Video: http://www.youtube.com/watch?v=I5nqChfTCWk
26
E-BOOK
ISBD 2014 E-Book offer delegates a convenient and enjoyable way to access
conference content on the move. Available on any smart device such as Apple
or Android, mobile website and via browser the e-book enables the meeting
organizer to publish content in a structured way using keyword
indexing and a customized view. Delegates can add bookmarks
or highlight texts. Text is searchable and can be hyperlinked,
enabling readers to jump back-and-forth between chapters or
the index. The E-Book will allow organizers to make content
available for usage by participants even after the event.
http://ebooks.meetingxpert.net/isbd
CARING FOR THE ENVIRONMENT

ISBD 2014 and appointed Conference organizer Kenes International are devoted
to promoting environmentally friendly practice in all of our operations. Our
responsibility to our Conference participants, staff, environment and society is
paramount in all of our decisions, policies and practices. We continue to learn and
strive to integrate new practices all the time. Here are a few of the practices we
have undertaken for this Conference:
Reducing print: The Final Program and Conference Abstracts are published
in online electronic versions rather than printed books.
Recycling onsite: Please recycle paper, plastic and glass items.
Paperless Scientific Program - Smartphone and Online Application:
The Scientific Program of the 16th Annual Conference of the International Society
for Bipolar Disorders is available via the paperless application designed for cross
platform access via laptop, mobile devices such as Smartphones, iPhone, Android
etc. Participants will have full access to the scientific program and the posters
including the abstracts. The application has smart search possibilities within the
scientific program by session type, hall or the faculty. The paperless application
gives the participant the power to choose and plan and, therefore, make the most
out of the conference.
To view the ISBD 2014 Scientific Program on your personal device, please visit:
http://isbd.meetingxpert.net
27
INFORMATION FOR PRESENTERS

Please check the Scientific Program in case of last minute scheduling changes.
ORAL PRESENTATIONS
All speakers presenting in sessions are requested to submit their presentations
to the Speakers Ready Room at least 1 hour before the start of their session.
The Speakers Ready Room is located on the 1st floor of the Conference Center.
SPEAKERS READY ROOM HOURS
Friday March 21, 2014
08:00 20:30
06:30 19:00
06:30 18:30
06:30 15:00
DATA PRESENTATION
If using a PowerPoint (or any other computer) presentation, please note you need
to bring it on a CD, a DVD or on a disk on key Memory stick (using the USB port
in the computer) and load it on one of the Meeting computers in the Speakers
Ready Room, at least 1 hour before the start of the session.
Please note that the Conference computers in the session halls are being supplied
with Office 2010.
If combining video films with PowerPoint, please make sure to check it in the
session hall where your lecture is taking place during a coffee or lunch break
prior to your session, at least 30 minutes before the start of the session even after checking it in the Speakers Ready Room.
Alternatively you may supply your own laptop computer. In such a case please
confirm that it has a VGA socket for external signal and come to check it first in the
Speakers Ready Room as soon as you arrive and later on in the session hall where
your lecture is taking place during the coffee or lunch break prior to your session,
at least 30 minutes before the start of the session.
28
IMPORTANT NOTE FOR MACINTOSH USERS:

In order to use MAC presentations on a PC compatible computer please note that
you need to prepare it according to the instructions below, before bringing it to the
Speakers Ready Room:
1. Use a common font, such as Arial, Times New Roman, Verdana etc.
(special fonts might be changed to a default font on a PowerPoint based PC).
2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not
be visible on a PowerPoint based PC).
3. Use a common movie format, such as AVI and WMV
(MOV files from QuickTime will not be visible on a PowerPoint based PC).
Alternatively you may use your own Macintosh laptop computer. In such a case
please confirm you provide it with a VGA adaptor for external signal and come
to check it first in the Speakers Ready Room as soon as you arrive and later on
in the session hall where your lecture is taking place during the coffee or lunch
break prior to your session, at least 30 minutes before the start of the session.
Please note that VHS Video projection, 35 mm slide projection and Overhead
projection (projection of transparencies) will not be available.
Please note: in compliance with EACCME requirements all speakers are
requested to include a slide disclosinig conflicts of interest at the beginning of
their presentation
29
POSTER PRESENTATIONS
Please see the Scientific Program for the board number on which you should
display your poster. Posters should be hung on the day of your presentation and
must be removed by the end of sessions on the same day.
Posters will be on display on three days:
Regional Poster Session:


15:00 - 15:30
Poster Session I:


17:00 - 18:30
Poster Session II:


17:00 - 18:30
REGIONAL POSTER SESSION

This poster session will be held on Tuesday March 18, 2014 in the Poster
Area between 15:00-15:30. During this time presenters are requested to
stand by their posters.
This session will showcase presentations from Asian scholars, and researchers
from Asian Regions on topics related with bipolar disorder, and other areas of
psychiatry, including schizophrenia, depression, and anxiety disorders.
Regional Posters may be mounted from 08:30 AM on Tuesday 18th March and
should be displayed until the end of the day.
Please check the Final Program for the poster board number allocated to you.
POSTER SESSION I & POSTER SESSION II
These poster sessions will be held on Wednesday, March 19 and Thursday, March
20 respectively in the Poster Area. These posters will be on display all day with the
poster sessions occuring between 17:00-18:30 each evening.
Presenters are requested to stand by their posters during the Poster Session
between 17:00-18:30. Presenters are able to set up their posters from 06:45 on
the day of presentation. Posters should be removed after 18:30 at the conclusion
of the Poster Session on the day of presentation.
30
POSTER OVERVIEW
Date of Presentation
Session
Poster Topic
Tuesday,
March 18
Regional Posters
Presentations from Asian scholars, and

researchers from Asian Regions on topics
related with bipolar disorder, and other
areas of psychiatry, including schizophrenia,
depression, and anxiety disorders.
Wednesday,
March 19
Session I
Biological Topics
Animal Models
Biomarkers
1
2 - 14
15 - 17
Chronobiology
18 - 21
Clinical Case Studies
22 - 23
Comorbidities
24 - 26
27
Early Intervention/Prodrome
28 - 29
Miscellaneous
30 - 37
Neurobiology
38 - 48
Neuroimaging
49 - 60
Other Interventions
Pharmacological Interventions
Womens Health
Session II
Non-Biological Topics
1 - 65
Child and Adolescent
Diagnosis
Thursday,
March 20
Board
No.
Child and Adolescent

Chronobiology
Clinical Case Studies
Clinical Trials Methodology
61
62 - 76
77
1-5
6
7 - 12
13
Cognition
14 - 33
Comorbidities
34 - 43
Diagnosis
44 - 51
Early Intervention/Prodrome
52 - 54
Elderly
55 - 56
Gender Issues
57 - 58
Miscellaneous
59 - 71
Neurobiology
Neuroimaging
New Technologies
72
73
74 - 75
Psychosocial Intervention
76 - 86
Social functioning
87 - 89
Womens Health
90
R egis t r a t ion A r ea
09
08
P o s t er A r e a
ENTR A NCE
11
Hall A
En t r anc e L e v el
07
06
Hall B
05
04
03 A
Hall C
31
VENUE FLOOR PLANS
ISBD
O f f ic e
Hall E
Me e t ing
R o om 1
Hall D
Me e t ing
R o om 2
Fir s t L e v el
Sp e ak er s '
R e a dy
R o om
Hall F
Me e t ing
R o om 3
32
SCIENTIFIC
PROGRAM
Tuesday, March 18, 2014
SAVE THE DATE
SCIENTIFIC PROGRAM TUESDAY, MARCH 18, 2014
SCIENTIFIC PROGRAM
TUESDAY, MARCH 18, 2014
9:30 - 9:40
Hall B
THE 6TH CONFERENCE OF THE ASIAN NETWORK OF BIPOLAR DISORDER:

OPENING REMARKS
P. Udomratn, Chairman ANBD
W. Nolan, Chairman ISBD
9:40 - 11:00
1
2
Hall B

EAST ASIAN BIPOLAR FORUM: MANAGEMENT OF BIPOLAR DISORDER IN ASIA
Chairpersons: S. Kanba (Japan) 3

M. Wong (Hong Kong, China) 4
9:45
PATTERN OF PHARMACOTHERAPY BY EPISODE TYPE FOR

PATIENTS WITH BIPOLAR DISORDERS AND ITS CONCORDANCE
WITH TREATMENT GUIDELINES
J.H. Baek (USA)

10:10
GUIDELINE CONCORDANCE OF PHARMACOLOGICAL

TREATMENT OF BIPOLAR DISORDERS IN CHINA
Y. Fang (China)
10:35
COGNITIVE IMPAIRMENT IN BIPOLAR DISORDER

Y.W.E. Cheung (Hong Kong, China)
35
36

11:00 - 12:30
Hall B

SOUTHEAST ASIA AND SOUTH ASIA BIPOLAR FORUM:
BIPOLAR DISORDER IN SOUTHEAST AND SOUTH ASIA, CLINICAL
CHARACTERISTICS AND BIOLOGICAL TREATMENT
Chairpersons: P. Udomratn (Thailand) 8

M.S. Reddy (India) 9
11:00
NEUROCOGNITIVE FUNCTIONING, CLINICAL PROFILES,

AND PSYCHOPATHOLOGY IN BIPOLAR DISORDER AND
SCHIZOPHRENIA: CLARIFYING CONCEPTS OF DICHOTOMY
VERSUS CONTINUUM
10
K. Sim (Singapore)
11:20
IRRITABILITY AS A CRITERION: DANGEROUS POTHOLE IN THE

DIAGNOSIS OF BIPOLAR DISORDER
11
M.S. Reddy (India)

11:40
PRESCRIPTION PATTERN OF DRUG TREATMENT IN BIPOLAR

DISORDER IN SINGAPORE
12
Y.M. Mok (Singapore)

12:00
ELECTROCONVULSIVE TREATMENT IN BIPOLAR DISODER:

EXPERIENCE FROM MALAYSIA
O.H. Koh (Malaysia)
12:30 - 13:30
LUNCH BREAK
13

13:30 - 15:00
Hall B

EXPERIENCE FROM LATIN AMERICA:
ISBD GLOBAL NETWORK - STORIES OF SUCCESS IN EDUCATION,
RESEARCH AND COMMUNITY INVOLVEMENT
Chairperson: M. Sanchez de Carmona (Mexico) 14
13:30
COMMUNITY INVOLVEMENT WITH THE MEXICAN BIPOLAR

POPULATION, EDUCATION IN DIFFERENT LEVELS
15
M. Sanchez de Carmona (Mexico)

13:50
BIPOLAR CLINICAL GUIDELINES IN PRIMARY CARE SETTING
16
D. Quiroz (Chile)
12:10
ISBD AS A FRAME TO ENCOURAGE PUBLICATION OF LOCAL

RESEARCH IN BIPOLAR DISORDERS - AN INTERNATIONAL
JOURNAL OF PSYCHIATRY AND NEUROSCIENCES
17
S. Strejilevich (Argentina)
12:30
THE CONSTRUCTION OF A NETWORK OF RESEARCH IN

BIPOLAR DISORDER IN BRAZIL
F. Kapczinski (Brazil)
18
37
38

9:30 - 9:40
Hall C
THE KOREAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY SYMPOSIA:

OPENING REMARKS
J. S. Lee (President KACAP) 19
Y.H. Joo (Chairman ISBD, Korea) 20
9:40 - 11:30
Hall C
THE KOREAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY SYMPOSIUM:

CONCURRENT MEDICAL CONDITIONS WITH PEDIATRIC BIPOLAR DISORDER
Chairpersons: T.W. Park (Korea) 21

K. Chang (USA) 22
9:40
PEDIATRIC CASES OF MOOD DISORDER DUE TO GENERAL

MEDICAL CONDITION
23
H.W. Kim (Korea)

10:15
INITIAL EVALUATION FOR THE FIRST-EPISODE MANIA
24
Y.S. Joung (Korea)

10:50
PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER

K. Chang (USA)
11:30 - 12:30
LUNCH BREAK
25

12:30 - 15:00
Hall C
THE KOREAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY SYMPOSIUM:

PEDIATRIC BIPOLAR DISORDER: UPDATE
Chairpersons: S.C. Cho (Korea) 26

E. Youngstrom (USA) 27
12:30
PEDIATRIC BIPOLAR DISORDER AND DISRUPTIVE MOOD

DISORDER IN DSM-5
28
B.N. Kim (Korea)

13:05
LONG-TERM F/U RESULTS OF THE BIPOLAR OFFSPRING
29
B. Birmaher (USA)
13:40
NEUROIMAGING FINDINGS OF BIPOLAR OFFSPRING
30
M. Singh (USA)
14:15
BIOMARKERS OF PEDIATRIC BIPOLAR DISORDER

B. Goldstein (Canada)
31
39
40

9:00 - 16:00
Hall D
PRE-CONFERENCE COURSE:
STATE-OF-THE-ART IN DIAGNOSING, ASSESSING AND TREATING BIPOLAR DISORDER:
A TRAINING COURSE TO IMPROVE YOU SKILLS AS A BIPOLAR EXPERT
Bipolar disorder is a heterogeneous clinical condition, confronting clinicians with
diagnostic dilemmas and complex treatment decisions. This course provides an
overview for clinicians who are relatively new in the field of bipolar disorder, addressing
diagnosis in adults and children using the new DSM-5 classification and going beyond
that in real world clinical practice, how to assess and how to treat (psychologically and
pharmacologically) patients with bipolar disorder. The course will include 6 sessions of
45 or 60 minutes each, consisting of short presentations by experts on the topics, each
followed by or alternated with extensive discussions and including exercises using clinical
case vignettes, to ensure much interaction with the course participants. Basic elements
as well as some controversial issues and common pitfalls are presented and interactively
illustrated with clinical examples. Participants are encouraged to present questions and
dilemmas from their own clinical experience.
9:00
DIAGNOSIS, ASSESSMENT OF BIPOLAR DISORDER IN ADULTS
32
R. Kupka (The Netherlands)

9:45
DIAGNOSIS AND ASSESSMENT OF BIPOLAR DISORDER IN

CHILDREN AND ADOLESCENTS
33
E. Youngstrom (USA)
10:30
BREAK
11:00
PSYCHOEDUCATION
34
F. Colom (Spain)
11:45
PSYCHOTHERAPY
35
F. Colom (Spain)
12:30
LUNCH BREAK
13:30
ACUTE PHARMACOTHERAPY FOR BIPOLAR DEPRESSION
14:30
MAINTENANCE PHARMACOTHERAPY
15:30
INTEGRATION AND GENERAL DISCUSSION
36
W. Nolen (The Netherlands)
J. Calabrese (USA) 37
38
W. Nolen (The Netherlands)
J. Calabrese (USA) 39
R. Kupka (The Netherlands)
40

13:00 - 16:30
Hall E
PROPER USE OF MOOD STABILIZERS IN LONG TERM TREATMENT OF BIPOLAR
DISORDERS
Pharmacological treatment with mood stabilizers is essential for the long-term (relapsepreventive) treatment of bipolar disorder. More than 60 years since the breakthrough of
identifying lithium salts as having antimanic and prophylactic activity, modern research
serves to further substantiate lithiums position at the front-line in the treatment of
bipolar disorder. The drug continues to prove itself as an effective mood stabilizer, which
also possesses unique anti-suicidal and antidepressant properties. Despite the successes
achieved through application of lithium treatment, the drug remains an ineffective option
for a proportion of bipolar patients. Not all patients are so-called lithium responders
and it has become a task of great importance to be able to establish whether or not a
given patient will benefit from its treatment. It is also important to establish whether even
non-responders to mood stabilizing effects of lithium may still benefit from some of the
other actions of this element (e.g., from its anti-suicide effects). Anticonvulsants and
some of the atypical antipsychotic medications are alternatives as are other additional
medications in the long-term treatment of bipolar disorder. The major questions are who
is getting which medication, at which point, and what algorithm can be offered in case a
patients fails to first/second and further options, monotherapy vs, combination therapy.
Presentors:

M. Gitlin (USA) 41
M. Bauer (Germany) 42
41
42

13:00 - 16:30
Hall F
TREATMENT OF BIPOLAR DISORDER DURING PREGNANCY AND THE POST-PARTUM:
CLINICAL PEARLS AND GUIDELINES
Treatment of bipolar disorders in women who are pregnant, are planning on becoming
pregnant, or who choose to nurse remains one of the most difficult of therapeutic
challenges in our field. While it is clear that some primary mood stabilizers are associated
with increased risk of congenital malformations, other adverse neonatal effects, and
poorer compatibility with breast feeding, it is also clear that relapse risk is increased if
treatment is stopped. In recognition of these challenges, recently developed guidelines
have been developed with the dual aims of minimizing fetal/neonatal medication
exposure and exposure to untreated disease. However, there is uncertainty regarding
the reproductive and lactation safety for most commonly prescribed treatments for
bipolar disorders, and their effectiveness for treating or preventing acute mood episodes
during the antepartum and post-partum period. Specific content areas will include the
following: (a) Review of effectiveness data for pharmacological and non-pharmacological
treatments of bipolar disorder in pregnancy; (b) update on reproductive and lactation
safety data for the major bipolar pharmacotherapies; (c) review of recommendations from
published guidelines addressing the treatment of bipolar disorder during pregnancy and
post-partum period; and (d) overview of management strategies for women with bipolar
disorder who desire to nurse their infant.
Presentor: A. Ozerdem (Turkey) 43
13:00
PRE-PREGNANCY PLANNING FOR WOMEN WITH BIPOLAR

DISORDERS
44
B. Frey (Canada)
13:30
TREATMENT OPTIONS FOR BIPOLAR DISORDERS IN PREGNANT

WOMEN: CURRENT STATE OF EVIDENCE
45
F. Akdeniz (Turkey)
14:00
THE COMPARATIVE FETAL AND OBSTETRIC SAFETY OF

BIPOLAR PHARMACOTHERAPIES
46
W. Bobo (USA)
14:30
PSYCHOSOCIAL NEEDS AND A PREVENTION PLAN FOR THE

PREGNANT AND POSTPARTUM PERIOD OF BIPOLAR WOMEN
47
A. Stevens (The Netherlands)
B. Geerling (The Netherlands) 48
15:00
COFFEE BREAK
15:15
DISCUSSANT
N. Rasgon (USA)
49

15:00 - 15:30
COFFEE BREAK AND POSTER VIEWING
15:30 - 17:00
Hall A
INDUSTRY SATELLITE SYMPOSIUM

not included in main event CME/CPD credit
17:00 - 18:00
Hall A
OPENING AND AWARDS CEREMONY

17:00
WELCOME BY PRESIDENT, ISBD
50
W. Nolen

WELCOME BY PRESIDENT, KOREAN NEUROPSYCHIATRIC

ASSOCIATION
51
Y.H. Kim

WELCOME BY CHAIRMAN, ISBD KOREA
52
Y.H. Joo

INTRODUCTION TO CONFERENCE, CHAIR OF SCIENTIFIC

COMMITTEE
53
K. Ha
17:30
17:40
GERSHON AWARDS
54
G. Malhi, Chairman Awards Committee

M. Sanchez de Carmona, President-elect ISBD
55
WORLD BIPOLAR DAY: INTRODUCTION
56
W. Nolen, President ISBD

P. Udomratn, Chairman ANBD
57
43
44

18:00 - 19:30
Hall A
KEYNOTE LECTURE
Chairpersons: W. Nolen (The Netherlands) 58

Y.H. Kim (Korea) 59
18:00
THE ROLE OF BIOMARKERS IN CLINICAL PRACTICE:

LESSONS FROM BIPOLAR DISORDER
60
L.T.Young (Canada)
18:45
THE NEUROIMAGING STUDIES IN SUBJECTS ATULTRA-HIGH

RISK FOR PSYCHOSIS
61
J.S. Kwon (Korea)

19:30 - 20:30
WELCOME RECEPTION
Exhibition area
SCIENTIFIC
PROGRAM
Wednesday, March 19, 2014
46
SCIENTIFIC PROGRAM WEDNESDAY, MARCH 19, 2014
SCIENTIFIC PROGRAM
WEDNESDAY, MARCH 19, 2014
7:00 - 8:30
Hall D
BRAINSTORMING SESSION:
LITHIUM PHOBIA: SCIENCE OR SUPERSTITION?
In a curious paradox, the use of lithium for the treatment of bipolar disorder appears to
be declining even as evidence of its efficacy increases, as does knowledge regarding its
safety. Recent meta-analyses confirm the benefits of maintenance lithium treatment,
along with reduced sucidality and, possibly, diminished risk of developing dementia.
Sodium Valproate, on the other hand, continues to be the most widely used mood
stabiliser despite scarse evidence for its effectiveness. Being an element, lithium cannot
be patented and the consequent lack of pharmaceutical industry interest in its promotion
is probably the single most important factor in its under-use. The use of lithium appears
to be in decline, possibly because of insufficient training of psychiatrists in the use
of lithium therapy and the aggressive marketing of alternative medications that are
patentable and therefore more profitable. Empirical studies in USA Canada, Germany,
Switzerland and Austria have demonstrated this unfortunate trend. In fact, either as
a result of a deliberate disinformation campaign or simply due to ignorance, there
appears to be an almost superstitious fear of lithium, with the risks of renal damage and
hypothyroidism being magnified beyond belief. The proposed brainstorming session aims
to review the present state of our knowledge in this area, identify the drivers of lithium
phobia, and discuss remedial strategies.
Chairperson: D. Goel (New Zealand) 62
7:00
LITHIUM: IS IT EFFECTIVE? IS IT SAFE?
63
S.Kumar (New Zealand)

7:45
LITHIUM: THE WAY FORWARD

M.Isaac (Australia)
64

7:00 - 8:30
Hall F
CLINICAL AND THERAPEUTIC PECULIARITIES OF BIPOLAR DISORDER IN LATE LIFE
Although Bipolar Disoder (BD) among the elderly is only slightly less common than among
younger age groups, it has received much less attention from clinicians and researchers.
Geriatric BD has sometimes been considered as a manic-like presentation related to a
physical condition, thereby raising the need to differentiate between late and early onset
of the illness. A closer relation to BD albeit with some clinical and treatment differences
has been reported recently even for late onset patients (1). Furthermore, the use of
some pharmacological treatments in this population requires especial considerations.
Unfortunately there are no current evidence-based recommendations for managing BD
in late life and little is known about recommended medications or doses in older patients.
Clinical features of BD in the elderly, including differences between types I and II and
between patients with early- vs late-onset will be presented. A discussion related to the
need of increasing its recognition and improving an adequate follow-up of these patients
will follow. Finally we will discuss aspects related to specific treatment strategies for
acute affective episodes and for maintenance treatment.
Chairperson: J.M. Montes (Spain) 65
7:00
CLINICAL FEATURES OF BIPOLAR DISORDER IN LATE LIFE
66
V.Balanz-Martnez (Spain)
7:45
THERAPEUTIC STRATEGIES FOR GERIATRIC BIPOLAR DISORDER

J.Goikolea (Spain)
67
47
48

8:30 - 10:00
Hall A
SYMPOSIUM SESSION - TREATMENT:

PRESCRIPTION PATTERN IN THE TREATMENT OF BIPOLAR AFFECTIVE
DISORDER: WHAT THE REAL WORLD IS LIKE
Bipolar affective disorder is a mood disorder with different presentation at different phase
of the illness. There is no universally agreed protocol in the treatment of this disorder.
Instead there are different treatment guidelines and recommendations proposed by
different organizations, e.g the CANMAT and WFSBP guidelines. Despite the presence
of guidelines and recommendations, the pattern of drug use still different from place
to place. Also the use of drugs may deviate from the guidelines in the real world. This
symposium tries to look at the prescription pattern in different parts of the world so that
we can have an idea of how drug treatment is like in the global perspective. Also we can
have an idea of to what extend we are following the treatment guidelines. We will have
three papers in this symposium. The first paper looks at the pattern of drug treatment in
the outpatient clinics in Hong Kong. The second paper describes a multicentre study in
the Netherland which investigates the treatment of care as usual patients with bipolar
disorder in various outpatient treatment settings, and its concordance with current
treatment guidelines in relationship to symptomatic and functional outcome. The third
paper reports data from an ongoing, long-term naturalistic study in Europe and NorthAmerica and explored drug treatment patterns in bipolar disorder using six months
of daily self-reported data on psychotropic drug intake from patients who received
treatment as usual. These three studies show that the prescription pattern can be
quite different. For example, the three studies each have either Valproate, Lithium or
Lamotrigine as the most commonly prescribed mood stabilizers. Further collaboration is
needed to understand the reasons behind the discrepancy.
Chairpersons: M.C.M. Wong (Hong Kong, China) 68

C.Y. Kim (Korea) 69
8:30
PRESCRIPTION PATTERN IN THE TREATMENT OF BIPOLAR

AFFECTIVE DISORDER IN OUTPATIENTS IN HONG KONG
70
M.Wong, Y.W.E.Cheung (Hong Kong China)

9:00
TREATMENT OF BIPOLAR DISORDER IN THE NETHERLANDS

AND CONCORDANCE WITH TREATMENT GUIDELINES:
A LONGITUDINAL, NON-INTERVENTIONAL, NATION-WIDE STUDY
71
J.W.Renes, E.J.Regeer, W.A.Nolen, R.W.Kupka (The Netherlands)

9:30
DRUG TREATMENT PATTERNS IN BIPOLAR DISORDER:

POLYPHARMACY IS COMMONPLACE
M.Bauer (Germany)
72

8:30 - 10:00
Hall B
SYMPOSIUM SESSION - CLINICAL MANIFESTATION:

BIPOLAR DISORDER IN CHILDREN AND ADOLESCENTS COMPARED WITH
ADULT BIPOLAR DISORDER
Over the past 15 there has been substantial growth in the evidence base regarding bipolar
disorder among children and adolescents. Whereas controversies arguably exceeded data
until recently, the accumulation of findings regarding the phenomenology, assessment,
course, treatment, and neurobiology of child and adolescent bipolar disorder has
coincided with increasing consensus among researchers in the field regarding important
topics. For example, discrete manic/hypomanic episodes are the foundation of diagnosing
bipolar disorder among children and adolescents, as they are among adults. Although
manic episodes among most youth have elation/euphoria, the small subset of youth with
episodic irritable-only mania/hypomania have comparable demographic, clinical, and
familial characteristics compared to youth with elation /- irritability. Neurobiological
research has identified numerous key findings that overlap with adult bipolar disorder,
as well as some distinguishing findings (most notably, small amygdalae). Treatmentrelated findings are generally continuous with those observed among adults, with some
exceptions, such as greater relative efficacy of second-generation antipsychotics, and
greater relative sensitivity to their metabolic side effects. Despite recent progress, there
remains a perception of sparse data that is belied by the voluminous literature. This
symposium provides a critical review and selective synopsis of the extant literature as it
relates to developmental similarities and differences in bipolar disorder across childhood,
adolescence, and adulthood. Three presentations will review epidemiology
and phenomenology, including screening instruments and assessment approaches
(Dr. Youngstrom), longitudinal course and outcome (Dr. Birmaher), including recent
findings extending into young adulthood, and biology and treatment (Dr. Goldstein).
Chairpersons: R. Post (USA) 73

Y.S. Kwak (Korea) 74

ADVANCES IN EPIDEMIOLOGY AND ASSESSMENT ENABLE FAST AND

FRUGAL METHODS OF DETECTION WITHOUT OVER DIAGNOSIS
75
E.Youngstrom, B.Goldstein (USA)

WHAT HAPPENS OVER TIME WITH YOUTH THAT HAVE BEEN

DIAGNOSED WITH BIPOLAR SPECTRUM DISORDERS?
76
B.Birmaher, B.Goldstein (USA)

UPDATE ON BIOLOGICAL AND TREATMENT FINDINGS AMONG

CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER
B.Goldstein (Canada)
77
49
50

8:30 - 10:00
Hall C
SYMPOSIUM SESSION - NEUROBIOLOGY:

MOLECULAR MECHANISMS OF BIPOLAR DISORDER
There have been a number of hypotheses on the molecular biological basis of bipolar
disorder. Among them, circadian rhythm dysregulation, ion transport dysfunction/
intracellular signaling abnormalities, inflammation and oxidative stress/mitochondrial
dysfunction are popular hypotheses. In this session, neurobiological studies of bipolar
disorder using animal models, cellular models, or clinical samples, will be presented.
(Comments: Whereas many of sessions in ISBD2014 will be focused on the clinical
aspects, a symposium focusing on recent progress in biological research will be useful
for clinicians to update the knowledge on the causes of bipolar disorder.)
Chairpersons: T. Kato (Japan) 78

E.J. Joo (Korea) 79
8:30
FROM ION PUMP DYSFUNCTIONS TO ABNORMALITIES IN

SIGNAL TRANSDUCTION PATHWAYS IN BIPOLAR DISORDER:
OAUBAIN RAT MODEL FOR MANIA
80
S.K.Kim, Y.S.Kim, Y.M.Ahn (Korea)

9:00
CIRCADIAN RHYTHM DISTURBANCES IN BIPOLAR DISORDER:

APPROACHES USING ANIMAL MODELS
81
S.Honma, A.Natsubori, Y.Yamanaka, A.Toyomaki, T.Inoue, K.Honma (Japan)

9:30
OXIDATIVE STRESS AND INFLAMMATION IN BIPOLAR

DISORDER: THE PUTATIVE ROLE OF ACTIVATED MICROGLIAL CELLS 82
F.K.Kapczinski (Brazil)

8:30 - 10:00
Hall D
SYMPOSIUM SESSION - IMAGING:

APPLICATIONS OF NOVEL IMAGING TECHNIQUES TO GAIN NEW INSIGHTS INTO
BIPOLAR DISORDER
Advances in imaging technology and related analytic strategies allow sophisticated
testing of neurobiological models of disease pathology in psychiatric disorders. Research
that highlights innovative approaches applying MR imaging techniques, that include highly
resolved 2-D and 3-D structural magnetic resonance imaging (MRI), functional magnetic
resonance imaging (fMRI), magnetization transfer and multi-nuclear magnetic resonance
spectroscopy (MRS), to systematically investigate bipolar disorder will be presented.
A particular focus of this symposium will be on the longitudinal characterization of
metabolic, functional and structural changes associated with treatment, and how
characterization of treatment effects provides a strategic approach for advancing
models of pathophysiology underlying Bipolar Disorder. Dr. In Kyoon Lyoo will present
work investigating bipolar disorder that applies cortical thickness measurements,
subcortical shape analysis and voxel based morphometry to evaluate longitudinal
effects of treatment. These studies document the differential effects of both illness and
treatment on brain anatomy. Dr. Deborah Yurgelun-Todd will present work applying fMRI
to characterize alterations in connectivity and cerebral activity that are associated with
affective and cognitive changes in bipolar disorder across the lifespan. Central to this
work is emerging evidence for a failure of appropriate regulation of limbic structures by
the prefrontal cortex. Dr. Stephen Dager will present work using multi-nuclear MRS to
assess brain metabolic status in relationship to mood state and the effects of treatment.
A growing literature that supports the presence of brain metabolic alterations in bipolar
disorder has important treatment implications. These studies have led to the identification
and evaluation of novel treatments for bipolar disorder.
Chairperson: P. Renshaw (USA) 83
8:30
GREY MATTER DENSITY AND STRUCTURAL CHANGES DURING

TREATMENT IN MEDICATION-FREE BIPOLAR DISORDER PATIENTS
84
I.K.Lyoo, S.R.Dager, C.S.Jun, J.E.Kim, Y.J.Jun, P.F.Renshaw (Korea)

9:00
FUNCTIONAL MAGNETIC RESONANCE IMAGING BIPOLAR DISORDER 85

D. Yurgelun-todd, M.L. Lopez-Larson, E. McGlade (USA)
9:30
IMAGING BRAIN METABOLISM: EVIDENCE FOR ALTERED BRAIN

BIOENERGETICS IN BIPOLAR DISORDER
S.R. Dager, N.M. Corrigan, T. Richards, D. Dunner, I.K. Lyoo,
P.F. Renshaw (USA)
86
51
52

8:30 - 10:00
Hall F
RAPID COMMUNICATION SESSION:

ORAL COMMUNICATIONS
Chairpersons: R. Belmaker (Israel) 87

H.S. Cho (Korea) 88

INDICATIONS OF A DOSE-RESPONSE RELATIONSHIP BETWEEN

CANNABIS USE AND AGE AT ONSET IN BIPOLAR DISORDER
89
T.V.Lagerberg, L.Kvitland, S.R.Aminoff, M.Aas, P.A.Ringen,

O.A.Andreassen, I.Melle (Norway)

MYOCARDIAL INFARCTION SURVIVAL IN PATIENTS WITH BIPOLAR

DISORDER OR SCHIZOPHRENIA SPECTRUM DISORDERSA NATIONWIDE COHORT STUDY
90
R.Bodn, E.Molin, T.Jernberg, H.Kieler, B.Lindahl, J.Sundstrm (Sweden)

SIMILAR WHITE MATTER CHANGES IN SCHIZOPHRENIA AND BIPOLAR

DISORDER: A TBSS STUDY
L.Squarcina, M.Bellani, C.Perlini, G.Rambaldelli, V.Marinelli,
N.Dusi, R.Cerini, R.Pozzi-Mucelli, M.Tansella, A.Bertoldo,
P.Brambilla (Italy)
10:00 - 10:30
COFFEE BREAK
91

10:30 - 12:00
Hall A
KEYNOTE LECTURE
Chairpersons: S. Frangou (USA) 92

Y.H. Joo (Korea) 93
10:30
NEUROBIOLOGICAL BASIS OF BIPOLAR DISORDER
94
T.Kato (Japan)
11:15
EARLY INTERVENTION IN BIPOLAR DISORDER IN A MOOD

DISORDER CLINIC
95
L.Vedel Kessing (Denmark)

12:00 - 13:30
12:00 - 13:30
LUNCH BREAK
Hall A
53
54

13:30 - 15:00
Hall A

WHAT DO WE KNOW ABOUT LITHIUMS ROLE IN MAINTENANCE TREATMENT OF
BIPOLAR DISORDER, 60 YEARS AFTER ITS DISCOVERY?
Since its introduction into modern psychiatry in 1949, many new aspects of lithiums use
in psychiatry and the neurosciences have been discovered in basic and clinical research.
More than 60 years from the breakthrough of identifying lithium salts to have antimanic
and prophylactic activity, modern research serves to further substantiate lithiums
position at the front-line in the treatment of bipolar disorder. The drug continues to prove
itself as an effective mood stabilizer, which also possesses unique anti-suicidal and
antidepressant properties. Unfortunately, lithium is not widely used in clinical practice
in many countries today. In this symposium, the latest research into the effects of lithium
on different levels of clinical investigation, from placebo-controlled trials to naturalistic
investigations will be covered by three prominent speakers in the respective field. This
includes also data from a new meta-analysis on the reassessment of the evidence for
lithium in relapse prevention of bipolar disorder. W. Nolen will discuss three recent
studies: one proving lithiums long-term efficacy, but only at plasma levels =0.6 mmol/l,
and two (an effectiveness study and a pharmaco-epidemiological study) indicating
lithiums superiority over valproate. R. Licht will cover lithiums position in international
guidelines and discuss methodological considerations that have major clinical
implications. Specifically, he will not only review the evidence for long-term treatment of
lithium, stressing the distinction between evidence obtained from enriched and nonenriched trials, referring to the WFSBP guidelines approach, but will also discuss the
implications in terms of generalizability. T. G. Schulze will present the latest findings
from the international Consortium on Lithium Genetics (www.ConLiGen.org), the worlds
largest effort to study the genomics and genotype-phenotype relationships of lithium
response in bipolar disorder. The current sample size comprises close to 3000 bipolar
individuals from 4 continents, rigorously phenoytped for lithium response and genotyped
on a genome-wide level.
Chairpersons: M. Bauer (Germany) 96

J. Yi (Korea) 97
13:30
LITHIUM: STILL A CORNERSTONE IN THE LONG-TERM

TREATMENT OF BIPOLAR DISORDER
98
W.Nolen (The Netherlands)

14:00
LITHIUM IN LONG-TERM TREATMENT OF BIPOLAR DISORDER:

METHODOLOGICAL CONSIDERATIONS WITH MAJOR CLINICAL
IMPLICATIONS.
99
R.Licht (Denmark)
14:30
GENOMIC AND PHENOMIC CORRELATES OF LITHIUM

RESPONSE IN BIPOLAR DISORDER: A CONSORTIUM ON
LITHIUM GENETICS (CONLIGEN) REPORT
T.Schulze (Germany)
100

13:30 - 15:00
Hall B

THE BIPOLAR PRODROME: CAN WE IDENTIFY AT-RISK INDIVIDUALS?
Despite therapeutic advances, bipolar disorder remains one of the most severe and
debilitating psychiatric disorders. Therefore, early identification and interventions during
the prodromal (subsyndromal) stages of bipolar disorder have attracted increasing
attention. This session aims at summarizing the knowledge about precursors, risk
factors, terminology, specific instruments, emerging risk criteria and experience from
a dedicated bipolar high-risk program helping clinicians and researchers to begin
incorporating the concept of the bipolar prodrome into their respective practice. Dr. Anna
Van Meter will review the evidence for precursors and risk factors for bipolar disorder.
She will summarize information about the role of temperament, cyclothymic disorder,
disruptive mood dysregulation disorder, and behavioral disorders as comorbidities or
prodromal/subsyndromal manifestations. Attention will paid to the overlap between
criteria and specificity as well as predictive validity of disorders or symptom constellation
alone or in the context of familial high risk.Dr. Christoph Correll will summarize existing
and emerging terminology, models and operational criteria for individuals considered
at-risk for bipolar disorder and present data from an interview study of 205 youth aged
12-23 years and/or their caregivers that investigated the psychometric characteristics
of the Bipolar Prodrome Symptom Scale-Prospective (BPSS-P), the first dedicated
bipolar at-risk interview/rating scale. Dr. Andrea Pfennig will present data from their
dedicated bipolar at-risk clinic, including a description of assessment instruments and
data from the first 180 help-seeking persons who were assessed with a standardized
diagnostic procedure. She will also present the frequency of at-risk status, using as risk
factors for bipolar disorders familial risk, increasing mood swings, subsyndromal (hypo)
manic symptoms, specific sleep and circadian rhythm disturbances, anxiety/fearfulness,
affective disorder, decreased psychosocial functioning, increasing periodic substance
use, and attention-deficit/hyperactivity disorder. Finally, treatment recommendations
for at-risk subjects will be summarized.Data suggest that in a relevant subgroup, there
is a clinically identifiable prodromal symptom stage. While more phenomenological,
pathophysiological and biomarker data are needed, early identification and interventions,
following a staging paradigm, seem possible. To advance the field, common terminology,
assessment instruments, outcomes and criteria need to be established and implemented.
The ISBD Bipolar Prodromes Task Force is currently working toward these goals.
Chairpersons: B. Birmaher (USA) 101

Y.C. Chung (Korea) 102
13:30
PRECURSORS AND RISK FACTORS FOR BIPOLAR DISORDER:

THE ROLE OF TEMPERAMENT, CYCLOTHYMIC DISORDER,
DISRUPTIVE MOOD DYSREGULATION DISORDER, AND
BEHAVIORAL DISORDERS
103
A.Van Meter, E.Youngstrom (USA)

14:00
CHARACTERIZING AND OPERATIONALIZING RISK FOR BIPOLAR

DISORDER: TERMINOLOGY, TOOLS AND CRITERIA FOR THE
MANIA-AT-RISK SYNDROME
B. Birmaher (USA)
104
55
56
14:30
IDENTIFICATION, CHARACTERISTICS AND NATURALISTIC

TREATMENT OF INDIVIDUALS AT-RISK FOR BIPOLAR
DISORDER: RESULTS FROM THE FIRST 3 YEARS OF THE
DRESDEN HIGH-RISK PROGRAM
A.Pfennig, K.Leopold (Germany)
105

13:30 - 15:00
Hall C

THE INVOLVEMENT OF MITOCHONDRIA IN BIPOLAR DISORDER AND ITS
TREATMENT
Convergent data implicate mitochondrial dysfunction as an important component of
the pathophysiology of bipolar disorder, possibly amended by mood stabilizers. Takaoki
Kasaharas group generated transgenic mice in which mutant POLG (mtDNA polymerase)
was expressed in a neuron-specific manner. Dr Kasahara will elaborate on the phenotype
of these mice, exhibiting forebrain-specific defects of mtDNA, altered monoaminergic
functions in the brain, a distorted day-night rhythm and a robust periodic activity pattern
associated with estrous cycle, behaviors resembling mood disorder worsened by tricyclic
antidepressant treatment and improved by lithium. Dr Kasahara will suggest that
accumulation of mtDNA defects in brain cause mood disorder-like mental symptoms
responding to treatments of bipolar disorder. Galila Agams group performed a DNAmicroarray study searching for pathways commonly affected by chronic lithium-treatment
and by the knockout of each of two genes (IMPA1, Slc5a3) encoding for proteins related to
inositol-metabolism which exhibit a lithium-like behavioral phenotype. All bioinformatics
analyses revealed up-regulation of mitochondrial-function. Differential-expression
of three gene members of the mitochondrial electron-transfer-chain commonly
differentially-expressed in the three paradigms was verified by real-time PCR analysis.
A further proteomics study indicated that the mitochondrial function-related process,
autophagy, is enhanced. The result of the bioinformatics analysis was consistent with an
observed interrelationship between treatment with lithium and rotenone, an inhibitor
of mitochondrial-function, in the forced-swim test and the amphetamine-inducedhyperlocomotion paradigm. The results support the notion that the amelioration of
aberrant mitochondrial function by lithium is mediated via the drugs effect on inositol
metabolism. Michael Berk will discuss the implication of the neuroprogressive nature
of bipolar disorders clinical process as reflected by both progressive neuroanatomical
changes and evidence of cognitive decline. The biochemical foundation of this process
appears to incorporate changes in inflammatory cytokines, cortisone, neurotrophins and
oxidative stress, some of which relate to mitochondrial function. He will provide evidence
to suggest that these markers may differ between the early and late stages of the
disorder and that most of the currently used mood stabilisers share effects on oxidative
stress and neurotrophins. Dr Berk will suggest that the development of novel potentially
neuroprotective agents currently under process need to be combined with service
initiatives to maximise the opportunities for early diagnosis and intervention.
Chairperson: G. Agam (Israel) 106
13:30
MICE WITH NEURON-SPECIFIC ACCUMULATION OF MTDNA

DELETIONS, THE DSM-5-VALIDATED ANIMAL MODEL FOR
MOOD DISORDER
T.Kasahara, T.Kato (Japan)
107
57
58
14:00
A MICROARRAY AND PROTEOMICS STUDY OF LITHIUMTREATED MICE AND KNOCKOUT MICE WITH LITHIUM-LIKE
BEHAVIOR REVEALS A COMMON EFFECT ON MITOCHONDRIAL
FUNCTION AND AUTOPHAGY
108
G.Agam, L.Toker, Y.Bersudsky, R.H.Belmaker, D.Moechars, G.Berry (Israel)

14:30
THE MITOCHONDRION AS A THERAPEUTIC TARGET IN BIPOLAR

DISORDER.
G.Agam, M.Berk (Australia)
109

13:30 - 15:00
Hall D

THE POTENTIAL CLINICAL AND THERAPEUTIC RELEVANCE OF IMAGING AND
COGNITIVE STUDIES IN BIPOLAR DISORDER
Bipolar disorder is a highly heritable disorder, the underlying neurobiology, cognition
and aetiopathogenesis of which remains unclear. There is increasing neuroimaging and
neuropsychological evidence that it is associated with subtle abnormal neural networks
underlying cognitive function and mood regulation. In particular, there is evidence that
disturbed structural integrity characterises both adult and pediatric bipolar disorder and
potentially genetic liability for this illness. Also, it has become apparent that in addition
to the discernible cognitive compromise patients with bipolar disorder experience when
depressed or manic, their neurocognition is also impaired when euthymic, also present
in subjects at risk to develop the disorder. Furthermore, recent bioinformatic techniques
allow to automatically differentiate patients with bipolar based on imaging and cognitive
data, which have potential translational clinical impact. Recognized scientists from USA
and Italy will debate such issues.
Chairpersons: P. Brambilla (Italy) 110

J.J. Kim (Korea) 111
13:30
THE PREDICTIVE VALUE OF STRUCTURAL MAGNETIC

RESONANCE SCANS IN BIPOLAR DISORDER USING PATTERN
CLASSIFICATION APPROACHES
112
S.Frangou (USA)
14:00
A PROSPECTIVE COHORT STUDY OF COGNITION AND BRAIN

MORPHOLOGY IN PATIENTS WITH FIRST EPISODE MANIA
113
L.Yatham (Canada)
14:30
CHANGES IN BRAIN MORPHOLOGY AND COGNITIVE OUTCOME

IN JUVENILE PATIENTS WITH BIPOLAR DISORDER
(FOR SYMPOSIUM SUBMISSION BY P. BRAMBILLA ET AL)
J.C.Soares (USA)
114
59
60

13:30 - 15:00
Hall F

ORAL COMMUNICATIONS
Chairpersons: T. Kato (Japan) 115

K.S. Hong (Korea) 116

GENOME-WIDE ASSOCIATION STUDY OF LITHIUM RESPONSE IN A

SWEDISH POPULATION
117
S.Bergen, J.Song, P.Lichtenstein, M.Landen (Sweden)

SINGLE INFUSION OF KETAMINE IN BIPOLAR DEPRESSION:

EFFICACY AND RELATED FACTORS
118
J.Rybakowski, M.Skibinska, A.Bartkowska-Sniatkowska,

A.Permoda-Osip (Poland)

THE OFFSPRING OF EXCELLENT LITHIUM RESPONDERS:

NEUROBIOLOGICAL AND TEMPERAMENTAL FINDINGS
119
J.Rybakowski, E.Ferensztajn, M.Kaczmarek, J.Losy, M.Skibinska (Poland)

THE EFFICACY AND SAFETY OF QUETIAPINE EXTENDED RELEASE

(XR) AS MONO-THERAPY IN THE TREATMENT OF CHINESE PATIENTS
WITH BIPOLAR OR DEPRESSION
H.F.Li, N.F.Gu, H.Y.Zhang, G.Wang, Q.R.Tan, P.D.Yang, Y.P.Ning,
H.G.Zhang, Z.Lu, X.F.Xu, J.G.Shi, C.G.Gao, L.J.Li, K.R.Zhang,
H.J.Tian, X.P.Wang, K.Q.Li, H.C.Li, Y.Xu, X.Yu (China)
15:00 - 15:30
COFFEE BREAK
120

15:30 - 17:00
Hall A

CLINICAL GUIDELINES FOR BIPOLAR DISORDER
Bipolar Disorders are common disorders, associated with significant personal and
social burden. They have a chronic and relapsing course, and may present challenges
in their management. There have been many attempts to streamline the approach and
management of people with Bipolar Disorders, in order to improve outcomes. Several
National and International organizations have published clinical guidelines ranging from
consensus of expert opinions to evidence-based ones. CANMAT is a non-profit educational
and research academic organization with a long history in the development of evidencebased guidelines. Following a major new edition of the CANMAT Guidelines in 2005, there
have been frequent updates every few years with the more recent versions published
in collaboration with the International Society for Bipolar Disorders (ISBD). The latest
update was published in Bipolar Disorders in 2013. The objective of this symposium is to
review the pros and cons of guidelines, examine the ways to make them more clinician
friendly in order to increase the uptake of evidence based management, and review latest
guidelines on management of patients with and without co-morbidities.
Chairpersons: L. Yatham (Canada) 121

J.S. Yoon (Korea) 122
15:30
FROM EVIDENCE TO TREATMENT GUIDELINES FOR BIPOLAR

DISORDER: A BRIDGE TOO FAR?
123
R.Milev, K.N.Founoulakis (Greece)

16:00
CANMAT/ISBD GUIDELINES FOR BIPOLAR DISORDER:

A CONSTANT EVOLUTION - 2013 UPDATE
124
R.Milev (Canada)
16:30
MANAGEMENT OF COMORBIDITIES IN BIPOLAR DISORDER

PATIENTS - A CANMAT TASK FORCE
R.Milev, A.Schaffer (Canada)
125
61
62

15:30 - 17:00
Hall B

UNIQUE FEATURES OF BIPOLAR DISORDER IN OLDER ADULTS
This symposium reflects the ongoing work of the ISBD Taskforce on bipolar disorders in
older adults. The taskforce highlights those aspects of bipolar disorder that are unique to
later life including late age of onset, medical and neurological comorbidities, cognition,
and risk of dementia. The study of older adults presents the opportunity to identify
subtypes and to learn more about the long term clinical course and neurobiological
pathways central to bipolar disorder in mixed age patients. In this symposium, we will
present data on ethnic and racial differences in medical comorbidities which are so
prevalent in late-life mania, the relative risk of dementia and the double-edged sword
of lithium therapy in older adults where toxicity and neuroprotection are both important
considerations.
Chairpersons: K. Shulman (Canada) 126

H.Y. Jung (Korea) 127
15:30
BIPOLAR DISORDER IN OLD AGE AND THE RISK OF DEMENTIA
128
L.Vedel Kessing (Denmark)

16:00
SIMILARITIES AND DIFFERENCES IN MEDICAL MORBIDITY

BETWEEN EASTERN AND WESTERN OLDER BIPOLAR PATIENTS
129
S.Tsai, K.H.Chung, S.H.Huang, P.H.Chen (Taiwan)

16:30
RISKS AND BENEFITS OF LITHIUM CARBONATE IN OLD AGE

K.Shulman (Canada)
130

15:30 - 17:00
Hall C

DIET, EXERCISE, AND WEIGHT: MODIFIABLE DRIVERS OF DISEASE SEVERITY
AND PROGRESSION IN PEOPLE WITH MOOD DISORDERS?
The last half-century has seen profound changes in dietary composition, physical activity, and
rates of obesity in the Western world. Over that time, there has been a marked increase in the
consumption of sugar-, fat-, and energy-dense foods, and a reduced intake of high-nutrient
foods such as vegetables and fruits. Modern conveniences, the built environment, and new
forms of recreation mean that people are far less physically active than previously. Currently,
similar changes are happening in developing countries with growing middle classes, making
this a truly global problem. As a result, worldwide obesity rates are skyrocketing. The World
Health Organization has estimated that by 2015, 1.6 billion adults will be overweight, and an
additional 700 million will be obese, and that, for the first time in human history, mortality
attributable to obesity will outweigh that from malnutrition. As prevalent as these problems
are in the general population, they disproportionately affect people with mood disorders, and
their rise has coincided with a marked increase in the prevalence of mood illnesses. People
with bipolar disorder (BD) are two-thirds again more likely to be obese than people without
the illness. This symposium will provide an in-depth review of a number of relevant topics
including 1) patterns of food intake, exercise, and obesity in people with mood disorders; 2)
evidence that diet, physical activity, and weight are intimately related to important clinical
outcomes, including the amount of time spent with mood symptoms, response rates to
pharmacotherapy, inter-episode cognitive abilities, and overall psychosocial functioning;
and 3) ground-breaking evidence that their impact on these outcomes is mediated by diet-,
exercise- and obesity-related changes in neurobiological illness severity and progression.
Particular attention will be paid to 1) the partly overlapping and partly distinct effects
of nutrition, physical activity, and weight on key biological pathways implicated in mood
illnesses, including inflammatory processes, synaptic plasticity, oxidative stress, and the
impact of adipokines on brain structure and function; and 2) evidence that intervening to
improve diet, increase physical activity, and reverse weight gain positively impacts on clinical
and neurobiological outcomes in people with major depressive disorder and bipolar disorder.
Chairpersons: D. Bond (Canada) 131

Y.C. Park (Korea) 132
15:30
DIET AND NUTRITION: NEW OPPORTUNITIES FOR THE

PREVENTION AND TREATMENT OF MOOD AND ANXIETY
DISORDERS ACROSS THE LIFECOURSE
133
F.Jacka (Australia)
16:00
EXERCISE TREATMENT FOR MOOD DISORDERS:

A NEUROBIOLOGICAL RATIONALE
134
M.Alsuwaidan (Kuwait)
16:30
THE IMPACT OF OBESITY ON CLINICAL AND NEUROBIOLOGICAL

DISEASE PROGRESSION IN BIPOLAR DISORDER
D.J.Bond (Canada)
135
63
64

15:30 - 17:00
Hall D

CROSSING BORDERS IN COGNITIVE ASSESSMENT OF BIPOLAR DISORDERS
Assessing cognitive functioning in bipolar disorders has become one of the crucial
steps for establishing prognosis and maximizing functional outcome and treatment
response, particularly, but not only, in cases of late onset that can resemble other
neurological disorders, such as dementias and Alzheimers Disease. Proper comorbidity
among the aforementioned conditions, moreover, is not so infrequent to encounter in
clinical practice. The present session is, therefore, specifically aimed to examine in
detail prevalence, crossing borders, overlaps and peculiarities, as well as comorbidity
patterns of bipolar disorder, dementias and Alzheimers Disease, after having provided
a preliminary overview of main cognitive and neuroimaging findings related to bipolar
disorders. Specific attention to genetic markers, functional neuroimaging data and
implications for treatment will be paid by distinguished speakers with well-established
expertise in these specific fields.
Chairpersons: C. Altamura (Italy) 136

T. Ketter (USA) 137
15:30
NEUROIMAGING AND COGNITIVE IMPAIRMENT IN BIPOLAR

DISORDERS
138
P.Brambilla (Italy)
16:00
DIFFERENTIAL DIAGNOSIS AND COMORBIDITY BETWEEN

FRONTOTEMPORAL DEMENTIA AND BIPOLAR DISORDER
139
S. Elio (Italy)
16:30
HOW CAN PHARMACOLOGICAL TREATMENT IMPROVE

COGNITION IN MAJOR PSYCHOSES
140
T.Sumiyoshi (Japan)
17:00 - 18:30
Poster Area
POSTER SESSION I
18:00 - 19:00
ISBD GENERAL MEMBERSHIP MEETING
For members only
Hall F
SCIENTIFIC
PROGRAM
Thursday, March 20, 2014
66
SCIENTIFIC PROGRAM THURSDAY, MARCH 20, 2014
SCIENTIFIC PROGRAM
THURSDAY, MARCH 20, 2014
7:00 - 8:30
Hall C
NEW PSYCHOSOCIAL TREATMENTS FOR BIPOLAR DISORDER
Pharmacotherapy is the first line of treatment for patients with bipolar disorder. However,
these treatments fail to bring most patients to sustained remission. Thus, despite advances
in the pharmacologic treatment of bipolar disorder, it is clear that additional strategies
are needed to provide patients with longer-term mood stability. The past two decades
have witnessed the development of a number of psychosocial strategies for BP applied
adjunctive to ongoing pharmacotherapy. This includes Interpersonal and Social Rhythm
Therapy (IPSRT), Family-Focused Therapy (FFT) and cognitive behavioral approaches
(CBT). Overall, these psychotherapies have documented efficacy for improving medication
adherence, speeding up recovery from depressive episodes, reducing residual mood
symptoms and improving psychosocial functioning. However, recent studies suggest these
treatments are not consistently successful at preventing mood episode relapses, especially
for patients with severe symptoms or a high number of previous episodes (Scott et al.,
2006; Scott, Colom, & Vieta, 2007; Meyer & Hautzinger, 2012). Thus, there exists a need for
adjunctive psychosocial interventions adapted for individuals who are less likely to benefit
from existing interventions. This symposium focuses on the second wave of psychosocial
treatments that have been designed for special subgroups of patients with bipolar disorder
to better address their specific needs. We will present three new treatment approaches:
(1) Cognitive remediation for bipolar disorder, (2) mindfulness-based cognitive therapy for
bipolar disorder, and (3) an internet-based self-help program (MoodSwings.net.au). Amy
Peters and Thilo Deckersbach, PhD will present a cognitive rehabilitation approach to for
patients with bipolar disorder with cognitive and work functioning difficulties. They will also
present a new mindfulness-based cognitive therapy developed for bipolar disorder with
preliminary efficacy for patients with particularly severe bipolar disorder. The incorporation
of psychosocial interventions into routine management plans is often confounded by cost
and access constraints among individuals with bipolar disorder. Michael Berk, MD, PhD,
will present an internet-adaptation of a validated, face-to-face group based psychosocial
intervention for bipolar disorder. For each of these treatments we will present an overview
of the treatment, critical treatment elements and how they are implemented for patients
with bipolar disorder. In addition, preliminary feasibility and efficacy data for these new
approaches will be presented as a basis for the discussion.
Chairperson: T. Deckersbach (USA) 141
7:00
COGNITIVE REMEDIATION AND MINDFULNESS-BASED

COGNITIVE THERAPY FOR BIPOLAR DISORDER
142
A.Peters, L.G.Sylvia, A.A.Nierenberg, N.Hansen, J.P.Stange,

A.D.Peckham, T.Deckersbach (USA)
7:45
A RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY OF

MOODSWINGS.NET.AU: AN INTERNET BASED SELF-HELP
PROGRAM FOR BIPOLAR DISORDER
143
S.Lauder, A.Chester, D.Castle, S.Dodd, E.Gilddon, L.Berk,

J.Chamberlain, B.Klein, M.Gilbert, D.Austin, M.Berk (Australia)
7:00 - 8:30
Hall D
HOW TO MANAGE BIPOLAR DISORDER IN PREGNANCY AND POSTPARTUM DISORDER
Treatment of women with bipolar disorder during pregnancy and in the postpartum
period is a major challenge. Decisions must be made about whether or not to take
psychiatric medication while pregnant and/or breastfeeding. It is important to weigh the
risks for the mother and the (unborn) child with or without medication. Especially the
postpartum period is associated with an increased risk for the onset or exacerbation
of bipolar disorder and maternal death.Pregnant women and their partners have to
face uncertainties about the course of the bipolar disorder during pregnancy and the
postpartum period and uncertainties of the effect of the bipolar disorder en when
used, medication, on their baby.When is medication necessary and if necessary, what
medication should we give?
Chairperson: B. Geerling (The Netherlands) 144
7:00
WEIGHING THE RISKS
145
A.Stevens, B.Geerling, W.Bobo (The Netherlands)

7:45
MEDICATION DURING PREGNANCY AND BREASTFEEDING

W.Bobo, A.Stevens, B.Geerling (USA)
146
67
68

7:00 - 8:30
Hall F
STAGING AND PROFILING BIPOLAR DISORDER:
CONCEPTUAL AND CLINICAL APPROACHES
Staging of psychiatric disorders is an evolving area that will add dimensional aspects
to the current classification, leading to a better understanding of pathophysiology and
treatment response. Several approached have been suggested for staging bipolar
disorders, focussing more on illness progression or on interepisodic functioning. Bipolar
disorder seems to progress in portion with the number of episodes in some bipolar
patients. Thus, preventing episodes may be a means to avoid progression from early stage
BD into more refractory and severe late-stage BD. Recent evidence suggests that apart
from number of episodes, the level of funtioning during euthymia may have important
clinical use. Next to defining the stage of illness progression, an individual profile of
protective versus harmful factors may have prognostic value and help to choose effective
interventions and avoid treatment reistance. The aim of this brain storm is to help
investigators to establish a common language in terms of staging in order to plan future
prospective studies.
Chairperson: R. Kupka (The Netherlands) 147
7:00
STAGING AND PROFILING: COMPLEMENTARY APPROACHES TO

IMPROVE TREATMENT
148
F.Kapczinski (Brazil)
7:45
CLINICAL PROFILING AND STAGING

R.Kupka (The Netherlands)
149

8:30 - 10:00
Hall A

THE CHALLENGE OF DESIGNING CLINICAL TRIALS: AN ISBD TASK FORCE REPORT
Bipolar disorder presents special challenges for researchers who conduct clinical
trials. Because of the complexity of the disorder with multiple domains of symptoms
(e.g. depression, mania, anxiety, psychosis) along with a chronic cycling course and
polypharmacy, studies of interventions that inform clinical care have inherent strengths
and limitations. Researchers must decide on who is most appropriate for the study using
inclusion and exclusion criteria while trying to maximize generalizability, the duration of the
study, and whether or not to include active comparators or placebo. Depending on the goals
of the study, researchers must choose an efficacy or effectiveness study. This symposium
will discuss the benefits and risks of different research designs of clinical trials.
Chairpersons: A. Nierenberg (USA) 150

C.H. Kim (Korea) 151
8:30
LONG-TERM TREATMENT OF MOOD DISORDERS: FOLLOWUP OF ACUTE TREATMENT PHASE STUDIES VERSUS
CONTINUATION AND MAINTENANCE PHASE STUDIES, AND
ENRICHED VERSUS NON-ENRICHED DESIGNS
152
W.Nolen, H.Grunze (The Netherlands)

9:00
QUALITATIVE ANALYSES OF PATIENT EXPERIENCES IN

CLINICAL TRIALS: A NAIL BITING ADVENTURE
153
M.Berk (Australia)
9:30
COMPARATIVE EFFECTIVENESS DESIGNS FOR BIPOLAR

DISORDER: SIGNAL OR NOISE?
A.Nierenberg (USA)
154
69
70

8:30 - 10:00
Hall B

NEUROENDOCRINE CHALLENGES AND GENDER DIFFERENCES IN BIPOLAR DISORDER:
AN ISBD TASK FORCE REPORT
Metabolic syndrome is a cluster of interrelated metabolic dysfunctions which pose risk
for the development of diabetes and cardiovascular disease. The prevalence of metabolic
syndrome is 30igher in bipolar patients compared to general population. Among several
risk factors of metabolic syndrome, hyperlipidemia is a pronounced feature in mood
disorders. Although some psychotropic drugs are known to cause an increase in serum
lipid concentrations, a possible and primary link between dyslipidemia, insulin resistance
and the mood disorder itself still remains to be elucidated. Among the wide range of
biological and lifestyle related risk factors for the development of metabolic syndrome
in mood disorders, specifically bipolar disorders, those that are related to HPA/HPG
axis function are of critical importance. Disturbances of thyroid metabolism are known
to cause mood and cognitive symptoms even in patients without underlying psychiatric
disorders. Some thyroid disorders are present more frequently in females including
those with unipolar depression and with rapid cycling bipolar disorder, and females with
bipolar disorder respond better to thyroid hormone therapy than do males. In patients
with mood disorders, the added burden of abnormal thyroid function as well as metabolic
dysfunctions including those related to dyslipidemia and altered insulin resistance may
have significant consequences that impact the course of illness, treatment selection
and response, and the clinical monitoring requirements. In this symposia, data on lipid
profiles and metabolic syndrome parameters of both treated and untreated depressed
as well as euthymic bipolar patients will be presented. Inter-relation between these
parameters and clinical features, specifically from treatment and gender difference point
of view will be discussed. In addition to this, gender differences in thyroid system function
in adults that are particularly relevant to the diagnosis and treatment of bipolar disorder
will be reviewed. Taken together, the pathogenesis of bipolar disorder from the HPA/HPG/
HPT axis window will be brought to the attention of the audience.
Chairpersons: A. Ozerdem (Turkey) 155

G. Malhi (Australia) 156
8:30
NEUROENDOCRINE AND METABOLIC CONTRIBUTIONS TO

SEX-SPECIFIC PRESENTATIONS OF BIPOLAR DISORDER
157
N.Rasgon (USA)
9:00
GENDER VULNERABILITY FOR ADVERSE LIPID PROFILE IN

BIPOLAR DISORDER
158
A.Ozerdem (Turkey)
9:30
GENDER DIFFERENCES IN THYROID SYSTEM FUNCTION:

RELEVANCE TO MOOD DISORDER AND ITS TREATMENT
M.Bauer (Germany)
159

8:30 - 10:00
Hall C

INVESTIGATIONS OF BIPOLAR DISORDERS WITH THE FOREFRONT
NEUROPHYSIOLOGUCAL METHODS
Recent development of electrophysiological investigation includes neural oscillation,
auditory steady state response, and feedback-related negativity with the use of multiplechannel EEG or magnetoencephalography (MEG). In this symposium, three speakers, as
following, present forefront data of electrophysiological investigations which explore
cognition, reward learning, and furthermore neurocircuitry in the cortex structures in
bipolar disorders. These studies will deepen our understanding of neuronal basis of bipolar
disorders. Also, these indices may be useful in differentiation between bipolar disorders
and schizophrenia. Onitsuka et al. will show that in bipolar disorders abnormal neural
oscillation measured by MEG may contribute to disturbances of cognitive and affective
integration. In addition, an auditory steady state response (ASSR) in bipolar disorder is
reduced in power and phase locking factors. These studies suggest that GABA inhibitory
interneuronal activity in bipolar disorder is disturbed. Chang JS et al. will show that
euthymic patients with BD I showed altered coordination between frontal alpha oscillation
and neurocardiac activity. They speculate that the neuronal networks linking frontal
activity to autonomic tone may be intact but their interactions are less efficient in patients
with BD I, especially when under stress. Ryu V, in the probabilistic reward task, observed
the reduced acquisition of the response bias toward rich rewarded stimuli and showed
attenuated feedback-related negativity in the early phase of the task compared to controls.
In ultimatum game, euthymic and manic patients rejected more than controls for unfair
offers and showed larger (more negative) FRN amplitude than controls for unfair offers.
Chairpersons: S. Kanba (Japan) 160

S.H. Lee (Korea) 161
8:30
INTEGRATIVE ASSESSMENT OF NEURAL OSCILLATION AND

CARDIAC AUTONOMIC REGULATION IN BIPOLAR PATIENTS
162
J.S.Chang, K.Ha, T.Ha (Korea)

9:00
ALTERED REWARD-RELATED NEUROPHYSIOLOGICAL

PROCESSING IN PATIENTS WITH BIPOLAR I DISORDER
163
V.RYU (Korea)
9:30
AUDITORY STEADY STATE RESPONSE AND GAMMA

OSCILLATION MEASURED BY MEG INBIPOLAR DISORDERS
T.Onitsuka (Japan)
164
71
72

8:30 - 10:00
Hall D

STRUCTURAL, FUNCTIONAL AND NEURORECEPTOR IMAGING IN AFFECTIVE DISORDERS
This symposium will provide new data using brain imaging technique in searaching
biomarkers and exploring neurocircuitry in bipolar disorder and major depression.
Dr. Ha from Korea, the first speaker, will present his study to differentiate bipolar I and
II disorders using structural and functional MRI. Dr. Li, the second speaker from Taiwan,
combined use of PET and MRI data obtained from patient with bipolar I and his unaffected
siblings and normals to characterize their brain features focusing on the abnormal
fronto-amygdala circuitry. The third speaker Dr. Yang from Taiwan used neuroreceptor
SPECT imaging to illustrate dopamine transporter and serotonin transporter by Trodate
and ADAM ligand separately in different kinds of depressed patients. These new data will
inspire new thinking on the possible mechanisms of mood disorders.
Chairpersons: T. Su (Taiwan) 165

K.Y. Mak (Hong Kong, China) 166
8:30
SIMILARITIES AND DIFFERENCES IN BRAIN IMAGING FINDINGS

BETWEEN BIPOLAR I AND II DISORDER
167
T.H.Ha, J.S.Kim, J.Y.Her, J.S.Chang, K.Ha (Korea)

9:00
ABNORMAL FRONTO-AMYGDALA CIRCUITRY IN BIPOLAR I

DISORDERS AND THEIR UNAFFECTED SIBLINGS: A COMBINED
RESTING-STATE FUNCTIONAL MRI AND PET STUDY
168
C.T.Li, T.P.Su, P.C.Tu (Taiwan)

9:30
MOLECULAR NEUROIMAGING STUDIES WITH DOPAMINERGIC

AND SEROTONINERGIC SYSTEMS IN MOOD DISORDER
Y.K.Yang (Taiwan)
169

8:30 - 10:00
Hall F
SYMPOSIUM SESSION - CULTURAL:

SOCIO-CULTURAL CHALLENGES IN THE MANAGEMENT OF BIPOLAR DISORDER
The current symposium will present new data from studies regarding patients with
bipolar disorder in ethnic minorities and immigrants from the USA and Norway. In
addition the first data from the ISBD transcultural task force ongoing research project will
be presented. In this study experts in bipolar disorders from more than 20 ISBD countries
have shared their insights into how bipolar disorder is managed in their particular
country, culture or part of the world. The purpose of the Symposium is to engage the
audience in a dialogue about culture, ethnicity and the practice of medicine related to
bipolar patients and how this might be helpful in providing more effective healthcare.
Chairpersons: P. Mitchell (Australia) 170

T.Y. Hwang (Korea) 171
8:30
CULTURAL INFLUENCES ON ASSESSMENT, DIAGNOSIS,

AND TREATMENT OF BIPOLAR DISORDER IN THE USA
172
E.Youngstrom, M.M.Jenkins, J.K.Youngstrom (USA)

9:00
COMPARING CLINICAL CHARACTERISTICS AND OUTCOME

MEASURES IN A NATURALISTIC COHORT STUDY OF
IMMIGRANT AND NON-IMMIGRANT BIPOLAR PATIENTS IN NORWAY 173
K.J.Oedegaard, L.Mellesdal, R.Gjestad, C.H.Oedegaard,
O.B.Fasmer (Norway)
9:30
SOCIO- CULTURAL CHALLENGES IN THE MANAGEMENT OF

BIPOLAR DISORDER: A TRANS- CULTURAL STUDY BY THE
INTERNATIONAL SOCIETY OF BIPOLAR DISORDERS
K.J.Oedegaard, C.H.Oedegaard, M.Berk, L.Berk, K.M.Moland,
O.B.Fasmer (Norway)
10:00 - 10:30
COFFEE BREAK
174
73
74

10:30 - 12:00
Hall A
KEYNOTE LECTURE
Chairpersons: L. Yatham (Canada) 175

S.H. Kim (Korea) 176
10:30
NOVEL THERAPIES: TRANSLATION, VALIDATION AND

IMPLEMENTATION
177
M. Berk (Australia)
11:15
CLINICAL STAGING IN BIPOLAR DISORDER
178
F.Kapczinski (Brazil)
12:00 - 13:30
12:00 - 13:30
LUNCH BREAK
Hall A

13:30 - 15:00
Hall B

NEW MEDICAL TREATMENTS TARGETING COGNITIVE DYSFUNTION IN BIPOLAR DISORDER
Bipolar disorder is associated with trait-related impairment of cognitive function in up to
50% of patients and this may be a key mediator of patients psychosocial and occupational
dysfunction. However, only few studies have investigated possible pharmacological
treatments targeting cognitive dysfunction. Purpose: This session will aim to highlight and
discuss pharmacological interventions with the potential to enhance cognitive function in
bipolar patients with cognitive deficits. We will also outline the challenges in conducting
cognitive trials in this heterogeneous sample and make preliminary recommendations
for optimising future study design (e.g. how to deal with mood changes, concomitant
medications etc.).Content: Methodological issues around study design will be discussed
and three different pharmacological treatment targets will be presented. In the context
of a recently published cognitive enhancement trial using the dopamine D2/D3 agonist,
pramipexole, in bipolar patients, Dr. Burdick will present several pitfalls and challenges
illustrated with concrete examples. Dr Miskowiak will describe novel results from a study
evaluating the effect of Erythropoietin (Epo) on cognition, a study that included 44 bipolar
patients in an 8-week, double blind, randomised design. Finally, Dr. Berk will focus on a
RCT of lithium compared to quetiapine in the progression of cognition after first episode
mania. Importance: New pharmacological treatment strategies are of major importance
for advancing the current treatment of bipolar disorder to improve patients prognosis.
The field appears to be moving rapidly in this direction and this session will represent a
timely summary of the findings to date.
Chairpersons: M. Vinberg (Denmark) 179

K.S. Oh (Korea) 180
13:30
METHODOLOGICAL CHALLENGES FOR COGNITIVE TRIALS IN

BIPOLAR DISORDER: LESSONS LEARNED
181
K.E.Burdick, R.J.Braga, A.K.Malhotra (USA)

14:00
RECOMBINANT HUMAN ERYTHROPOIETIN TO TARGET

COGNITIVE DYSFUNCTION IN BIPOLAR DISORDER:
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED
PHASE 2 TRIAL
182
M.Kamilla (Denmark)
14:30
A RCT OF LITHIUM COMPARED TO QUETIAPINE IN THE

PROGRESSION OF COGNITION AFTER FIRST EPISODE MANIA
M.Berk (Australia)
183
75
76

13:30 - 15:00
Hall C

METABOLIC SYNDROME AND BIPOLAR DISORDER
High prevalence rate of metabolic syndrome (MetS) in Bipolar disorder (BD) has
been recognized, but the prevalence of MetS across BP subtypes, the associated
inflammatory reaction, and clinical outcomes were less investigated. Furthermore,
genetic predisposition for MetS in those with BD has been suggested. Preclinical studies
suggested that the circadian system can regulate gene transcription in glucose and lipid
metabolism pathways and deletion of clock genes is associated with dysregulation of
inflammatory cytokines. But clinical studies among BD patients are relatively limited.
In this symposium, Prof. Chen will report a 12-week prospective study of 56 drugnave bipolar II patients, the prevalence of MetS increased from 7*o 109Repeated
measurements showed that the changes in metabolic indexes were not significant,
with the exceptions of BMI, waist circumference, and buttock circumference. But the
interaction between the improvement of hypomanic symptoms and BMI change was
significant. Then Prof. Bai will report the comparison of pro-inflammatory cytokines
among 130 patients with BD, 149 patients with depressive disorder and 130 age and
gender matched normal controls. After adjusting the medical comorbidity and BMI,
the BD patients had significantly higher levels of pro-inflammatory cytokines than the
patients with depressive disorder. The prevalence of MetS among the BD patients was
29.49The patients with MetS were noted with more previous hospitalizations, more
first mood episode with mania, more clinical side effects (extrapyrimal side effects
and tardive dyskinesia), poorer global functioning and social function, poorer insight,
more impairment of executive function by WCST, and higher levels of pro-inflammatory
cytokines. Finally, Professor Eun Young Kim will reported the standardized prevalence
ratio (95I) of MetS in patients with BD was 1.54 (1.052.03) and 1.98 (1.362.60) in Korea,
compared with general population, based on the criteria of ATPIII and IDF, respectively.
They assessed the association of several genetic polymorphisms, related with the
circadian system, with MetS risk in patients with BD. Period (Per2/Per3) genes were
associated with levels of serum HDL cholesterols. Albumin D-element binding protein
(Dbp), clock-controlled output genes, and casein kinase 1 epsilon (CSNK1E) gene were
associated with waist circumference and the number of metabolic syndrome diagnostic
criteria. Furthermore, the Akt/GSK-3 genes were significantly associated with metabolic
parameters in BD patients. They suggested the utility of circadian rhythm genes as a novel
candidate genetic marker for metabolic risk in patients with bipolar disorder.
Chairpersons: Y.S. Kim (Korea) 184

Y.M. Mok (Singapore) 185
13:30
THE PREVALENCE OF METABOLIC SYNDROME IN DRUG-NAVE

BIPOLAR II DISORDER PATIENTS
186
P.Chen, R.Lu, Y.Yang (Taiwan)

14:00
METABOLIC SYNDROME, INFLAMMATORY CYTOKINES, COGNITIVE

FUNCTION AND CLINICAL OUTCOMES IN BIPOLAR DISORDER
187
Y.M.Bai (Taiwan)
14:30
ASSOCIATION BETWEEN CIRCARDIAN RHYTHM GENES AND

METABOLIC SYNDROME IN PATIENTS WITH BIPOLAR DISORDER
E.Y.Kim, Y.M.Ahn (Korea)
188
77
78

13:30 - 15:00
Hall D

BIPOLAR DISORDER AND NEUROINFLAMMATION: WHAT CAN WE SEE?
The pathophysiology of bipolar disorder (BD) is complex. Both genetic and environmental
factors likely interact to predispose to the disorder, but the specific nature of the
gene-environment interactions shaping the neurobiology of BD remains unclear. The
monocyte-T-cell theory of mood disorders considers an activated inflammatory
response system to be a driving force behind mood disorders. In BD this hypothesis
is supported by many studies showing altered concentrations of immune-related
peripheral biomarkers, specifically elevated levels of pro-inflammatory cytokines,
aberrant expression of pro-inflammatory genes, alterations in the kynurenine pathway,
and immune modulating effect of several psychotropic drugs found to be effective in
BD. Several recent studies have examined the relationship between peripheral immune
markers and neuroimaging-derived measures of brain structure and brain function in the
context of BD. The first speaker will detail the relationship between serum concentrations
of kynurenine-pathway metabolites and gray matter volume of the hippocampus and
amygdala in healthy controls and unmedicated subjects with mood disorders. The
second speaker will present the association of cytokines with the serotonin transporter
in different brain regions in patients with BD-I in euthymic state. The third speaker
will present the results of a [11C]PK11195 PET study measuring microglia activation in
naturalistic treated euthymic BD-I patients compared to healthy controls.
Chairpersons: W. Nolen (The Netherlands) 189

Y. Chou (Taiwan) 190
8:30
NEUROPROTECTIVE AND NEUROTOXIC KYNURENINE PATHWAY

METABOLITES ARE ASSOCIATED WITH HIPPOCAMPAL AND
AMYGDALAR VOLUMES IN DEPRESSION
191
J.Savitz, W.C.Drevets, T.A.Victor, J.Bodurka, T.K.Teague, R.Dantzer (USA)

9:00
INTERACTION OF CYTOKINES AND SEROTONIN TRANSPORTER

IN BIPOLAR I DISORDER
192
Y.Chou (Taiwan)
9:30
NEUROINFLAMMATION IN BIPOLAR DISORDER? AN [11C]

PK11195 PET STUDY IN EUTHYMIC PATIENTS
B.Haarman, J.Doorduin, R.F.Riemersma - van der Lek,
T.E.Zandstra, H.A.Drexhage, W.A.Nolen (The Netherlands)
193

13:30 - 15:00
Hall F

IDENTIFYING MOOD DISORDER AND CORRELATES IN YOUTH FROM DIFFERENT CULTURES
This symposium investigates similarities and differences in the assessment and expression
of pathological mood among youth in the US and Korea.Recent epidemiological and clinical
studies have drawn attention to the prevalence of serious mood disorders worldwide.
Although pediatric mood disorders can cause significant impairment, it often takes many
years before an accurate mood disorder diagnosis is made, leading to a worse prognosis
over time.Research into the evidence-based assessment of mood disorders, and into risk
factors related to psychopathology, aims to improve early identification and intervention.
Pediatric bipolar disorder (PBD) has been a controversial diagnosis. Though there are tools
that reliably distinguish PBD from other childhood disorders in American youth, not all work
equally well. Even less is known about how these tools perform in other cultures, where
semantic differences and variability in the subjective experience of mood could render even
well-established methods ineffective.This symposium examines the discriminative validity of
parent, child, and teacher checklists for assessing PBD in the US, and compares these results
to effect sizes from a Korean youth sample (Youngstrom et al.). Next, we will compare youth
and parent report on a diagnostic checklist for PBD, elaborating on the different validity of
parent report in the Korean sample (Kim et al.). Finally, we will investigate the prevalence of
traits associated with PBD among American and Korean college students, and assess the
relation between these measurable risk factors and negative outcomes including suicidal
ideation, self-injury, and suicide attempt (Van Meter et al.).
Chairpersons: S.C. Cho (Korea) 194

E. Youngstrom (USA) 195
13:30
ADOLESCENTS-PARENTS AGREEMENT ON MOOD SYMPTOMS

IN KOREAN ADOLESCENTS
196
H.W.Kim, H.J.Lee, Y.Joo, E.A.Youngstrom, S.Y.Yum (Korea)

14:00
TEMPERAMENT AND BIS-BAS: CROSS-CULTURAL INDICATORS

OF SUICIDALITY AND SELF-INJURY IN YOUNG ADULTS
197
A.Van Meter, J.Genzlinger, E.A.Youngstrom (USA)

14:30
BENCHMARKING KOREAN DATA AGAINST A META-ANALYSIS

OF THE DISCRIMINATIVE VALIDITY OF CAREGIVER, TEACHER,
AND YOUTH CHECKLISTS FOR ASSESSING PEDIATRIC BIPOLAR
DISORDER
E.Youngstrom, A.Van Meter, J.Genzlinger, G.Egerton, C.Sowder,
E.McKinney, H.W.Kim (USA)
15:00 - 15:30
COFFEE BREAK
198
79
80

15:30 - 17:00
Hall A
SYMPOSIUM SESSION - TREATMENT: PREDICTORS AND MODERATORS OF

PSYCHOSOCIAL TREATMENT OUTCOME FOR BIPOLAR DEPRESSION: RESULTS
FROM THE SYSTEMATIC TREATMENT ENHANCEMENT PROGRAM FOR BIPOLAR
DISORDER (STEP-BD)
Bipolar disorder is characterized by recurrent manic and/or depressive episodes that
affect approximately 5.7 million (2.6adult Americans. Pharmacotherapy is the first
line of treatment, but unfortunately, these treatments fail to bring many patients with
bipolar disorder to sustained symptomatic and functional remission. Empirically tested
adjunctive psychosocial treatments for bipolar disorder have demonstrated efficacy
for increasing medication adherence, preventing relapse, enhancing family functioning
and shortening the length of depressive episodes. Yet, despite these advancements,
many individuals with bipolar disorder continue to show impairments in psychosocial
functioning and overall quality of life. Clinically, depression is the biggest unresolved
problem for patients with bipolar disorder both in terms of recurrence as well as
response to pharmacotherapy or psychosocial treatment. This symposium focuses on
moderators of response to psychosocial treatment for acute depression in patients with
bipolar disorder using data from the Systematic Enhancement Program for Bipolar
Disorder (STEP-BD). STEP-BD is the largest multi-site longitudinal study of bipolar
disorder to date, enrolling 4361 participants across 21 sites. Embedded within STEPBD was a randomized controlled trial of psychotherapy for bipolar depression (n=293
patients) comparing intensive psychotherapy (cognitive-behavior therapy [CBT], familyfocused therapy [FFT], or interpersonal and social rhythm therapy [IPSRT]) with a
brief intervention drawing on the most common psychosocial strategies shown to offer
benefit for bipolar disorder (collaborative care). Overall, results indicated that adjunctive
intensive psychotherapy was more beneficial in achieving and reducing time to recovery
from a depressive episode than collaborative care. No differences were found among
the 3 intensive psychosocial treatments in their capacity to aid and sustain recovery. In
this symposium we will review predictors and moderators of treatment response for
this STEP-BD randomized controlled trial. Andrew Nierenberg, MD will provide a brief
overview of the STEP-BD study and present findings that patients with anxiety disorders
benefit more from psychotherapy for depression than patients without anxiety disorders.
Amy Peters will review the role of age of onset, chronicity (previous mood episodes), and
illness duration in predicting and moderating treatment response. David Miklowitz, PhD
will provide new findings on the role of extreme attributions as a predictor of response
to psychotherapy and transition to mania after a depressive episode. The talks will be
integrated and discussed by Thilo Deckersbach, PhD.
Chairpersons: T. Deckersbach (USA) 199

M.S. Lee (Korea) 200
15:30
CO-MORBID ANXIETY MODERATES PSYCHOSOCIAL TREATMENT

OUTCOME FOR BIPOLAR DEPRESSION
201
A.Nierenberg, N.Hansen, A.Peters, L.G.Sylvia, P.V.Magalhaes,

M.Berk, M.Otto, D.Miklowitz, E.Frank, T.Deckersbach (USA)
16:00
AGE OF ONSET, COURSE OF ILLNESS, AND RESPONSE TO

PSYCHOTHERAPY FOR BIPOLAR DEPRESSION
202
A.Peters, L.G.Sylvia, P.V.Magalhaes, D.Miklowitz, E.Frank,

M.Otto, M.Berk, A.Nierenberg, T.Deckersbach (USA)
16:30
EXTREME ATTRIBUTIONS PREDICT THE COURSE OF BIPOLAR

DISORDER FOLLOWING PSYCHOTHERAPY TREATMENT FOR
DEPRESSION
D.Miklowitz, J.Stange, L.G.Sylvia, P.V.Magalhaes, M.Otto,
E.Frank, A.Peters, M.Berk, A.Nierenberg, T.Deckersbach (Australia)
203
81
82

15:30 - 17:00
Hall B

SUICIDE IN BIPOLAR DISORDER: AN ISBD TASK FORCE REPORT
Objectives: Bipolar disorder (BD) is associated with an elevated risk of suicide and
suicide attempts. The goals of the International Society for Bipolar Disorders Task Force
on Suicide were to identify and quantity the risks, characteristics, and neurobiological
correlates of suicide and suicide attempts in BD, and to examine treatment interventions
for suicide prevention in this patient population. Methods: The task force was comprised
of 21 international experts in the areas of BD and/or suicide. Four working groups
were organized to focus on: 1) Prevalence and characterization of suicide and suicide
attempts in BD; 2) Risk stratification to identify high risk groups; 3) Neurobiological
aspects of suicide in BD, and 4) Clinical interventions for suicide prevention in BD. Each
working group completed a comprehensive literature review of papers published since
1980 on suicide or suicide attempts in BD among people age 15 or older, and metaanalyses were conducted for variables with sufficient data. Results: A summary of the
key findings from three of these groups will be presented in this symposium. Most of
the literature to date has focused on suicide attempts rather than completed suicide in
BD, yet there are several large recent studies of suicide in BD that have found high rates
compared to other psychiatric conditions. There are numerous studies that have focused
on identifying high risk BD groups, based on sex, age of illness onset, polarity of 1st
episode, polarity of recent episode, psychosis, substance use, anxiety, personality, bipolar
subtype, and family history. Meta-analyses confirmed the associations of a number of
these sociodemographic and clinical variables. Conclusions: There is a growing body of
literature that provides key insights into the rates of suicide and suicide attempts in BD
and is beginning to replicate data on specific high risk groups. There is a paucity of data
on neurobiology of suicide specific to BD or on effective diagnosis-specific treatment
interventions. Impact: Understanding the current state of knowledge on suicide and
suicide attempts in BD can inform clinical, research, and educational needs in this critical,
but understudied area.
Chairpersons: A. Schaffer (Canada) 204

Y. Lee (Korea) 205
15:30
PREVALENCE AND CHARACTERISTICS OF SUICIDE IN BIPOLAR

DISORDER
206
D.Moreno (Brazil)
16:00
FACTORS THAT INFLUENCE THE RISK OF SUICIDE ATTEMPTS

OR SUICIDE IN BIPOLAR DISORDER
207
A.Schaffer (Canada)
16:30
CLINICAL INTERVENTIONS FOR SUICIDE PREVENTION IN

BIPOLAR DISORDER
L.Yatham (Canada)
208

15:30 - 17:00
Hall C

GLUTAMATERGIC SYSTEM IN BIPOLAR DISORDERS:
FROM ETIOLOGY TO TREATMENT
Glutamate (Glu) is the most abundant neurotransmitter in the brain and glutamatergic
neurotransmission plays a key role in brain function. Abnormalities in glutamatergic
neurotransmission are also implicated in mood disorders. Neuroimaging studies
indicated an elevated glutamine/glutamate ratio (Gln/Glu) in bipolar mania and with
antidepressant treatment in bipolar depression, and a reduced Gln/Glu in major
depression. In line with the findings from neuroimaging studies, genetic studies
supported the importance of glutamate metabolism in mood and psychotic disorders. It
was reported that variation in GLS1 (the gene encoding the brain isoform of glutaminase,
which catalyzes Gln-to-Glu conversion) is associated with Gln/Glu measured in vivo in
two brain regions. These findings suggest that genetic variation in a key component of
glutamatergic machinery is associated with a putative in vivo index of glutamatergic
neurotransmission. Genetic findings also led to the development of novel therapeutic
agents that modulate the glutamate system. For instance, the NMDA antagonist ketamine
is effective not only in unipolar but also bipolar depression and lithium has been shown
to increase the synaptic uptake of glutamate possibly the mechanism responsible for
its neuroprotective effect. Recently, methylene blue (MB) which is known to inhibit nitric
oxide synthase, one of downstream targets of glutamate signaling, was found to have a
robust effect on symptoms of depression and anxiety among thirty-seven bipolar patients
in a study by Alda and colleagues. Under the lights of these evidence role of glutamate in
bipolar disorders(BD) from etiology to treatment will be discussed. Firstly, Dr. ngr will
overview neuroimaging studies of glutamate in BD and later on Dr. Altinbas will present
the data from genetic studies on glutamate in BD. Lastly, Dr. Alda will discuss the current
and future upcoming glutamatergic treatments.
Chairpersons: K. Altinbas (Turkey) 209

J. Rybakowski (Poland) 210
15:30
NEUROIMAGING STUDIES OF GLUTAMATE ABNORMALITIES IN

BIPOLAR DISORDER
211
D.Ongur (USA)
16:00
GENETICS OF GLUTAMATERGIC SYSTEM IN BIPOLAR DISORDERS
212
K.Altinbas (Turkey)
16:30
GLUTAMATE AND TREATMENT OF BIPOLAR DISORDER

M.Alda (Canada)
213
83
84

15:30 - 17:00
Hall D
SAMUEL GERSHON AWARD:

AWARD WINNERS ORAL PRESENTATIONS
The International Society for Bipolar Disorders (ISBD) recognizes the vital role of
developing the next generation of leaders in the field of bipolar disorders and will offer
4 awards for original research publication submissions. In order to promote research
interest in bipolar disorders in developing countries, two of the awards will be reserved
for those from low and middle-income countries, as defined by the 2013 World Bank
Classification. The award recipients will present their abstracts in this session.
Chairperson: G. Malhi (Australia) 214
15:30
EXOME SEQUENCING IN BIPOLAR DISORDER: FAMILY

AND CASE-CONTROL RESULTS IMPLICATE A SET OF TEN
INTERACTING GENES
215
F.Goes, J.Parla, M.Pirooznia, M.Kramer, P.Zandi,

W.R.McCombie, J.Potash (USA)
15:50
EARLY SIGNS OF ANOMALOUS NEURAL FUNCTIONAL

CONNECTIVITY IN HEALTHY OFFSPRING OF PARENTS WITH
BIPOLAR DISORDER
216
M.Singh, K.D.Chang, R.G.Kelley, M.Saggar, A.Reiss, I.H.Gotlib (USA)

16:10
KETAMINE MODULATES BEHAVIORAL AND NEUROCHEMICAL

ALTERATIONS INDUCED BY STRESS:NOVEL EVIDENCE FOR
TREATMENT OF MOOD DISORDERS
217
G.Reus, M.P.Nacif, H.Abelaira, F.Dal Pizzol, E.Streck, J.Quevedo (Brazil)

16:30
LATE-ONSET MANIA: WHITE MATTER INTEGRITY AND

COGNITIVE IMPLICATIONS.
J.Ramrez-Bermdez, C.Berlanga, A.Guadamuz,
O.Marrufo-Melendez, P.Alvarado, C.Atriano, R.Favila,
J.Taboada, R.Carrillo-Meza (Mexico)
218

15:30 - 17:00
Hall F

CULTURAL ISSUES AND BIPOLAR DISORDER IN CHINA
Bipolar Diagnosis and Management in Chinese Context
Chairpersons: Z. Jingping (China) 219

S.J. Kim (Korea) 220
15:30
BIPOLARITY INDEX AS AN ASSESSMENT INSTRUMENT IN THE

DIAGNOSIS AND ONE YEAR OUTCOME OF BIPOLAR DISORDERS
221
X.Yu, Y.Ma, T.Si, J.I.N.G.Li, Z.Liu, G.A.N.G.Wang, J.I.N.G.Sun,

Y.I.R.U.Fang, H.Yang, Y.Zhang, X.Wang, S.Gary (China)
16:00
MICROAARAY-BASED ANALYSIS OF MICRO-RIBONUCLEIC ACID

EXPRESSION IN AN ANIMAL MODEL OF MANIA
222
H.Rong, T.B.Liu, H.C.Yang, J.Zhang, H.Z.Yang, J.Q.Bi, Q.J.Shen (China)

16:30
CHARACTERISTICS OF UNRECOGNIZED BIPOLAR DISORDER

IN PATIENTS TREATED FOR MAJOR DEPRESSIVE DISORDER IN
CHINA: GENERAL VS. PSYCHIATRIC HOSPITALS
223
G.Wang, Y.Xiang, F.Chen (China)

17:00 - 18:30
POSTER SESSION II
Poster Area
85
86
SCIENTIFIC
PROGRAM
Friday, March 21, 2014
88
SCIENTIFIC PROGRAM FRIDAY, MARCH 21, 2014
SCIENTIFIC PROGRAM
FRIDAY, MARCH 21, 2014
7:00 - 8:30
Hall D
TRANSCRANIAL MAGNETIC STIMULATION BIOMARKER AND
THERAPEUTIC STUIDES IN BIPOLAR DISORDER
This session will review current investigations employing transcranial magnetic
stimulation (TMS) to study the neurophysiology of psychiatric illnesses and its application
as a treatment modality. There is a critical need for biomarkers in bipolar disorder to
assist with early identification, treatment selection, and monitoring illness progression.
Further, bipolar depression is a devastating condition with suboptimal treatments.
Brain stimulation modalities such as TMS may play a role in addressing biomarker
development and providing additional treatment options. Work with bipolar disorder
is nascent, but presenters will focus on existing literature as a basis for interactive
discussions. This dialogue will explore options for integrating TMS into future research
protocols and clinical practice for patients with bipolar disorders. TMS non-invasively
stimulates cortical neurons with rapidly oscillating magnetic fields which thereby induce
electrical currents in the brain. Three types of delivery include single-pulse, pairedpulse, and repetitive stimulation (rTMS). Protocols often combine TMS stimulation with
electromyography (EMG), electroencephalography (EEG), or neuroimaging to study brain
functions. For example, existing paradigms examine motor evoked potentials or cortical
oscillations as indirect measures of gamma-aminobutyric acid (GABA) and glutamatergic
functioning. Prior rTMS research has examined its effects in the treatment of anxiety
disorders, mood disorders, and psychotic disorders. Dr. Chae will give an overview of
rTMS and discuss its applications in depression and anxiety disorders. Dr. Daskalakis
will discuss prior neurophysiologic research and potential future directions in bipolar
disorder. Ongoing rTMS work targeting working memory deficits in schizophrenia will
serve as one model of how meaningful research and clinical applications could address
neurocognitive deficits in bipolar disorder. The session chair, Dr. Croarkin has prior
experience in TMS research with special populations such as children and adolescents.
This will be integrated into the ongoing dialogue of the session to examine opportunities
across the lifespan. The presenters will maximize opportunities for interactive
discussions with attendees, with the goal of forming effective international collaborations
that will maximize the clinical and research applications of TMS for bipolar disorders.
Chairperson: P. Croarkin (USA) 224
7:00
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION

TREATMENT STUDIES IN DEPRESSION AND ANXIETY DISORDERS
225
J.H.Chae (Korea)
7:45
TRANSCRANIAL MAGNETIC STIMULATION AS A

NEUROPHYSIOLOGIC AND THERAPEUTIC TOOL IN BIPOLAR
DISORDERS
Z.J.Daskalakis (Canada)
226

7:00 - 8:30
Hall F
STIGMA AS PERCEIVED BY PATIENTS WITH BIPOLAR DISORDER.
CULTURAL DIFFERENCES BETWEEN THE NETHERLANDS AND JAPAN
An unfortunate reality is that nine out of ten patients with mental illnesses experience
stigmatization. Often a distinction is made between us, the normal people and them,
the people with mental illnesses. In literature, different types of stigma are described.
Public stigma is the negative reaction that the general population has to people with
mental illness. Self-stigma is when a patient internalize public stigma and experience
diminished self-esteem and self-efficacy Structural stigma is when the policies of private
and governmental institutions intentionally restrict the opportunities of people with
mental illness. And associative stigma is when stigmatization not only affects people
with mental illnesses, but their families as well. The effects of stigma on patients with
mental illnesses are; diminished self-esteem and self-efficacy; isolation from others;
not taking part in everyday activities; difficulties in finding or holding a job; avoid seeking
help because they fear being labeled as crazy, dangerous, unreliable, or even contagious
and negative health outcomes. Beside these personal effects, stigmatization causes
financial burden on families and society. Culture shapes how individuals perceive and
respond to others with mental illness. Studies have suggested that Asians and Asian
Americans typically endorse greater stigma of mental illness compared to Westerners
(White Europeans and Americans).In this brainstorm session we will give an overview
of the different kinds of stigma perceived by patients with a bipolar disorder from The
Netherlands and from Japan. We interviewed patients to collect their stories on how they
encounter stigmatization, how it affects them, and how they coped with it. We will discuss
with the audience which strategies they know and use to help their patients dealing with
the consequences of perceived stigma or self-stigma. We will give an overview of facts
that might have influenced the general populations attitudes towards people with mental
illnesses. We will give examples of anti-stigma campaigns from Westerners and Asian
countries and discuss with the audience if they think these campaigns could be carried out
in their home country or why they could not.
Chairperson: A. Stevens (The Netherlands) 227
7:00
HOW DO PATIENTS WITH BIPOLAR DISORDER IN THE

NETHERLANDS PERCEIVE STIGMATIZATION
228
P.Goossens (The Netherlands)

7:45
HOW ATTITUDES OF THE GENERAL POPULATION AND A

CULTURAL PERSPECTIVE AFFECT LIVES OF THE PEOPLE WITH
BIPOLAR DISORDER IN JAPAN
Y.Omori (Japan)
229
89
90

8:30 - 10:00
Hall A
SYMPOSIUM SESSION - ADVOCACY:

THE FUTURE CARE OF BIPOLAR DISORDER: TRIALOGICAL APPROACHES
Outcome criteria for the treatment of patients with bipolar disorder has changed in the
last couple of decades. While immediate treatment response to pharmacotherapy was
the main focus, good quality of life and psychosocial functioning, as well as absence of
cognitive disturbances, are now important goals for remission and recovery for both the
patients and their relatives. Bifocal psychoeducation, for example, tries to establish more
shared decision-making within the doctor-patient relationship. This approach attempted
to actively integrate patients and relatives in the treatment process in order to reach
the goals in a joint process. However, experiences have revealed that organizational
forms of a trialogical approach improve effectiveness on all levels in balancing the
relationships between professionals, patients and relatives. Furthermore, integration of
the patient and relative into developing guidelines or research programs produce even
more efficacy. Anti- stigma campaigns and public education contribute to the trialogical
approach. Ultimately, these initiatives will change the atmosphere between patients with
bipolar disorder and the mental health system in which their services are rendered. This
symposium will present trialogical approaches and perspectives from Germany as well as
from the US.
Chairpersons: M. Bauer (Germany) 230

L. Vedel Kessing (Denmark) 231
8:30
THE TRIALOGICAL GERMAN ASSOCIATION FOR BIPOLAR

DISORDER AND ITS DEVELOPMENT OF NATIONAL TREATMENT
GUIDELINES
232
M.Bauer (Germany)
9:00
LIVING TRIALOGUE AS A PATIENTS SPEAKER
233
M.K.Kolbe (Switzerland)
9:30
ADVOCACY AS PART OF THE TREATMENT PLAN

M.Walker (USA)
234

8:30 - 10:00
Hall B

BIPOLAR DEPRESSION: PHENOMENOLOGY, BRAIN IMAGING AND PREDICTORS
OF TREATMENT RESPONSE
Bipolar depression is a topic arousing considerable controversy, particularly with
regard to its recognition and treatment. This symposium will address three main areas:
phenomenology / clinical recognition; brain imaging; and predictors of response to
treatment. Recent phenomenological data from Australia and China will be presented,
focusing on the distinctions between bipolar and unipolar depression, and bipolar I and
bipolar II depression. Data on using factor analyses to identify potential predictors of
response to pharmacological treatment in bipolar depression will be outlined. fMRI data
from China on bipolar depression will also be discussed.Furthermore, recent US MR
spectroscopy data will address the issue of understanding drug mechanism of action.
The resonance frequency of several metabolites on the 1H-MRS spectrum can be reliably
quantified and can be used to probe drug mechanism of action in bipolar disorder. This
presentation will review key clinical treatment intervention studies evaluating change in
N-acetylaspartate (NAA), glutamate / glutamine, choline and myoinositol focusing on how
MR imaging can delineate either therapeutic drug mechanism of action or disease burden
of illness.
Chairperson: P. Mitchell (Australia) 235
8:30
PHENOMENOLOGY OF BIPOLAR I AND II DEPRESSION

COMPARED TO UNIPOLAR DEPRESSION, AND PREDICTORS OF
RESPONSE TO TREATMENT.
236
P.Mitchell, A.Frankland, G.Roberts (Australia)

9:00
ON THE FEATURES OF BIPOLAR COMPARED TO UNIPOLAR

DEPRESSION IN CHINA
237
T.Si (China)
9:30
MR SPECTROSCOPY TO STUDY DRUG MECHANISM OF ACTION

IN BIPOLAR DISORDER
M.Frye (USA)
238
91
92

8:30 - 10:00
Hall C

INFLAMMATORY MARKERS AND NEW THERAPEUTIC CHALLENGE IN BIPOLAR DISORDER
Bipolar disorder has been reconceptualized as a multisystem disease associated with
mood, cognitive, metabolic, immunomodulatory, and autonomic dysfunctions. However,
there are currently no biological tests that differentiate patients with bipolar disorder
from major depression or schizophrenia. Accordingly, recent studies have focused on the
identification of biomarkers related to the pathophysiological mechanisms underlying
the development, clinical presentation, and course of bipolar disorder. The existing
evidence suggests that a single biomarker will not be able to cover the biological and
clinical complexity of bipolar disorder. Alternatively, a composite of biomarkers, including
inflammatory parameters, neurotrophic factors, and oxidative stress molecules, may be
promising to identify altered mood states and neuroprogression in bipolar disorder. It
is well known that the involvement of immune system dysfunction is possibly related to
disease activity. However, results in individual studies remain inconsistent and clinical
studies examining longitudinal changes within individuals are recommended. Vitamin
D receptors and vitamin D metabolizing enzymes are present in the central nervous
system. Calcitriol (the active vitamin D hormone) affects numerous neurotransmitters
and neurotrophic factors, relevant for mental disorders. In the case of depressive
disorders, considerable evidence supports a role of suboptimal vitamin D levels.
Therefore, repurposed drugs, which are approved for other medical conditions, represent
an underutilized therapeutic resource for patients who have not responded to moodstabilizing drugs. Treatment outcome of bipolar disorder may be improved by additional
use of certain nutraceuticals with conventional pharmacotherapies. Biomarker studies
should also be carried out to identify subgroups of patients who do respond to these
drugs. This symposium will focus on the current evidence in these areas, particularly
inflammatory marker, and providing a critical look at use of neutraceuticals to provide a
new perspective for treatment of bipolar disorder. Three speakers topics will cover: (1)
the various alternations of inflammatory markers in bipolar depression and mania from
acute episode to full remission compared with healthy controls, (2) vitamin D deficiency
or insufficiency in bipolar disorder as schizophrenia and major depression compared to
healthy controls, and (3) the potentiality of biologically active form of folate correcting
mood stabilizer-associated functional folate deficiency and aiding in improving treatment
outcomes, particularly bipolar depression.
Chairpersons: A. Nierenberg (USA) 239

F. Kapczinski (Brazil) 240
8:30
THE DIFFERENCE IN ALTERED INFLAMMATORY MARKERS

THROUGHOUT ACUTE EPISODE BETWEEN BIPOLAR MANIA
AND DEPRESSION
241
S. Tsai, K.H. Chung, S.H. Huang, P.H. Chen (Taiwan)

9:00
ONE CARBON METABOLISM AND BIPOLAR DISORDER
242
J.H.Baek, E.E.Bernstein, A.A.Nierenberg (USA)

9:30
VITAMIN D DEFICIENCY IN BIPOLAR DISORDER

B.Cha (Korea)
243

8:30 - 10:00
Hall F

ORAL COMMUNICATIONS
Chairpersons: Y. Chou (Taiwan) 244

P. Udomratn (Thailand) 245

CORRELATION OF SERUM BDNF LEVEL WITH CLINICAL SYMPTOM

DOMAINS IN BIPOLAR DISORDER-I
246
B.Chatterjee, R.Sagar, S.Vivekanandan, A.Sahu (India)

SIMILARITIES AND DIFFERENCES IN BRAIN IMAGING FINDINGS

BETWEEN BIPOLAR I AND II DISORDERS
247
T.Ha, J.Kim, J.Her, J.Chang, K.Ha (Korea)

SURVEY OF THE PSYCHOTROPIC DRUGS IN OUTPATIENTS WITH

BIPOLAR DISORDER IN JAPAN: PRELIMINARY CROSS-SECTIONAL STUDY
248
T.Hashimoto, M.Koseki, D.Sakurai, T.Hasegawa, N.Kanahara,

I.Masaomi (Japan)

DIAGNOSTIC STABILITY AND INTERCHANGE OF SCHIZOPHRENIC AND

BIPOLAR DISORDERS
249
S.K.Lin, Y.N.Hung, S.Y.Yang (Taiwan)

THOUGHT DISORDER IN MANIC PATIENTS: WHERES THE IMPAIRMENT?

D.Raucher-Chn, S.Terrien, F.Gierski, S.Caillies,
C.Besche-Richard, A.Kaladjian (France)
10:00 - 10:30
COFFEE BREAK
250
93
94

10:30 - 12:00
Hall A
KEYNOTE LECTURE
Chairpersons: M. Sanchez de Carmona (Mexico) 251

K. Ha (Korea) 252
10:30
PSYCHOEDUCATION AND OTHER PSYCHOLOGICAL

INTERVENTIONS: CLASS EFFECT OR SPECIFIC TREATMENT
MODALITIES?
253
F. Colom (Spain)
11:15
GRASSROOTS ADVOCACY; HOPE, RESOURCES, SUPPORT
254
M.Walker (USA)
12:00 - 13:30
12:00 - 13:30
LUNCH BREAK
Hall A

13:30 - 15:00
Hall A
SYMPOSIUM SESSION - ADVOCACY:

SELF-MANAGEMENT IN BIPOLAR DISORDER
The dynamic and continuous process of self-monitoring and regulation of symptoms,
treatment, and life style changes inherent in living with a chronic disease is called
self-management. Teaching patients and informal caregivers to recognize and respond
to signs of recurrence is a goal in todays treatment. Although self-management is a
desirable outcome of patient education, studies have found a varying success rates. No
figures predict a sustainable long-term positive effect on health. During this symposium
we will explore the concept of self-management from different perspectives. Firstly
results of a phenomenological study of clinical experiences and tacit knowledge of
patients, caregivers and professionals about self-management strategies will be
presented. Secondly we will discussed specific challenges of self-management during
pregnancy and in the postpartum period where there is an increased risk for recurrence
and maternal death. It is important to give the woman and her partner tools to manage
this period in such a way that they can manage problems that they will probably face.
Psycho education and the development of a specific pregnancy related relapse prevention
plan for the different periods will be discussed. Thirdly the development and testing of
Care Indicator will be presented. Care Indicator is an E-Health tool that monitors the
mental disposition of a patient based on observations of the patient, the professional
caregiver and a support group. If there are critical changes in the mental state of the
patient, Care Indicator gives a signal to the patient, the professional caregiver and
(selected) members of the support group.
Chairpersons: P. Goossens (The Netherlands) 255

M. Walker (USA) 256
13:30
TRIANGULATING PERSPECTIVES ON SELF-MANAGEMENT

OF BIPOLAR DISORDER: A PHENOMENOLOGICAL STUDY OF
PATIENTS, CAREGIVERS AND PROFESSIONALS
257
S. Van den Heuvel, P. Goossens, C.Terlouw,

T.Van Achterberg (The Netherlands)
14:00
SELFMANAGEMENT IN PREGNANCY AND POSTPARTUM PERIOD
258
A.Stevens, S.Van de Heuvel, P. Goossens, B.Geerling (The Netherlands)

14:30
CAREINDICATOR, A SELF-MANAGEMENT E-TOOL FOR EARLY

SIGNALING AND INTERVENTION IN BIPOLAR DISORDER
B.Geerling, P. Goossens, A. Stevens,
S. Van den Heuvel (The Netherlands)
259
95
96

13:30 - 15:00
Hall B

DIFFERENT ASPECTS OF MIXED DEPRESSION
Placement of mixed features specifier in the case of major depression in the latest version
of diagnostic and statistical manual for mental disorders (DSM 5) has the potential of
revitalizing the already existing challenge on the mixed phenomenon. The controverises
related to the pathophysological and clinical properties of the mixed states in the broad
sense reflect on the treatment practice,in particular, use of antidepressants, treatment
response, , occurrence of manic switch and transition from unipolar (UP) to bipolar
disorders (BD). Gender is one of the factors that is considered to impact the clinical
representation of depression. Most of the studies on mixed depression indicated that it
is more common among females. Syndromes arising from sudden dopamine depletion
such as neuroleptic dysphoria or withdrawal syndromes from dopaminergic drugs, bear
remarkable clinical similarities with mixed depression. These syndromes are subject to
further research and may thus provide a model for the pathophysiology of mixed states.
Based on the paucity of data on the etiopathogenesis a better comprehension of the
biological basis of mixed phenomenology is needed. In this symposia, the first speaker
will review the current data on mixed depression and present the interpretations for
the clinical practice. The second speaker will present a data driven discussion on the
influence of gender on the representation of mixed features in depression. Lastly, the
third speaker will argue a novel etiological hypothesis for mixed depression.
Chairpersons: K. Altinbas (Turkey) 260

M. Frye (USA) 261
13:30
UNIPOLAR VERSUS BIPOLAR MIXED DEPRESSION:

INTERPRETATIONS FOR THE CLINICAL PRACTICE
262
K.Altinbas (Turkey)
14:30
DOPAMINE DYSREGULATION AS A NEUROBIOLOGICAL

HYPOTHESIS FOR MIXED DEPRESSION
263
D.Quiroz, S.Strejilevich (Chile)

14:00
FEMALE GENDER AND THE CO-OCCURING MANIC SYMPTOMS

IN DEPRESSION
A.Ozerdem (Turkey)
264

13:30 - 15:00
Hall C

GENETIC STUDIES ON BIPOLAR DISORDERS
In this session, I invited 3 speakers, from mainland China, Taiwan, and Korea, to introduce
their researches and findings that focus on the genetic studies of mechanism and etiology
in bipolar disorders.
Chairperson: Y. Fang (China) 265
13:30
ASSOCIATION STUDY OF 43 CANDIDATE GENES WITH BIPOLAR

I AND II DISORDER IN THE KOREAN POPULATION
266
S.Ryu, I.Huh, J.Baek, E.Cho, T.Park, J.Kim, K.Lee, K.Ha, K.Hong (Korea)
14:30
BRAIN-DERIVED NEUROTROPHIC FACTOR LEVELS PREDICT

BIPOLAR DISORDERS IN THEIR FIRST DEPRESSIVE EPISODE:
RESULT OF A LONGITUDINAL STUDY
267
C.Zhang, Z.Li, Y.Fang (China)

14:00
GENETIC PROFILES IN DISTINGUISHING BIPOLAR SUBTYPE I

AND II DISORDER
268
P. Kuo, C.f. Kao, H.c. Chen, Y.h. Chiu, M.c. Huang, R.b. Lu (Taiwain)
13:30 - 15:00
Hall F
RAPID COMMUNICATION SESSION: ORAL COMMUNICATIONS

Chairperson: M.C.M. Wong (Hong Kong, China) 269

NEUROPSYCHOLOGICAL PERFORMANCE IN PATIENTS WITH SOFT

BIPOLAR SPECTRUM DURING A MAJOR DEPRESSIVE EPISODE
270
K.Lin, G.Xu, W.Lu, H.Ouyang, Y.Dang, K.So, T.Lee (Hong Kong China)

BIPOLARITY INDEX AS AN ASSESSMENT INSTRUMENT IN THE

DIAGNOSIS AND ONE YEAR OUTCOME OF BIPOLAR DISORDERS
271
Y.Ma, X.I.N.Yu, T.Si, J.I.N.G.Li, Z.Liu, G.A.N.G.Wang, J.I.N.G.Sun,

Y.I.R.U.Fang, H.Yang, Y.Zhang, X.Wang, S.Gary (China)

COMPARING COGNITIVE DEFICITS IN PATIENT WITH SOFT BIPOLAR

DISORDER WITH THOSE WITH BIPOLAR I DISORDER
G.Xu, W.Lu, H.Ouyang, Y.Dang, Y.Guo, K.Lin (China)
272
97
98

13:30 - 16:30
Hall D
KOREAN ADVOCACY MEETING (IN KOREAN)

Chairperson: K. Ha (Korea) 273
13:30
INTRODUCTION
274
K. Ha (Korea)
13:50
SHARING EXPERIENCE: LIVING WITH BIPOLAR DISORDER
14:30
BIPOLAR DISORDER: AN OVERVIEW
275
Y.H. Joo (Korea)

15:00
HOW TO TREAT BIPOLAR DISORDER: UPDATE
276
H.S. Cho (Korea)

15:30
MANAGEMENT OF EVERYDAY LIFE OF BIPOLAR PATIENTS
277
H.J. Lee (Korea)

16:00
HOW TO HELP BIPOLAR PATIENTS: CAREGIVERS

UNDERSTANDING AND ROLE
S. Oh (Korea)
278
REGIONAL
POSTER
SESSION
Tuesday, March 18, 2014
100
REGIONAL POSTER SESSION TUESDAY, MARCH 18, 2014
BOARD N
15:00 - 15:30
Poster Area
REGIONAL POSTER SESSION

P-001
OLANZAPINE-INDUCED DIABETIC KETOACIDOSIS IN A SAUDI FEMALE
279
H.Al Amri (Saudi Arabia)

P-002
THE ASSOCIATION BETWEEN THYROID STIMULATING HORMONE

(TSH) AND BRAIN-DERIVED NEUROTROPHIC FACTORS (BDNF) IN
MAJOR DEPRESSIVE DISORDER
280
J.H.Baek, E.S.Kang, M.Fava, D.Mischoulon, B.H.Yu, D.Lee,

H.D.Park, H.J.Jeon (USA)
P-003
NEUROCOGNITIVE IMPAIRMENTS IN INDIVIDUALS AT ULTRA-HIGH

RISK FOR PSYCHOSIS: WHO WILL REALLY CONVERT?
281
M.J.Bang, K.R.Kim, Y.Y.Song, J.Y.Park, S.Y.Baek, E.Lee, S.K.An (Korea)

P-004
STABILITY OF A DIAGNOSIS OF DEPRESSION IN ADMISSIONS TO A

SPECIALIST MOOD DISORDERS UNIT IN SINGAPORE
282
N.Chandwani (Singapore)
P-005
CLINICAL FACTORS ASSOCIATED WITH COMORBID MAJOR

DEPRESSIVE DISORDER IN PATIENTS WITH PANIC DISORDER
283
H.C.Chang, S.W.Lim, K.S.Oh (Korea)

P-006
EFFECTS OF GENETIC VARIATIONS IN NRG1 ON COGNITIVE DOMAINS

IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY SUBJECTS
284
Y.Cho, S.H.Ryu, I.S.Huh, E.Y.Cho, H.J.Oh, Y.S.Lee, T.S.Park,

K.S.Hong (Korea)
P-007
MENTAL DISORDERS IN OFFSPRING OF PARENTS WITH BIPOLAR

DISORDERS IN KOREA
285
Y.Cho, S.Shim, Y.Kwon, H.Lee (Korea)

P-008
A CORRELATIONAL STUDY BETWEEN SOCIAL WITHDRAWAL AND

PSYCHOPATHOLOGY AMONG KOREAN ADOLESCENT
T.Y.Choi, Y.J.Lee (Korea)
286
BOARD N
P-009
RELATIONSHIP BETWEEN EMOTIONAL DISTRESS, HEALTH RELATED

QUALITY OF LIFE, AND GENETIC POLYMORPHISM IN THE KOREAN
HEMODIALYSIS PATIENTS
287
W.J.Choi, J.H.Sohn, H.C.Park, J.H.Seok (Korea)

P-010
IMPROVEMENT IN OBJECTIVE AND SUBJECTIVE NEUROCOGNITIVE

FUNCTION IN MELANCHOLIC AND NON-MELANCHOLIC SUBTYPES
OF MAJOR DEPRESSIVE DISORDER AFTER 12-WEEK SELECTIVE
SEROTONIN REUPTAKE ENHANCER(SSRE; TIANEPTINE) TREATMENT
288
J.Y.Heo, I.K.Yu, B.H.Yu (Korea)

P-011
THE RELATIONS AMONG QUALITY OF LIFE, NEUROCOGNITION AND

PSYCHOPATHOLOGY OF ELDERLY SCHIZOPHRENIA
289
K.K.Hong, J.N.Lee, S.J.Yim, J.M.Kim, E.H.Na (Korea)

P-012
THE EFFECT OF PHYSICAL AND PSYCHO-SOCIAL STRESSORS ON

MOOD CHANGES OF WOMEN REFERRING TO THE HEALTH CLINICS,
SHIRAZ-IRAN
290
I.Jahanbin, G.Yadollahikhales (Iran)

P-013
DIFFERENCES IN DEPRESSIVE SYMPTOMS BETWEEN KOREAN AND

AMERICAN OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
291
H.Jeon, R.S.Walker, A.Inamori, J.P.Hong, M.J.Cho, L.Baer,

A.Clain, M.Fava, D.Mischoulon (Korea)
P-014
KOREAN MEDICATION ALGORITHM PROJECT FOR BIPOLAR DISORDER

2014: RAPID CYCLING
292
J.Jeong, D.I.Jon, J.S.Seo, J.G.Lee, Y.S.Woo, M.D.Kim, I.G.Son,

S.H.Shim, K.J.Min, Y.C.Shin, W.M.Bahk (Korea)
P-015
PREVALENCE STUDY OF SENILE DEMENTIA IN A RURAL AREA OF

MINIA DISTRICT
293
N.Kamal, R.Sadek, M.El Sherif, F.Mosalem (Egypt)

P-016
FUNCTIONAL CONNECTIVITY MRI EVIDENCE OF THE EFFECT OF

A 2-WEEK REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
TREATMENT IN MAJOR DEPRESSION; A DOUBLE-BLIND SHAM
CONTROLLED STUDY
J.I.Kang, H.L.Lee, J.M.Kim, K.Namkoong, E.Lee (Korea)
294
101
102
BOARD N
P-017
CIRCADIAN PREFERENCE AND IMPULSIVITY: HIGH IMPULSIVITY IS

RELATED TO EVENING TYPES
295
J.I.Kang, K.A.Cheon, H.W.Kim, C.I.Park, Y.Y.Nam, S.J.Kim (Korea)

P-018
SIMPLE SNORING SUBJECTS SHOWED MORE PSYCHIATRIC

SYMPTOMS THAN OBSTRUCTIVE SLEEP APNEA PATIENTS
IN SCL-90-R SCALE: PRELIMINARY DATA
296
S.G.Kang, H.J.Lee, K.S.Na, J.M.Kang, S.T.Kim, K.H.Park (Korea)

P-019
METABOLIC DISTURBANCES INDEPENDENT OF BODY MASS IN

PATIENTS WITH SCHIZOPHRENIA TAKING ATYPICAL ANTIPSYCHOTICS
297
S.Kang, J.I.Lee (Korea)

P-020
TYPE OF PSYCHIATRIC WARD ON DEPRESSION PREVALENCE IN

PSYCHIATRIC NURSE WHO WORKS IN RAZI HOSPITAL
298
S.H.Kavari, K.Nourozi (Iran)

P-021
COMPARISON STUDY OF THE PREVALENCE OF DEPRESSION IN

WIDOW ELDERLY WHO LIVE IN NURSING HOME AND THE ELDERLY
REMARRIAGE USE OF DAY CARE
299

P-022
SURVEY OF IMPACT RELIGIOUS PRETENTIOUSENESS AND

HEDONISITIC IN RUNAWAY AND NON - RUNAWAY GRILS IN SHIRAZ
300
S.H.Kavari (Iran)
P-023
ASSESS TO THE EFFECTS OF TAI CHI CHUAN ON REDUCE IN WOMEN

WITH ACUTE STRESS REACTION
301

P-024
SERIOUSNESS OF FIRST SUICIDE ATTEMPTER IS EQUIVALENT AS

MULTIPLE SUICIDE ATTEMPTER: A PRELIMINARY ANALYSIS FROM
KOREA NATIONAL SUICIDE SURVEY IN 2010 AND 2012
302
B.KIM, E.Y.KIM, K.S.HA, Y.M.Ahn (Korea)

P-025
DIAGNOSTIC UTILITY OF QUANTITATIVE EEG IN UN-MEDICATED

SCHIZOPHRENIA
J.Kim (Korea)
303
BOARD N
P-026
THE EFFECT OF ALPHA-LIPOIC ACID ON ATYPICAL ANTIPSYCHOTICS

INDUCED WEIGHT GAIN AND METABOLIC ABNORMALITIES
OF SCHIZOPHRENIA PATIENTS: A DOUBLE-BLIND,
PLACEBO-CONTROLLED, RANDOMIZED TRIAL
304
N.Kim, Y.Song, E.Kim, H.Cho, S.Kim, J.Park (Korea)

P-027
EMOTIONAL DYSREGULATION, ATTRIBUTIONAL BIAS,

NEUROCOGNITIVE IMPAIRMENT IN ULTRA-HIGH RISK FOR
PSYCHOSIS AND SCHIZOPHRENIA: ITS ASSOCIATION WITH PARANOIA
305
N.Kim, Y.Song, J.Park, S.Baek, J.Kang, E.Lee, S.An (Korea)

P-028
THE ASSOCIATION BETWEEN THE COMT VAL158MET POLYMORPHISM

AND ALEXITHYMIA IN OBSESSIVE-COMPULSIVE DISORDER
306
M.J.Koh, J.I.Kang, H.W.Kim, K.Namkoong, S.J.Kim (Korea)

P-029
UPPER AIRWAY RESISTANCE SYNDROME PATIENTS TEND TO BE

MORE NEUROTIC, ANXIOUS AND SENSITIVE THAN OBSTRUCTIVE
SLEEP APNEA SYNDROME
307
S.J.So, H.J.Lee, S.G.Kang, C.H.Cho, H.K.Yoon, K.Y.Jung,

C.S.Han, L.Kim (Korea)
P-030
ASSOCIATION OF THE RORA GENE POLYMORPHISM AND SEASONAL

VARIATIONS IN MOOD AND BEHAVIOR
308
H.I.KIm, S.J.So, H.J.Yang, H.M.Song, J.H.Moon, H.K.Yoon,

S.G.Kang, Y.M.Park, S.H.Lee, H.G.Jeong, L.Kim, H.J.Lee (Korea)
P-031
HIGH ALTITUDE REMAINS ASSOCIATED WITH ELEVATED SUICIDE

RATES AFTER ADJUSTING FOR SOCIOECONOMIC STATUS: A STUDY
FROM SOUTH KOREA
309
J.Kim, N.Choi, Y.J.Lee, H.An, N.Kim, M.S.Lee, E.S.Won, H.J.Lee (Korea)

P-032
ASSOCIATION OF SLEEP IRREGULARITY WITH FIRST-NIGHT EFFECT

IN YOUNG ADULT MALE SUBJECTS
310
D.H.Lee, C.H.Cho, H.K.Yoon, S.G.Kang, S.H.Son, Y.K.Kim,

S.H.Kim, K.N.Bok, E.I.Lee, H.J.Lee, L.Kim (Korea)
P-033
IMPROVEMENT ON DYSLIPIDEMIA AND NEGATIVE SYMPTOMS BY

ZIPRASIDONE AUGMENTATION IN CLOZAPINE-RESISTANT PATIENTS
WITH SCHIZOPHRENIA
H.B.Lee, S.J.Yim, M.Sim (Korea)
311
103
104
BOARD N
P-034
SUBJECTIVE DEPRESSIVE SYMPTOMS AND METABOLIC SYNDROME

IN GENERAL POPULATION
312
S.J.Rhee, E.Y.Kim, S.H.Kim, H.J.Lee, B.Kim, D.H.Yoon, Y.M.Ahn (Korea)

P-035
A STUDY ON CHANGE OF METABOLIC PARAMETERS WITH

ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIC PATIENTS:
12-MONTH PROSPECTIVE NATUALISTIC STUDY
313
I.S.Hwang, J.Lee (Korea)

P-036
RISK FACTOR FOR EXECUTIVE COGNITIVE DYSFUNCTION IN ALCOHOLICS
314
K.S.LEE (Korea)
P-037
COMPARING STRESS PERCEPTION AND LEISURE TYPE PREFERENCE

BETWEEN SMOKING AND NONSMOKING CASINO EMPLOYEES
315
T.LEE, C.K.LEE, H.M.LEE, H.J.Shaffer (Korea)

P-038
THE DIFFERENCES BETWEEN IMPULSIVE SUICIDE ATTEMPTS AND

NON-IMPULSIVE SUICIDE ATTEMPTS
316
M.Lim, S.W.Kim, Y.Y.Nam, E.Moon, J.Yu, S.Lee, J.S.Chang,

J.H.Jhoo, B.Cha, J.S.Choi, J.I.Park (Korea)
P-039
VARIABLES INFLUENCING SUBJECTIVE WELL-BEING IN PATIENTS

WITH SCHIZOPHRENIA
317
J.S.Oh, Y.H.Ko, J.W.Paik, M.S.Lee, C.S.Han, H.G.Jeong, S.H.Kim (Korea)

P-040
CHANGES OF PLASMA CATECHOLAMINE LEVELS AFTER PAROXETINE

TREATMENT IN PANIC DISORDER PATIENTS
318
J.Y.Oh, J.Y.Heo, B.H.Yu (Korea)

P-041
CLINICAL DETERMINANTS AND COGNITIVE EFFECTS OF

ANTIPSYCHOTIC POLYPHARMACY FOR KOREAN PATIENTS WITH
SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
319
J.Choi, S.Kang, J.Lee, Y.Ha, H.Yoon, E.Park, D.Park (Korea)

P-042
A STUDY ON RELIABILITY AND VALIDITY OF THE KOREAN VERSION

OF IMPACT OF FUTURE EVENTS SCALE
E.Park, S.Choi, I.C.Jung (Korea)
320
BOARD N
P-043
NEURAL NETWORKS INVOLVED IN SELF-REFERENTIAL PROCESSING

AND PERSPECTIVE TAKING IN HEALTHY PEOPLE: ITS ASSOCIATION
WITH THEORY OF MIND ABILITY AND ANOMALOUS SELF EXPERIENCE
321
K.Park, H.Y.Park, M.Bang, S.K.An (Korea)

P-044
NEURAL NETWORKS INVOLVED IN SELF-REFERENTIAL PROCESSING

AND PERSPECTIVE TAKING IN HEALTHY PEOPLE: ITS ASSOCIATION
WITH THEORY OF MIND ABILITY AND ANOMALOUS SELF EXPERIENCE
322
K.Park, H.Y.Park, M.Bang, S.K.An (Korea)

P-045
MULTIPLE OSCILLATORS ASSURE SOFT MARGIN OF DIURNAL

FUNCTION AND ARE THE RESULT OF ALTERNATE SPLICING AND
LATER GENETIC REARRANGEMENT: POSSIBLE ROLE IN BIPOLAR DISORDER 323
K.Pirkalani, Z.Talaeerad, H.Bigdeli (Iran)
P-046
BIPOLAR MOOD DISORDER (BMD) IS THE RESULT OF AMBIGUITY

BETWEEN MASTER AND SLAVE CIRCADIAN OSCILLATOR
324
K.Pirkalani, Z.Talaeerad (Iran)

P-047
GENERAL RESULTS OF PERSONALITY SCORES OF BIPOLAR PATIENTS

STUDIED BY MCMI-III DURING INTER-ATTACK PERIODS AND
RELEVANCE TO CLINICAL COURSE
325
K.Pirkalani, Z.Talaeerad, H.Bigdeli, M.Nazari, R.Khodabakhsh

Pirkalani (Iran)
P-048
BIPOLAR MOOD DISORDER BMD CAN BE CLASSIFIED INTO 4-5 BROAD

MOLECULAR CATEGORIES BASED ON PARAMETRIC OSCILLATION
THEORY AND SIGNS AND SYMPTOMS
326
K.Pirkalani, Z.Talaeerad, M.Mehdizadeh, M.Saghaei, M.Nazari (Iran)

P-049
DESCRIPTION OF DEPRESSIONS LEVEL IN STUDENTS OF MEDICAL

FACULTY UNIVERSITY OF MUHAMMADIYAH JAKARTA 2013
327
R.Rifa Imaroh, I.N.G.E.Inge Dackrisna Daud, I.R.F.A.Irfa Irawati (Indonesia)

P-050
PREVALENCE AND CORRELATES OF SUICIDAL BEHAVIOR:

A NATIONWIDE STUDY OF KOREAN MEDICAL STUDENTS
M.Roh, H.Lee, M.J.Cho, B.J.Hahm (Korea)
328
105
106
BOARD N
P-051
SOCIO-DEMOGRAPHIC FACTORS ASSOCIATED WITH THE USE OF

MENTAL HEALTH SERVICES IN DEPRESSED ADULTS: RESULTS FROM
THE KOREA NATIONAL HEALTH AND NUTRITION EXAMINATION
SURVEY (KNHANES)
329
S.Roh, M.Soh, S.J.Park, H.J.Jeon, J.Y.Kim, S.Kim (Korea)

P-052
DIAGNOSING BIPOLAR DISORDER IN SEVERELY INTELLECTUALLY

DISABLED PATIENTS- A CHALLENGE WORTH TAKING!
330
S.Sajith, A.Su (Singapore)

P-053
ASSESSMENT OF RISK TAKING AND IMPULSIVE BEHAVIORS IN

OBSESSIVE-COMPULSIVE DISORDER
331
S.J.Kim, S.Y.Sohn, D.H.Song, H.W.Kim, J.I.Kang, C.I.Park (Korea)

P-054
IMPACT OF HIV/AIDS ON THE ELDERLY:

A CASE STUDY OF CHIRADZULU DISTRICT IN MALAWI
332
A.Sefasi, A.P.Sefasi (Malawi)

P-055
A PILOT STUDY OF THE EFFECTIVENESS OF ISLAMIC COGNITIVE

THERAPY (ICT) THERAPY IN MANAGING DEPRESSION AND
CONTROLLING SMOKING
333
T.Seghatoleslam, H.Habil (Malaysia)

P-056
KOREAN MEDICATION ALGORITHM FOR BIPOLAR DISORDER 2014:

DEPRESSIVE EPISODE
334
J.SEO, W.M.Bahk, J.G.Lee, Y.S.Woo, J.H.Joeng, M.D.Kim,

I.G.Son, Y.J.Min, D.I.Jon, Y.C.Shin, B.H.Yoon (Korea)
P-057
ASSOCIATIONS OF DEPRESSION AND EMOTIONAL EATING IN

BARIATRIC SURGERY PATIENTS
335
G.Sevincer, N.Konuk (Turkey)

P-058
INFLUENCE OF POSITIVE THINKING IN DEPRESSIVE SYMPTOMS IN

E.Shin, K.S.Oh (Korea)
336
BOARD N
P-059
THE RELATIONSHIPS BETWEEN POST-TRAUMATIC STRESS

SYMPTOMS, DEPRESSIVE SYMPTOMS, AND STRESS COPING
STRATEGIES IN CIVIL AFFAIRS OFFICIALS
337
J.A.Kim, M.SIm, K.A.Jeong, D.S.Yong, H.B.Lee, I.Y.Kang,

J.I.Yang, O.J.Kim, Y.R.Lee (Korea)
P-060
THE EFFECTS OF EXPOSURE TO TRAUMATIC EVENTS AND

PERSONALITY DIMENSIONS ON POST-TRAUMATIC STRESS
SYMPTOMS IN POLICE OFFICERS
338
O.J.Kim, M.Sim, J.I.Yang, I.Y.Kang, H.B.Lee, K.A.Jeong, J.A.Kim,

D.S.Yong, Y.R.Lee (Korea)
P-061
SELF-REPORTED EMPATHIC ABILITIES IN SCHIZOPHRENIA AND

ULTRA-HIGH RISK FOR PSYCHOSIS
339
Y.Song, K.Jhung, Y.Nam, S.An (Korea)

P-062
LONG-TERM USE OF RISPERIDONE IN KOREAN CHILDREN AND

ADOLESCENTS WITH AUTISM SPECTRUM DISORDERS
340
E.Won, J.Park, J.Choi, H.Min, Y.Kim (Korea)

P-063
KOREAN MEDICATION ALGORITHM FOR BIPOLAR DISORDER 2014:

MANIC EPISODE
341
Y.S.Woo, W.M.Bahk, D.I.Jon, J.S.Seo, J.G.Lee, J.H.Jeong,

M.D.Kim, I.G.Son, S.H.Shim, K.J.Min, B.H.Yoon, Y.C.Shin (Korea)
P-064
RELATIONS OF SELF-ESTEEM WITH PARANOIA IN HEALTHY

CONTROLS, INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS AND
WITH RECENT ONSET SCHIZOPHRENIA
342
H.Yoon, Y.Y.Song, J.I.Kang, S.K.An (Korea)

P-065
THE RELATION BETWEEN DEPRESSION AND DOODLES

M.Zokaee (Iran)
343
107
108
BOARD N
POSTER
SESSION I
Wednesday, March 19, 2014
110
POSTER SESSION 1 WEDNESDAY, MARCH 19, 2014
BOARD N
17:00 - 18:30
Poster Area
SESSION I
P-001
LATERAL HYPOTHALAMIC KINDLING INDUCES MANIC-LIKE

BEHAVIOR IN RATS: A NOVEL ANIMAL MODEL
344
O.Abulseoud, U.M.Camsari, C.L.Ruby, K.Mohamed,

N.Abdel Gawad, A.Kasabeh, M.Y.Yuksel, D.S.Choi (USA)
P-002
NEUROMODULATION OF THE DLPFC INDUCED BY RTMS ASSESSED

WITH OCULOMOTRICITY AND CORTICAL EXCITABILITY IN BIPOLAR
DISORDER
345
L.Beynel, A.Chauvin, N.Guyader, S.Harquel, T.Bougerol,

C.Marendaz (France)
P-003
SACCADIC INHIBITION - A TRAIT BIOMARKER OF BIPOLAR DISORDER
346
A.Chauvin, N.Guyader, L.Beynel, S.Harquel, B.Fredembach,

T.Bougerol, C.Marendaz, M.Polosan (France)
P-004
EPIGENETIC REGULATION OF EAAT2 (SLC1A2) IN BIPOLAR DISORDER

PATIENTS
347
J.Ayers Ringler, N.Kang, Y.Choi, D.Choi, M.Veldic (USA)

P-005
SERUM MYELIN OLIGODENDROCYTE GLYCOPROTEIN LEVELS ARE

STABLE IN DEPRESSED FEMALES WITH BIPOLAR DISORDER
348
M.Sehmbi, L.Cudney, R.B.Sassi, M.Steiner, B.N.Frey (Canada)

P-006
MOOD AND COGNITION IN BIPOLAR DISORDER - THE ASSOCIATION

WITH GLYCOGEN SYNTHASE KINASE-3 BETA
349
A.S.Jacoby, M.Vinberg, K.Munkholm, L.Kessing (Denmark)

P-007
STRONG EVIDENCE FOR AN ASSOCIATION BETWEEN

ELECTRODERMAL HYPOREACTIVITY AND SUICIDE PROPENSITY IN
BIPOLAR DISORDER
350
W.Kaschka, L.H.Thorell, S.Hodgkinson, J.Steyer, R.Straub,

M.Wolfersdorf, M.Jandl (Germany)
P-008
METABOLIC PARAMETERS IN FIRST EPISODE MANIA

S.Kesebir, E.Tatlidil Yaylaci, N.Atgden, M.Altintas (Turkey)
351
BOARD N
P-009
THYROID FUNCTIONING IN FIRST EPISODE MANIA
352
S.Kesebir, E.Tatlidil Yaylaci, N.Atgden, M.Altintas (Turkey)

P-010
ARE ICAM, VCAM AND E-SELECTIN LEVELS DIFFERENT IN FIRST

MANIC EPISODE AND SUBSEQUENT REMISSION?
353
S.Kesebir, C.Turan (Turkey)

P-011
SEROTONERGIC DYSFUNCTION IN PATIENTS WITH BIPOLAR

DISORDER ASSESSED BY THE LOUDNESS DEPENDENCE OF THE
AUDITORY EVOKED POTENTIAL (LDAEP)
354
S.Lee (Korea)
P-012
INFLUENCE OF AHI1 VARIANTS ON DIAGNOSIS AND TREATMENT

OUTCOME IN MOOD DISORDERS
355
C.Pae, S.Porcelli, B.Balzarro, O.Bianchini, C.Han, S.Lee, S.Lee,

P.S.Masand, A.Serretti (Korea)
P-013
QUANTITATIVE ELECTROENCEPHALOGRAM (QEEG) FINDINGS

SUGGESTING BIPOLARITY IN PATIENTS WITH DEPRESSIVE EPISODE:
A PRELIMINARY REPORT
356
S.Ryu, H.Jeon, B.Lee, Y.Cho, Y.Kim, E.Lee, S.Yoon, K.Hong, B.Yu (Korea)
P-014
LITHIUM AMELIORATES ROTENONE-INDUCED METHYLATION AND

HYDROXYMETHYLATION OF DNA IN CORTICAL PRIMARY NEURONS
357
G.Scola, H.H.Kim, M.Salvador, L.T.Young, A.C.Andreazza (Canada)

P-015
CORRELATION BETWEEN PERIPHERAL BDNF LEVELS AND

HIPPOCAMPUS VOLUME IN CHILDREN AND ADOLESCENTS WITH
BIPOLAR DISORDER
358
T.L.Peruzzolo, M.Anes, G.L.C.L.Motta, L.S.Motta, A.C.Louredo,

J.B.Brun, R.Rodrigues, F.Kapczinski, S.Tramontina, C.P.Zeni (Brazil)
P-016
AMYGDALAR VOLUMETRIC CORRELATES OF SOCIAL ANXIETY IN

BIPOLAR OFFSPRING WITH SUBTHRESHOLD MOOD SYMPTOMS AND
HIGH SOCIAL ANXIETY
359
M.H.Park, A.Garrett, S.Boucher, M.Howe, E.M.Sanders,

J.G.Pearlstein, M.K.Singh, K.D.Chang (USA)
P-017
LAMOTRIGINE TREATMENT OF ADOLESCENTS WITH UNIPOLAR AND

BIPOLAR DEPRESSION: A RETROSPECTIVE CHART REVIEW
S.H.Shon, H.W.Kim, Y.H.Joo, J.S.Lee (Korea)
360
111
112
BOARD N
P-018
CIRCADIAN RHYTHM DISRUPTION IN WOMEN WITH BIPOLAR AND

PREMENSTRUAL DYSPHORIC DISORDER DURING REMISSION:
PRELIMINARY RESULTS
361
S.K.Syan, M.Smith, N.Snelgrove, M.Sehmbi, O.Allega, L.Minuzzi,

B.N.Frey (Canada)
P-019
DOES PREGNANCY AFFECT CIRCADIAN RHYTHMS IN WOMEN WITH

MOOD DISORDERS DURING REMISSION?
362
E.Krawczak, M.Sehmbi, B.N.Frey (Canada)

P-020
IRREGULARITY IN SLEEP AND MEALTIME IN THE PATIENTS WITH

BIPOLAR DISORDERS: A PRELIMINARY STUDY
363
E.Joo, E.Kim, K.Lee, C.W.Yeom (Korea)

P-021
SEASONALITY AND ITS DISTINCT CLINICAL CORRELATES IN BIPOLAR

II DISORDER: A COMPARISON STUDY WITH BIPOLAR I DISORDER AND
364
J.Kim, T.H.Ha, Y.S.Park, J.S.Chang, J.Kim, K.S.Hong, K.S.Ha (Korea)

P-022
CHANGES IN SLEEP ARCHITECTURE AND QUALITY IN MINIMAL

HEPATIC ENCEPHALOPATHY PATIENTS AND RELATIONSHIP TO
PSYCHOLOGICAL DYSFUNCTION
365
C.Liu, J.Zhou (China)

P-023
ULTRA-BRIEF RIGHT UNILATERAL ECT IS RAPIDLY EFFECTIVE IN

AMELIORATING SEVERE MANIA-A CASE SERIES
366
P.Mayur, A.Sidorov, A.Harris (Australia)

P-024
OSTEOPOROSIS: A NEGLECTED MEDICAL CO-MORBIDITY IN MOOD

DISORDERS
367
M.Berk, J.A.Pasco, F.N.Jacka, J.M.Hodge, A.Stuart, A.Torpy,

S.Dodd, L.Williams, Y.Gilbert (Australia)
P-025
CIRCADIAN GENES AND RISK OF THE METABOLIC SYNDROME IN

PATIENT WITH BIPOLAR DISORDERS
368
E.Y.Kim, Y.M.Ahn, S.H.Kim (Korea)

P-026
COULD METABOLIC SYNDROME COMORBIDITY IN BIPOLAR DISORDER

BE OVERRATED?: A STUDY OF METABOLIC SYNDROME IN YOUNG
SUBPOPULATION OF BIPOLAR DISORDER PATIENTS
N.Yalin, O.U.Agdanli, G.Ergr, Z.Tunca, S.Vitoratou, A.Ozerdem (Turkey)
369
BOARD N
P-027
ARE EEG SPECTRAL POWER DENSITY OF BD I AND II DIFFERENT?
370
S.Kesebir, S.Sayaki Grdal, R.M.Demirer (Turkey)

P-028
CANNABIS USE IN FIRST EPISODE BIPOLAR DISORDER IS

ASSOCIATED WITH ELEVATED MOOD AFTER ONE YEAR
371
L.Kvitland, P.A.Ringen, S.R.Aminoff, O.A.Andreassen, C.Demmo,

T.V.Lagerberg, I.S.Melle (Norway)
P-029
CLINICAL AND BIOLOGICAL CHARACTERISATION OF YOUNGPEOPLE

AT HIGH GENETIC RISK FOR BIPOLAR DISORDER
372
P.Mitchell (Australia)
P-030
LONGITUDINAL CHANGE OF THE STATE OF METABOLIC SYNDROME IN

PATIENTS WITH BIPOLAR DISORDER
373
N.Y.Lee, S.H.Kim, Y.S.Kim, Y.M.Ahn (Korea)

P-031
ASSOCIATION OF SERUM BDNF WITH VERBAL AND VISUAL MEMORY

DEFICIT IN SUBJECTS WITH BIPOLAR DISORDER-I
374
B.Chatterjee, A.Sahu, R.Sagar, S.Vivekanandan (India)

P-032
STUDY TO DETERMINE APPROPRIATE TIME FOR SERUM LEVEL

ESTIMATION FOR ONCE A DAY ADMINISTRATION OF DIVALPROEX
SODIUM EXTENDED RELEASE PREPARATIONS
375
S.Damegunta, M.S Reddy (India)

P-033
STUDY TO DETERMINE APPROPRIATE TIME FOR SERUM LEVEL

ESTIMATION FOR ONCE A DAY ADMINISTRATION OF LITHIUM
376
S.Damegunta, M.S Reddy (India)

P-034
ANTIPSYCHOTIC USE AND DIFFERENTIAL MONITORING OF

CARDIOMETABOLIC HEALTH IN PATIENTS WITH BIPOLAR DISORDER
COMPARED TO PATIENTS WITH PRIMARY PSYCHOTIC DISORDERS
377
J.Kamath, R.Singh (USA)

P-035
EFFECT OF MEDITATION ON REDUCE IN GIRLS WITH ACUTE STRESS

REACTION IN TEHRAN MEDITATION SOCIETY IN 2013
378

P-036
MAINTENANCE ECT FOR BIPOLAR DISORDER

O.Koh, H.Habil (Malaysia)
379
113
114
BOARD N
P-037
COMPARISON OF BRAIN WHITE MATTER CONNECTIVITY BETWEEN

PANIC DISORDER WITH AND WITHOUT COMORBID BIPOLAR DISORDER
380
S.Kim, M.K.Kim, B.Kim, S.H.Lee (Korea)

P-038
MIRROR NEURON ACTIVITY AND SYMPTOM DIMENSIONS IN DRUGNAVE MANIA- A TRANSCRANIAL MAGNETIC STIMULATION STUDY
381
R.Basavaraju, U.M.Mehta, J.Thirthalli (India)

P-039
MATERNAL OXYTOCIN TO INDUCE LABOR INCREASES THE RISK FOR

OFFSPRING BIPOLAR DISORDER AND IMPAIRED COGNITION
382
D.Freedman, Y.Bao, L.Shen, C.A.Schaefer, A.S.Brown (USA)

P-040
A GENOME-WIDE ASSOCIATION STUDY OF BIPOLAR DISORDER USING

A SUBPHENOTYPE: SLEEPLESSNESS BIPOLAR MANIA
383
H.Lee, C.Cho, H.Woo, T.Greenwood, D.Kripke, J.Kelsoe (Korea)

P-041
CROSS-DISORDER GWAS OF ADHD AND BIPOLAR DISORDER
384
A.Reif, K.Van Hulzen, C.J.Scholz, A.Arias-Vasquez, K.P.Lesch,

S.V.Faraone, B.Franke (Germany)
P-042
SOCIOECONOMIC DECISION MAKING IN MANIC AND EUTHYMIC

PATIENTS WITH BIPOLAR DISORDER: THE FEEDBACK-RELATED
NEGATIVITY STUDY
385
R.Y.Ha, V.RYU, S.J.Lee, H.S.Ryu, H.S.Cho (Korea)

P-043
ELECTROPHYSIOLOGICAL FINDING OF SYNTACTIC ANOMALIES IN

PATIENTS WITH BIPOLAR DISORDER AND SCHIZOPHRENIA: A P600 STUDY
386
C.W.Lee, V.RYU, R.Y.Ha, S.J.Lee, H.S.Ryu, H.S.Cho (Korea)

P-044
EFFECTS OF ANTIPSYCHOTIC DRUGS ON THE EXPRESSION OF

SYNAPSE-ASSOCIATED PROTEINS IN THE FRONTAL CORTEX OF RATS
SUBJECTED TO IMMOBILIZATION STRESS
387
C.H.Lee, M.K.Seo, H.Y.Cho, J.G.Lee, B.J.Lee, S.W.Park, Y.H.Kim (Korea)

P-045
EFFECTS OF MOOD-STABILIZING DRUGS ON DENDRITIC OUTGROWTH

AND SYNAPTIC PROTEINS LEVELS IN THE PRIMARY HIPPOCAMPAL NEURONS 388
C.H.Lee, M.K.Seo, J.G.Lee, B.J.Lee, S.W.Park, Y.H.Kim (Korea)
BOARD N
P-046
EFFECTS OF TIANEPTINE ON MTOR SIGNALING IN RAT HIPPOCAMPAL

NEURONS
389
M.K.Seo, C.H.Lee, H.Y.Cho, S.W.Park, B.J.Lee, W.G.Seol,

J.G.Lee, H.Y.Kim (Korea)
P-047
DNA METHYLATION ANALYSIS OF QUETIAPINE: POSSIBLE ROLE AS A

MOOD STABILIZER
390
H.Sugawara, M.B.Bundo, T.A.Asai, F.S.Sunaga, J.U.Ueda,

J.I.Ishigooka, K.K.Kasai, T.K.Kato, K.I.Iwamoto (Japan)
P-048
THE EFFECT OF VITAMIN D TREATMENT ON GLIA DERIVED

NEUROTROPHIC FACTOR IN CORTICAL NEURONS
391
S.Yilmazer, T.Ulutin, E.Dursun, D.Gezen-Ak (Turkey)

P-049
NEUROANATOMICAL PREDICTORS OF PSYCHOEDUCATION RESPONSE

IN EUTHYMIC BIPOLAR PATIENTS: A VOXEL-BASED MORPHOMETRIC STUDY 392
P.Favre, M.Baciu, A.Perrin, C.Pichat, T.Bougerol, M.Polosan (France)
P-050
HIPPOCAMPAL VOLUMES ARE CORRELATED TO INFLAMMATORY

MARKERS IN EARLY STAGE BIPOLAR DISORDER
393
M.Vianna-Sulzbach, P.D.Goi, R.Massuda, M.Vasconcelos-Moreno,

B.Panizzutti, G.Colpo, R.Reckziegel, M.Costanzi, B.T.Dos Santos,
M.D.Curra, S.L.Polita, J.A.Duarte, A.L.Teixeira, F.Kapczinski,
C.S.Gama (Brazil)
P-051
REGIONAL GRAY MATTER VOLUME ABNORMALITIES RELATED TO

CYCLOTHYMIA IN FEMALE SUBJECTS WITH BIPOLAR II DISORDER
394
T.H.Ha, J.S.Kim, J.Y.Her, J.H.Kim, J.S.Chang, D.Y.Lee, K.Ha (Korea)

P-052
THE EFFECT OF CORTISOL AND BDNF ON SEROTONIN TRANSPORTER

IN BIPOLAR I DISORDER
395
W.C.Hsieh, Y.T.Jou, J.L.Lin, S.J.Wang, Y.H.Chou (Taiwan)

P-053
NEUROANATOMICAL CORRELATES OF INHIBITED TEMPERAMENT IN

OFFSPRING OF PARENTS WITH BIPOLAR DISORDER
E.J.Kim, A.Garrett, S.Boucher, M.Howe, E.Sanders, A.Reiss,
M.Singh, K.D.Chang (USA)
396
115
116
BOARD N
P-054
REGIONAL GRAY MATTER VOLUME ALTERATIONS RELATED TO

PREDOMINANT POLARITY IN BIPOLAR I DISORDER
397
J.Kim, T.H.Ha, J.Y.Her, J.Kim, J.S.Chang, K.Ha (Korea)

P-055
CORRELATION BETWEEN NEUROFUNCTIONAL AND

NEUROCOGNITIVE PERFORMANCE OF BD I EUTHYMIC PATIENTS
398
C.Lopez Jaramillo, C.Vargas, M.Valencia-Escobar, A.Vanegas,

S.Rascovsky (Colombia)
P-056
THE EFFECTS OF LITHIUM ON BRAIN FUNCTION: PRELIMINARY

NEURAL NETWORK CHANGES
399
G.Curran, P.Das, K.Fritz, G.S.Malhi (Australia)

P-057
BIPOLAR AND BORDERLINE PATIENTS DISPLAY DIFFERENTIAL

PATTERNS OF FUNCTIONAL CONNECTIVITY AMONG RESTING STATE
NETWORKS
400
P.Das, V.Calhoun, G.S.Malhi (Australia)

P-058
ALTERED AUDITORY STEADY-STATE MAGNETIC FIELDS IN BIPOLAR

DISORDERS: A SOURCE LOCALIZATION STUDY
401
Y.Oda, N.Hironaga, S.Hirano, R.Tsuchimoto, T.Maekawa,

T.Onitsuka, S.Tobimatsu, S.Kanba (Japan)
P-059
REDUCED ACTIVATION OF THE TEMPORAL CORTEX IN PATIENTS

WITH EUTHYMIC BIPOLAR DISORDER DURING A VERBAL FLUENCY
TASK: A MULTI-CHANNEL NEAR-INFRARED SPECTROSCOPY STUDY
402
N.Tsujii, W.Mikawa, H.Akashi, E.Tsujimoto, E.Kirime, T.Adachi,

M.Takaya, H.Ono, M.Yanagi, O.Shirakawa (Japan)
P-060
REDUCTION OF LEFT TEMPORAL CORTEX ACTIVATION IN SUICIDE

ATTEMPTERS WITH BIPOLAR DISORDER AFTER A VERBAL FLUENCY
TASK: A MULTI-CHANNEL NEAR-INFRARED SPECTROSCOPY STUDY
403
N.Tsujii, W.Mikawa, E.Tsujimoto, E.Kirime, H.Akashi, M.Takaya,

M.Yanagi, T.Adachi, H.Ono, O.Shirakawa (Japan)
P-061
DENSE CRANIAL ELECTROACUPUNCTURE STIMULATION, A NOVEL

BRAIN STIMULATION THERAPY FOR MOOD DISORDERS: RATIONALE
AND CLINICAL TRIALS
Z.Zhang (Hong Kong China)
404
BOARD N
P-062
EFFICACY OF CARIPRAZINE IN PATIENTS WITH ACUTE MANIC OR

MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER:
RESULTS FROM 2 PHASE III, PLACEBO-CONTROLLED TRIALS
405
J.Calabrese, K.Lu, I.Laszlovszky, M.Debelle, W.Earley, S.Durgam (USA)

P-063
SAFETY AND TOLERABILITY OF CARIPRAZINE IN PATIENTS WITH

ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I
DISORDER: RESULTS FROM 2 PHASE III PLACEBO-CONTROLLED TRIALS
406
T.Ketter, K.Lu, M.Debelle, I.Laszlovszky, S.Durgam, W.Earley (USA)

P-064
OLANZAPINE INDUCED PROLONGED THROMBOCYTOPENIA
407
N.Kathirvel, J.Xiao, C.Ankur, S.Naik (Singapore)

P-065
CLINICAL SATISFACTION AND PREFERENCE BETWEEN ORAL AND

LONG-ACTING INJECTABLE MEDICATION: VIEWS FROM PSYCHIATRISTS
408
J.Lee (Taiwan)
P-066
EFFECT OF LURASIDONE MONOTHERAPY OR ADJUNCTIVE THERAPY

ON ANXIETY SYMPTOMS IN PATIENTS WITH BIPOLAR I DEPRESSION
409
J.Cucchiaro, A.Pikalov, J.Hsu, H.Kroger, A.Loebel (USA)

P-067
SHORT- AND LONGER-TERM TREATMENT WITH LURASIDONE IN

PATIENTS WITH BIPOLAR I DEPRESSION: EFFECT ON
METABOLIC SYNDROME
410
S.McElroy, A.Pikalov, J.Cucchiaro, J.Hsu, H.Kroger, D.Phillips,

A.Loebel (USA)
P-068
EFFICACY AND SAFETY OF TREATMENT WITH LURASIDONE

ADJUNCTIVE WITH LITHIUM OR VALPROATE IN BIPOLAR I
DEPRESSION: RESULTS OF TWO 6-WEEK STUDIES
411
J.Calabrese, T.Suppes, K.Sarma, R.Silva, H.Kroger, J.Cucchiaro,

A.Pikalov, A.Loebel (USA)
P-069
MOOD-STABILIZING MEDICATION AFTER HOSPITALIZATION FOR

BIPOLAR DISORDER IN SWEDEN: A REGISTER-BASED COHORT STUDY
412
J.Reutfors, L.Scheen, L.Brandt, R.Bodn, A.Tanskanen,

M.Andersen, J.Tiihonen (Sweden)
P-070
EFFICACY OF LITHIUM IN THE LONG-TERM TREATMENT OF BIPOLAR

DISORDERS: A NEW META-ANALYSIS
E.Severus, M.Taylor, C.Sauer, A.Pfennig, M.Bauer, J.Geddes (Germany)
413
117
118
BOARD N
P-071
A PROSPECTIVE 4 YEARS NATURALISTIC FOLLOW UP OF 300

BIPOLAR I & BIPOLAR II PATIENTS
414
C.Simhandl, B.Knig, B.Amann (Austria)

P-072
PREDICTORS OF ADHERENCE TO PSYCHOPHARMACOLOGICAL AND

PSYCHOSOCIAL TREATMENT IN BIPOLAR I OR II DISORDERS - AN
18-MONTH PROSPECTIVE STUDY
415
K. Suominen, P. Arvilommi, O. Mantere, S. Leppmki,

H.V. Valtonen, E. Isomets (Finland)
P-073
MAINTENANCE TREATMENT IN PATIENTS WITH BDII MISDIAGNOSED

AS RDD IN RUSSIA
416
S.N.Mosolov, A.V.Ushkalova, E.G.Kostukova, A.A.Shafarenko (Russia)

P-074
GUIDELINES CONCORDANCE FOR ACUTE BIPOLAR DEPRESSION IN

MAINLAND CHINA
417
Z.Wang, W.Hong, M.Xing, Z.Wu, J.Chen, Y.Fang (China)

P-075
GUIDELINES CONCORDANCE FOR ACUTE MANIC AND MIXED

EPISODES IN MAINLAND CHINA
418
Z.Wang, W.Hong, M.Xing, Z.Wu, J.Chen, Y.Fang (China)

P-076
EFFECTIVENESS OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN

PATIENTS WITH BIPOLAR I DISORDER
419
Y.C.Yen, C.Y.Huang (Taiwan)

P-077
PSYCHOPHARMACOLOGICAL TREATMENT OF BIPOLAR DISORDER IN

PREGNANCY: RECOMMENDATIONS AND CLINICAL MONITORING SYSTEMS
420
M.Snellen, M.Assoc.Prof.Galbally (Australia)
P-078
LURASIDONE IN BIPOLAR I DEPRESSION: A 24 WEEK, OPEN-LABEL

EXTENSION STUDY
505
T.A. Ketter, A. Pikalov, K. Sarma, R. Silva, H. Kroger, J. Cucchiaro,

A. Loebel (USA)
P-079
EFFICACY AND SAFETY OF LURASIDONE IN BIPOLAR DEPRESSION:

RESULTS FROM TWO, DOUBLE BLIND, PLACEBO-CONTROLLED STUDIES
A. Loebel, A. Pikalov, J. Cucchiaro, R. Silva, K. Sarma, H. Kroger,
J. Calabrese, G. Sachs (USA)
506
POSTER
SESSION II
Thursday, March 20, 2014
120
POSTER SESSION 2 THURSDAY, MARCH 20, 2014
BOARD N
17:00 - 18:30
Poster Area
SESSION II
P-001
SMOKING DURING PREGNANCY AND THE RISK OF BIPOLAR DISORDER
421
R.Chudal, M.Gissler, A.Suominen, A.S.Brown, A.Sourander (Finland)

P-002
STANDARDIZATION OF BIPOLAR DEPRESSION RATING SCALE

(BDRS) IN KOREAN CHILDREN AND ADOLESCENTS WITH BIPOLAR
DISORDER: PRELIMINARY ANALYSIS
422
D.Y.Lee, E.K.Won, J.W.Choi, H.J.Min, K.S.Ha, J.S.Chang, Y.Kim (Korea)

P-003
OPPORTUNITIES AND CHALLENGES IN ESTABLISHING THE EMORY

LONGITUDINAL COHORT OF OFFSPRING OF MOTHERS WITH BIPOLAR
DISORDER (ELCOM-BD)
423
D.I.Simeonova, T.Nguyen, H.C.Hsu, S.Juul, J.Mast, T.Goldsmith,

E.Craighead, K.Ressler (USA)
P-004
ADOLESCENCE AND IMPULSIVITYEVOLUTION AND TREATMENT

OF ONE ADOLESCENT WITH COMORBIDITY BETWEEN BULIMIA
NERVOSA, BIPOLAR DISORDER, AND ADHD
424
J.A.Vargas Castro, A.Canudas, T.Grau, G.Faus, M.Snchez Povedano (Spain)

P-005
BIPOLAR DISORDER VS DISRUPTIVE MOOD DYSREGULATION

DISORDER: MRI STUDIES
425
C.P.Zeni, S.Tramontina, M.Anes, T.Peruzzolo, G.Motta, J.Brun,

F.P.Kapczinski, L.A.Rohde (Brazil)
P-006
PREDICTORS OF TRANSITION INTO BIPOLAR DISORDER AFTER THE

FIRST LIFETIME DEPRESSIVE EPISODE
426
J.D.Bukh, L.V.Kessing (Denmark)

P-007
LIFETIME EXPERIENCES OF HYPOMANIC SYMPTOMS ARE

ASSOCIATED WITH DELAYED AND IRREGULAR SLEEP-WAKE CYCLE
AND SEASONALITY IN NON-CLINICAL ADULT SAMPLES
427
M.Bae, K.Lee, J.S.Kim, Y.Cho, S.Ryu, J.H.Baek, K.Ha, K.S.Hong (Korea)

P-008
CLINICAL CORRELATES OF RESILIENCE IN EUTHYMIC PATIENTS

WITH BIPOLAR DISORDER
B.CHA, J.W.Choi, I.Y.Ahn, J.H.Jang, S.Y.Lee, C.S.Park, B.J.Kim,
C.S.Lee, S.J.Lee (Korea)
428
BOARD N
P-009
FIVE-YEAR OUTCOME OF BIPOLAR I AND II DISORDERS:

FINDINGS FROM THE JORVI BIPOLAR STUDY (JOBS)
429
E.Isometsa, S.Pallaskorpi, K.Suominen, O.Mantere, H.Valtonen,

P.Arvilommi, S.Leppamaki (Finland)
P-010
EFFECTS OF BIPOLARITY ON DRINKING BEHAVIOR ACCORDING TO

AGE AND GENDER
430
J.Lee (Korea)
P-011
LATENT BIPOLAR DISORDER (2 CASE REPORTS)
431
K.Nikaido (Japan)
P-012
PERSONALITY TRAITS DEPENDING ON MOOD STATE IN PATIENTS

WITH BIPOLAR DISORDER
432
S.Park, S.J.LEE, U.Yoon, Y.Joo (Korea)

P-013
INFORMING INTERVENTION STRATEGIES FOR BIPOLAR BISORDER

USING DYNAMIC TREATMENT REGIMES
433
F.Wu, E.Laber, I.Lipkovich, E.Severus (Germany)

P-014
SEMANTIC PRIMING AND HYPOMANIC PERSONALITY:

AN ELECTROPHYSIOLOGICAL STUDY
434
S.Terrien, G.Iakimova, C.Besche-Richard (France)

P-015
EMOTIONAL MEANING IN CONTEXT IN RELATION TO HYPOMANIC

TRAITS: AN ERP STUDY
435
C.Besche-Richard, S.Terrien, G.Iakimova, P.Mazzola-Pomietto,

V.Baltazart, A.Kaladjian (France)
P-016
IMPLICIT MOTOR LEARNING IN BIPOLAR DISORDER AND SCHIZOPHRENIA
436
A.Chrobak, K.Siuda, G.Siwek, M.Siwek, M.Pilecki, D.Dudek (Poland)

P-017
CARE-ORIENTED MORAL REASONING AMONG PATIENTS WITH

BIPOLAR DISORDER
437
N.Czyzowska, R.Epa, M.Siwek, D.Dudek, J.K.Gierowski (Poland)

P-018
EFFECTS OF COGNITIVE REMEDIATION ON COGNITIVE DYSFUNCTION

IN PARTIALLY OR FULLY REMITTED PATIENTS WITH BIPOLAR
DISORDER: A RANDOMISED CONTROLLED TRIAL
K.M.Demant, M.Vinberg, L.V.Kessing, K.W.Miskowiak (Denmark)
438
121
122
BOARD N
P-019
NEUROCOGNITIVE PERFORMANCE IN FIRST EPISODE BIPOLAR I

DISORDER COMPARED TO FIRST EPISODE SCHIZOPHRENIA AND
HEALTHY CONTROLS
439
C.Demmo, I.M.Melle, L.K.Kvitland, O.A.A.Andreassen,

T.V.L.Vik Lagerberg, T.U.Ueland (Norway)
P-020
TREATMENT NONADHERENCE IS NOT ASSOCIATED WITH COGNITIVE

IMPAIRMENT IN EUTHYMIC BIPOLAR DISORDER
440
R.Ekinci, E.Ozalp, E.Karakurt, E.Karslioglu, A.Caykoylu (Turkey)

P-021
THE RELATIONS BETWEEN THE BIPOLAR AFFECTIVE DISORDER AND

THE DEVELOPMENT OF JUSTICE-ORIENTED MORAL REASONING
441
R.Epa, N.Czyzowska, M.Siwek, J.K.Gierowski, D.Dudek (Poland)

P-022
IMPLICIT PROCESSING OF NEGATIVE EMOTION IMPAIRS SACCADIC

CONTROL IN EUTHYMIC BIPOLAR DISORDER
442
N.Guyader, A.Chauvin, L.Beynel, S.Harquel, B.Fredembach,

T.Bougerol, C.Marendaz, M.Polosan (France)
P-023
COMPARISON OF NEUROCOGNITIVE DEFICITS IN PATIENTS WITH

SCHIZOPHRENIA,BIPOLAR I DISORDER AND THEIR UNAFFECTED
FIRST-DEGREE RELATIVES
443
D.H.Kim, J.W.Kim, T.H.Koo, S.H.Won (Korea)

P-024
MENTAL ROTATION AND WORKING MEMORY IN EUTHYMIC PATIENTS

WITH BIPOLAR I DISORDER
444
J.Y.Kim, S.J.Lee, H.S.Ryu, V.Ryu, S.H.Lee, H.S.Cho (Korea)

P-025
PERCEPTUAL-ORGANIZATIONAL CHARACTERISTICS OF THE

RORSCHACH TASK IN PATIENTS WITH BIPOLAR MANIA WITH OR
WITHOUT PSYCHOTIC FEATURES: COMPARISON TO SCHIZOPHRENIA
PATIENTS
445
S.H.Kim, E.Lee, S.J.Lee, H.S.Ryu, R.Y.Ha, H.S.Cho (Korea)

P-026
AUTOBIOGRAPHICAL MEMORY AND ITS ASSOCIATION WITH

NEUROPSYCHOLOGICAL FUNCTION IN BIPOLAR DISORDER
446
W.J.Kim, R.Y.Ha, J.Y.Sun, V.Ryu, S.J.Lee, K.Ha, S.J.Kim, H.S.Cho (Korea)

P-027
RELATIONS OF EXECUTIVE COGNITIVE FUNCTIONS WITH RORSCHACH

VARIABLES IN PATIENTS WITH BIPOLAR MANIA
C.W.Lee, S.J.Lee, H.S.Ryu, R.Y.Ha, J.I.Kang, K.S.Ha, H.S.Cho (Korea)
447
BOARD N
P-028
MENTAL IMAGERY AND ITS RELATIONS WITH CLINICAL

CHARACTERISTICS IN EUTHYMIC PATIENTS WITH BIPOLAR I DISORDER
448
D.H.Oh, J.H.Seok, K.H.Huh, S.J.Lee, H.S.Ryu, H.S.Cho (Korea)

P-029
WORKING MEMORY CAPACITY AND EMOTIONAL REGULATION IN

EUTHYMIC PATIENTS WITH BIPOLAR I DISORDER
449
H.S.Cho, D.H.Oh, T.Y.Kim, S.J.Kim, R.Y.Ha, S.J.Lee, H.S.Ryu (Korea)

P-030
IMPLICIT SELF-ESTEEM IN BIPOLAR MANIC AND EUTHYMIC PATIENTS
450
J.Y.Park, V.Ryu, R.Y.Ha, S.J.Lee, W.J.Choi, K.Ha, H.S.Cho (Korea)

P-031
NEUROCOGNITIVE IMPAIRMENTS IN EUTHYMIC PATIENTS WITH

BIPOLAR DISORDER
451
S.Shimano, T.Miura, T.Onitsuka, Y.Kaneda, I.Sora, S.Kanba (Japan)

P-032
EVIDENCE FOR COGNITIVE SUBGROUPS IN BIPOLAR DISORDER AND

THE INFLUENCE OF SUBCLINICAL DEPRESSION
452
J.Volkert, J.Kopf, J.Kazmaier, F.Glaser, S.Kittel-Schneider,

A.Reif (Germany)
P-033
MAY A SEVERE COURSE OF ILLNESS CONTRIBUTE TO COGNITIVE

IMPAIRMENT IN BIPOLAR DISORDER?
453
M.Vrabie, V.Marinescu, A.Talasman, I.Miclutia (Romania)

P-034
VALUABLE INTERVENTION AGAINST THE EXCESS MORTALITY OF

PSYCHIATRIC PATIENTS
454
J.Aagaard, F.Nissen, A.Wernlund, L.Foldager, L.A.R.S.Merinder (Denmark)

P-035
PREVALENCE OF SUBSTANCE USE DISORDER IN THAI PATIENTS

WITH BIPOLAR DISORDERS
455
S.Arunpongpaisal, S.Maneeganondh, N.Jarassaeng, V.Pimpanit,

K.Boontooch (Thailand)
P-036
EFFECTS OF CHILDHOOD TRAUMA ON CLINICAL PRESENTATION AND

PROGNOSIS OF BIPOLAR DISORDERS
456
S.Cakir, R.Tasdelen, I.Ozyildirim (Turkey)

P-037
A CROSS SECTIONAL STUDY TO ESTIMATE CARDIOVASCULAR AND

METABOLIC RISK FACTORS IN PATIENTS WITH BIPOLAR DISORDER
S.Damegunta, G.Prasad Rao (India)
457
123
124
BOARD N
P-038
MDQ SCORE AS A PREDICTOR OF 6 MONTH OUTCOMES AMONG

PATIENTS WITH DEPRESSION MANAGED UNDER COLLABORATIVE CARE
458
R.DeJesus, M.Williams, K.Angstman (USA)

P-039
ANXIETY DISORDERS COMORBIDITY IN BIPOLAR PATIENTS IN TURKEY
459
N.Dilbaz, A.Darcin Enez (Turkey)

P-040
NICOTINE DEPENDENCE AND BIPOLAR DISORDERS
460
L.Gutirrez-Rojas, J.M.Martnez-Ortega, G.I.Goldstein (Spain)

P-041
COMPARISON OF CLINICAL CHARACTERISTICS BETWEEN PANIC

DISORDER WITH AND WITHOUT COMORBID BIPOLAR DISORDER
461
K.Kim, M.K.Kim, B.Kim, S.H.Lee (Korea)

P-042
INFLUENCE OF BIPOLARITY ON PROBLEMATIC DRINKING IN

DEPRESSIVE PATIENTS
462
E.Moon, J.M.Park, B.D.Lee, Y.M.Lee, H.J.Jeong, J.J.Lee, Y.Choi,

Y.I.Chung (Korea)
P-043
EVOLUTION TO BIPOLAR DISORDER FROM UNIPOLAR FIRST

DEPRESSIVE EPISODE IN A COHORT OF PATIENTS WITH SUBSTANCE
USE DISORDER COMORBIDITY. A THREE YEAR FOLLOW UP
PROSPECTIVE STUDY
463
A.Nieto (Mexico)
P-044
PSYCHOMETRIC PROPERTIES OF THE CHINESE VERSION OF THE

BIPOLAR SPECTRUM DIAGNOSTIC SCALE
464
K.Chou (Taiwan)
P-045
BIPOLARITY IN MEDICAL STUDENTS AT A PRIVATE UNIVERSITY IN

LIMA - PERU
465
E.Galli (Peru)
P-046
LIFETIME MOOD SPECTRUM SYMPTOMS AMONG BIPOLAR PATIENTS

AND HEALTHY CONTROLS
466
A.Ghouse, M.Sanches, Z.Soares, J.C.Soares (USA)

P-047
THE RELATIONSHIP BETWEEN TEMPERAMENT AND RESIDUAL

AFFECTIVE SYMPTOMS IN CLINICALLY STABLE PATIENTS WITH
BIPOLAR DISORDERS
D.Lee, J.S.Jang, J.Y.Kim, T.H.Ha, M.Lim, K.Ha (Korea)
467
BOARD N
P-048
VERIFICATION OF USABILITY OF THE HYPOMANIA CHECKLIST 32

(HCL-32) FOR THE SCREENING OF BIPOLAR DISORDER IN NONCLINICAL ADULT SAMPLES
468
K.Lee, H.Oh, E.H.Lee, J.H.Kim, J.H.Kim, K.S.Hong (Korea)

P-049
CLINICAL CHARACTERISTICS OF PATIENTS WITH RECURRENT MANIA
469
S.Lee, Y.Joo, H.Kim, S.Park (Korea)

P-050
A TALE OF TWO DIATHESES: TEMPERAMENT, BIS, AND BAS AS RISK

FACTORS FOR MOOD DISORDER
470
A.Van Meter, E.Youngstrom (USA)

P-051
BIPOLAR AFFECTIVE DISORDER: CONSTITUTIONAL-BIOLOGICAL,

CLINICAL-DYNAMIC AND CLINICAL-PROGNOSTIC REGULARITIES
471
I.Zrazhevskaya, A.Israelyan (Russia)

P-052
QUALITATIVE STUDY ON CHARACTERISTICS OF BIPOLAR DISORDER

AND DEPRESSION IN JAPAN
472
K.Koganei, H.Fujiu (Japan)

P-053
A COMPARISON OF PREDICTIVE PROPERTIES OF RISK MEASURES

FOR BIPOLAR DISORDER AMONG HELP-SEEKING YOUTH
473
A.Ratheesh, S.M.Cotton, B.N.Nelson, J.K.Betts, A.Chanen,

P.D.McGorry, M.Berk, A.Bechdolf (Australia)
P-054
THE BURDEN OF RECURRENT MOOD EPISODES IN BIPOLAR I

DISORDER: RESULTS FROM THE NATIONAL EPIDEMIOLOGICAL
SURVEY ON ALCOHOL AND RELATED CONDITIONS (NESARC)
474
A.Peters, A.West, L.Eisner, T.Deckersbach (USA)

P-055
THE RELATIONSHIP BETWEEN QUALITY OF LIFE IN ELDERLY

PATIENTS WITH BIPOLAR DISORDER AND LIVING IN REHABILITATION
CENTERS OR OWN HOME
475

P-056
THE PSYCHOLOGICAL EFFECTS OF DRAMA ACTIVITY ON DEPRESSED

OLDER PEOPLE: A LITERATURE REVIEW
W.C.Wong (Hong Kong China)
476
125
126
BOARD N
P-057
THE RELATIONSHIP OF IMPULSIVITY AND LIPID LEVELS IN BIPOLAR

PATIENTS: GENDER EFFECT
477
S.Kesebir, E.Tatlidil Yaylaci, A.Demirkan, M.Altintas (Turkey)

P-058
CURRENT PERSPECTIVES OF BIPOLAR DISORDER IN WOMEN:

GENDER DIFFERENCES OR GENDER BIAS?
478
D.Ray, V.G.Jhanwar, M.S.Reddy, R.Nagpal (India)

P-059
AN EXPLORATORY FACTOR ANALYSIS OF COPING INVENTORY FOR

STRESSFUL SITUATIONS (CISS) IN KOREAN ADULTS
479
Y.M.Choi, E.S.Moon, J.M.Park, B.D.Lee, Y.M.Lee, H.J.Jeong,

Y.I.Chung (Korea)
P-060
CONVERGENCE INSUFFICIENCY SYMPTOM IN BIPOLAR DISORDER

AND SCHIZOPHRENIA AND ITS ASSOCIATION WITH NES AND ICARS
480
A.Chrobak, K.Siuda, A.Arciszewska, M.Siwek, M.Pilecki, D.Dudek (Poland)

P-061
BIPOLAR II DISORDER IN TAIWAN: HIGHLY PREVALENT IN

OUTPATIENTS PRESENTING WITH DEPRESSION?
481
K.Chung, S.Y.Tsai, S.H.Huang, P.H.Chen (Taiwan)

P-062
DIFFERENCE IN PSYCHOLOGICAL RESILIENCE BETWEEN BPD I AND

BPD II: A PRELIMINARY STUDY
482
E.Joo, K.Lee, E.Kim, J.Yi (Korea)

P-063
POOLING CHILDHOOD & ADOLESCENT ONSET ATTENUATES EARLY

ONSET CLINICAL RELEVANCE IN BIPOLAR DISORDER
483
T.A.Ketter, J.Holtzman, S.Miller, F.Hooshmand, P.W.Wang, S.J.Hill (USA)

P-064
MORE LIBERAL WITH MIXED FEATURES THRESHOLD FOR BIPOLAR

DEPRESSION MAY BE NOT ONLY MORE INCLUSIVE, BUT ALSO MORE
CLINICALLY RELEVANT
484
W.Kim, S.Miller, F.Hooshmand, P.W.Wang, S.J.Hill, T.A.Ketter (USA)

P-065
EDUCATION ON BIPOLAR AFFECTIVE DISORDER IN HONG KONG
485
S.Law (Hong Kong China)

P-066
THE PRESTIGE MODEL OF SPECTRUM BIPOLARITY

J.Le Bas, R.Newton, D.OLoughlin, R.Sore, D.Castle (Australia)
486
BOARD N
P-067
CHARACTERISTICS OF COPING STYLE IN BIPOLAR PATIENTS
487
E.Moon, J.M.Park, B.D.Lee, Y.M.Lee, H.J.Jeong, J.J.Lee, Y.Choi,

Y.I.Chung (Korea)
P-068
EVOLUTIONARY ANTHROPOLOGICAL HYPOTHESES OF BIPOLAR DISORDER
488
H.Park, J.Choi, E.Woo, S.Park (Korea)

P-069
CLINICAL PROFILE OF PEOPLE WITH BIPOLAR DISORDER WHO DIE

BY SELF-POISONING
489
A.Schaffer, L.Weinstock, M.Sinyor, B.I.Goldstein, A.J.Levitt (Canada)

P-070
SUICIDE IN BIPOLAR DISORDER: CHARACTERISTICS AND SUBGROUPS
490
A.Schaffer, M.Sinyor, C.Reis, B.I.Goldstein, A.J.Levitt (Canada)

P-071
SOCIO-DEMOGRAPHIC CHARACTERISTICS OF ADMITTED MANIC

EPISODE OF BIPOLAR MOOD DISORDER PATIENTS IN A TERTIARY
PSYCHIATRIC HOSPITAL IN BANGLADESH
491
M.M.J.Uddin, H.U.Ahmed, M.T.Alam, M.F.Alam, M.A.Hamid,

W.A.Chowdhury, M.G.Rabbani (Bangladesh)
P-072
ELEVATED LEVELS OF URINARY MARKERS OF OXIDATIVELY

GENERATED DNA AND RNA DAMAGE IN BIPOLAR DISORDER
492
K.Munkholm, H.E.Poulsen, L.V.Kessing, M.Vinberg (Denmark)

P-073
COMPARISON OF DIFFERENT CREATIVITY BETWEEN BIPOLAR

DISORDERS AND NORMAL CONTROL AND CORRELATE WITH
FUNCTIONAL CONNECTIVITY IN THE BRAIN: PRELIMINARY FINDINGS
493
T.Su, Y.Kuan (Taiwan)

P-074
THE MONARCA PROJECT- ELECTRONIC DAILY SELF-MONITORING OF

SUBJECTIVE AND OBJECTIVE SYMPTOMS IN BIPOLAR DISORDER
494
M.Faurholt-Jepsen, M.V.Vinberg, A.S.Jacoby, E.M.Christensen,

M.Frost, J.Bardram, L.V.Kessing (Denmark)
P-075
THE EFFECTS OF DISTANCE LEARNING (BY MOBILE) ON THE ANXIETY

& DEPRESSION LEVEL OF NURSING CARE PATIENTS WITH BIPOLAR
DISORDER
495
127
128
BOARD N
P-076
EFFECTS OF ASSERTIVE COMMUNITY TREATMENT AFTER TWO

YEARS OF TREATMENT OF PATIENTS WITH SEVERE MENTAL ILLNESS
496
J.Aagaard, S.Skadhede, J.Achton Nielsen (Denmark)

P-077
NEEDS ASSESSMENT OF COMMUNITY FAMILIES TO PATIENTS WITH

SEVERE MENTAL ILLNESS (SMI)
497
J.Aagaard, P.Klbk, U.L.L.A.Vggemose, P.I.A.Vedel Ankersen (Denmark)

P-078
THE EFFICACY OF PSYCHOEDUCATION WITH HOME VISIT IN

PATIENTS WITH BIPOLAR AFFECTIVE DISORDER
498
T.A.Batista, C.Baes, M.F.Juruena (Brazil)

P-079
NURSING CARE FOR HOSPITALISED PATIENTS WITH ACUTE MANIA:

A DESCRIPTIVE STUDY
499
T.H.Daggenvoorde, B.Geerling, P.J.J.Goossens (The Netherlands)

P-080
ADDRESSING SUICIDE AND SELF-HARM IN YOUNG PEOPLE WITH

BIPOLAR DISORDER
500
M.L.Inder, M.T.Crowe, S.Moor, P.R.Joyce, J.Carter (New Zealand)

P-081
THE INTERNALIZED STIGMA AND ITS CORRELATES IN PATIENTS

WITH BIPOLAR I DISORDER IN KOREA
501
W.J.Kim, Y.J.Song, V.Ryu, J.M.Kim, R.Y.Ha, S.J.Lee, K.R.Kim,

H.S.Cho (Korea)
P-082
COMPREHENSIVE REHABILITATION PROGRAM IN BIPOLAR

DISORDER(PRISMA): A MULTIMODAL APPROACH
502
C.Lopez Jaramillo, C.Vargas, S.Saldarriaga-Gomez, J.D.Palacio,

J.Ospina-Duque, S.Ospina (Colombia)
P-083
OVERCOMING STIGMA: A NEW PSYCHOEDUCATIONAL AND BEHAVIOR

MODIFICATION COURSE
503
R.Milev, H.Stuart, C.Petznick (Canada)

P-084
A NEW CBT-TREATMENT FOR BIPOLAR DISORDER - RESULTS FROM

A PILOT-STUDY AND PLAN FOR FURTHER TESTING OF THE MODEL
INCLUDING AN INTERNET-MEDIATED SUPPORT SYSTEM
S.V.Pankowski, C.Svanborg, M.Adler, G.Andersson, N.Lindefors (Sweden)
504
BOARD N
P-085
SIMPLE PSYCHOEDUCATION CONDUCTED IN A CLINIC FOR PATIENTS

WITH BIPOLAR II DISORDER
505
Y.Saito-Tanji, A.Nishikawa, E.Tsujimoto, R.Taketani,

A.Maruyama, H.Ono (Japan)
P-086
GROUP PSYCHOEDUCATION TO BIPOLAR PATIENTS FROM SOUTH KOREA
506
S.Won, T.Koo, J.Kim, D.Kim (Korea)

P-087
RELATIONSHIP MANAGEMENT FUNCTIONALITY SUBTHRESHOLD

DEPRESSIVE SYMPTOMS IN BIPOLAR DISORDER
507
B.Erkek, E.Ozalp, E.H.Karslioglu, S.Peker, N.Sevil (Turkey)

P-088
CLINICAL AND NEUROCOGNITIVE PREDICTORS OF PSYCHOSOCIAL

FUNCTIONING IN EUTHYMIC BIPOLAR II PATIENTS
508
R.Ilhan, V.Senturk Cankorur (Turkey)

P-089
RELATIONSHIP BETWEEN PERCEIVED CRITICISM AND EMOTIONAL

SOCIAL SUPPORT TO DEPRESSIVE SYMPTOMS, AND SOCIAL
FUNCTIONING IN JAPANESE PATIENTS WITH BIPOLAR DISORDER:
A PRELIMINARY STUDY
509
M.Naruse, S.Horiuchi, Y.Sakano (Japan)

P-090
RELATION BETWEEN DEPRESSION, ANXIETY, SELF-ESTEEM,

DEMOGRAPHICAL FACTOR AND MATERNAL COMPLICATIONS WITH
FEAR OF CHILDBIRTH IN MARITAL SATISFACTION, NULLIPAROUS WOMEN
F.Akhlaghi, N.Mokhber, F.Shamsa (Iran)
510
129
130
BOARD N
INDEX
OF AUTHORS
132
Aagaard, J.
Aas, M.
Abdel Gawad, N.
Abelaira, H.
Abulseoud, O.
Achton Nielsen, J.
Adachi, T.
Adler, M.
Agam, G.
Agdanli, O.U.
Ahmed, H.U.
Ahn, I.Y.
Ahn, Y.M.
Akashi, H.
Akdeniz, F.
Akhlaghi, F.
Al Amri, H.
Alam, M.F.
Alam, M.T.
Alda, M.
Allega, O.
Alsuwaidan, M.
Altamura, C.
Altinbas, K.
Altintas, M.
Alvarado, P.
Amann, B.
Aminoff, S.R.
An, H.
An, S.
An, S.K.
Andersen, M.
Andersson, G.
Andreassen, O.A.
Andreassen, O.A.A.
Andreazza, A.C.
Anes, M.
Angstman, K.
Ankur, C.
Arciszewska, A.
Arias-Vasquez, A.
Arunpongpaisal, S.
Arvilommi, P.
Asai, T.A.
Atgden, N.
Atriano, C.
Austin, D.
Ayers Ringler, J.
Baciu, M.
Bae, M.
Baek, J.
Baek, J.H.
Baek, S.
Baek, S.Y.
Baer, L.
Baes, C.
Bahk, W.M.
Bai, Y.M.
Balanz-Martnez, V.
454, 496, 497

89
344
217
344
496
402, 403
504
106, 108, 109
369
491
428
80, 188, 302, 312, 368, 373
402, 403
45
510
279
491
491
213
361
134
136
209, 212, 260, 262
351, 352, 477
218
414
89, 371
309
305, 339
281, 321, 322, 342
412
504
89, 371
439
357
358, 425
458
407
480
384
455
415, 429
390
351, 352
218
143
347
392
427
266
5, 242, 280, 427
305
281
291
498
292, 334, 341
187
66
Baltazart, V.
435
Balzarro, B.
355
Bang, M.
321, 322
Bang, M.J.
281
Bao, Y.
382
Bardram, J.
494
Bartkowska-Sniatkowska, A.
118
Basavaraju, R.
381
Batista, T.A.
498
Bauer, M.
42, 72, 96, 159, 230, 232, 413
Bechdolf, A.
473
Bellani, M.
91
Belmaker, R.H.
87, 108
Benjamin, G.
77
Bergen, S.
117
Berk, L.
143, 174
Berk, M.
109, 143, 153, 174, 177, 183,

201, 202, 203, 367, 473
Berlanga, C.
218
Bernstein, E.E.
242
Berry, G.
108
Bersudsky, Y.
108
Bertoldo, A.
91
Besche-Richard, C.
250, 434, 435
Betts, J.K.
473
Beynel, L.
345, 346, 442
Bi, J.Q.
222
Bianchini, O.
355
Bigdeli, H.
323, 325
Birmaher, B.
29, 76, 101
Bobo, W.
46, 145, 146
Bodn, R.
90, 412
Bodurka, J.
191
Bok, K.N.
310
Bond, D.
131, 135
Boontooch, K.
455
Boucher, S.
359, 396
Bougerol, T.
345, 346, 392, 442
Braga, R.J.
181
Brambilla, P.
91, 110, 138
Brandt, L.
412
Brown, A.S.
382, 421
Brun, J.
425
Brun, J.B.
358
Bukh, J.D.
426
Bundo, M.B.
390
Burdick, K.E.
181
Caillies, S.
250
Cakir, S.
456
Calabrese, J.
37, 39, 405, 411
Calhoun, V.
400
Camsari, U.M.
344
Canudas, A.
424
Carrillo-Meza, R.
218
Carter, J.
500
Castle, D.
143, 486
Caykoylu, A.
440
Cerini, R.
91
Cha, B.
243, 428, 316
133
Chae, J.H.
Chamberlain, J.
Chandwani, N.
Chanen, A.
Chang, H.C.
Chang, J.
Chang, J.
Chang, J.S.
Chang, K.
Chang, K.D.
Chatterjee, B.
Chauvin, A.
Chen, F.
Chen, H.C.
Chen, J.
Chen, P.
Chen, P.H.
Cheon, K.A.
Chester, A.
Cheung, Y.W.E.
Chiu, Y.H.
Cho, C.
Cho, C.H.
Cho, E.
Cho, E.Y.
Cho, H.
Cho, H.S.

Cho, H.Y.
Cho, M.J.
Cho, S.
Cho, S.C.
Cho, Y.
Choi, D.
Choi, D.S.
Choi, J.
Choi, J.S.
Choi, J.W.
Choi, N.
Choi, S.
Choi, T.Y.
Choi, W.J.
Choi, Y.
Choi, Y.M.
Chou, K.
Chou, Y.
Chou, Y.H.
Chowdhury, W.A.
Christensen, E.M.
Chrobak, A.
Chudal, R.
Chung, K.
Chung, K.H.
Chung, Y.C.
Chung, Y.I.
Clain, A.
Colom, F.
Colpo, G.
Correll, C.
225
143
282
473
283
162
247
167, 316, 364, 394, 397, 422
22, 25
216, 359, 396
246, 374
345, 346, 442
223
268
417, 418
186
129, 241, 481
295
143
7, 70
268
383
307, 310
266
284
88, 276, 304
385, 386, 444, 445, 446,
447, 448, 449, 450, 501
387, 389
291, 328
194
26
284, 356, 427, 285
347
344
319, 340, 488
316
422, 428
309
320
286
287, 450
347, 462, 487
479
464
190, 192, 244
395
491
494
436, 480
421
481
129, 241
102
462, 479, 487
291
34, 35, 253
393
104
Corrigan, N.
86
Costanzi, M.
393
Cotton, S.M.
473
Craighead, E.
423
Croarkin, P.
224
Crowe, M.T.
500
Cucchiaro, J.
409, 410, 411, 505, 506
Cudney, L.
348
Curra, M.D.
393
Curran, G.
399
Czyzowska, N.
437, 441
Dager, S.R.
86
Dager, S.R.D.
84
Daggenvoorde, T.H.
499
Dal Pizzol, F.
217
Damegunta, S.
375, 376, 457
Dang, Y.
270, 272
Danilo, Q.
16
Dantzer, R.
191
Darcin Enez, A.
459
Das, P.
399, 400
Daskalakis, Z.J.
226
Debelle, M.
405, 406
Deckersbach, T. 141, 142, 199, 201, 202, 203, 474
DeJesus, R.
458
Demant, K.M.
438
Demirer, R.M.
370
Demirkan, A.
477
Demmo, C.
371, 439
Dilbaz, N.
459
Dodd, S.
143, 367
Doorduin, J.
193
dos Santos, B.T.
393
Drevets, W.C.
191
Drexhage, H.A.
193
Duarte, J.A.
393
Dudek, D.
436, 437, 441, 480
Dunner, D.
86
Durgam, S.
405, 406
Dursun, E.
391
Dusi, N.
91
Earley, W.
405, 406
Egerton, G.
198
Eisner, L.
474
Ekinci, R.
440
El Sherif, M.
293
Epa, R.
437, 441
Ergr, G.
369
Erkek, B.
507
Fang, Y.
6, 265, 267, 417, 418
Fang, Y.R.
221, 271
Faraone, S.V.
384
Fasmer, O.B.
173, 174
Faurholt-Jepsen, M.
494
Faus, G.
424
Fava, M.
280, 291
Favila, R.
218
Favre, P.
392
Ferensztajn, E.
119
134
Foldager, L.
454
Founoulakis, K.N.
123
Frangou, S.
92, 112
Frank, E.
201, 202, 203
Franke, B.
384
Frankland, A.
236
Fredembach, B.
346, 442
Freedman, D.
382
Frey, B.
44
Frey, B.N.
348, 361, 362
Fritz, K.
399
Frost, M.
494
Frye, M.
238, 261
Fujiu, H.
472
Galbally, M.
420
Galli, E.
465
Gama, C.S.
393
Gao, C.G.
120
Garrett, A.
359, 396
Gary, S.
221, 271
Geddes, J.
413
Geerling, B.
48, 144, 145, 146, 259, 499, 258
Genzlinger, J.
197, 198
Gezen-Ak, D.
391
Ghouse, A.
466
Gierowski, J.K.
437, 441
Gierski, F.
250
Gilbert, M.
143
Gilbert, Y.
367
Gilddon, E.
143
Gissler, M.
421
Gitlin, M.
41
Gjestad, R.
173
Glaser, F.
452
Goel, D.
62
Goes, F.
215
Goi, P.D.
393
Goikolea, J.
67
Goldsmith, T.
423
Goldstein, B.
31, 75, 76
Goldstein, B.I.
489, 490
Goldstein, G.I.
460
Goossens, P.
228, 255
Goossens, P.J.J.
257, 259, 499, 258
Gotlib, I.H.
216
Grau, T.
424
Greenwood, T.
383
Grunze, H.
152
Gu, N.F.
120
Guadamuz, A.
218
Guo, Y.
272
Gutirrez-Rojas, L.
460
Guyader, N.
345, 346, 442
Ha, K.
53, 162, 167, 247, 252,

266, 273, 274, 394, 397, 427, 446, 450, 467
HA, K.S.
302, 364, 422, 447
Ha, R.Y.
385, 386, 445, 446, 447, 449, 450, 501
Ha, T
247
Ha, T.
162
Ha, T.H.
167, 364, 394, 397, 467
Ha, Y.
319
Haarman, B.
193
Habil, H.
333, 379
Hahm, B.J.
328
Hamid, M.A.
491
Han, C.
355
Han, C.S.
307, 317
Hansen, N.
142, 201
Harquel, S.
345, 346, 442
Harris, A.
366
Hasegawa, T.
248
Hashimoto, T.
248
Heo, J.Y.
288, 318
Her, J
247
Her, J.Y.
167, 394, 397
Heuvel, S.C.G.H.
259
Hill, S.J.
483, 484
Hirano, S.
401
Hironaga, N.
401
Hodge, J.M.
367
Hodgkinson, S.
350
Holtzman, J.
483
Hong, J.P.
291
Hong, K.
266, 356
Hong, K.K.
289
Hong, K.S.
116, 284, 364, 427, 468
Hong, W.
417, 418
Honma, K.
81
Honma, S.
81
Hooshmand, F.
483, 484
Horiuchi, S.
509
Howe, M.
359, 396
Hsieh, W.C.
395
Hsu, H.C.
423
Hsu, J.
409, 410
Huang, C.Y.
419
Huang, M.C.
268
Huang, S.H.
129, 241, 481
Huh, I.
266
Huh, I.S.
284
Huh, K.H.
448
Hung, Y.N.
249
Hwang, I.S.
313
Hwang, T.
171
Iakimova, G.
434, 435
ilhan, R.
508
Imaroh, R.
327
Inamori, A.
291
Inder, M.L.
500
Inge Dackrisna Daud, I.N.G.E.
327
Inoue, T.
81
Irawati, I.R.F.A.
327
Isaac, M.
64
Ishigooka, J.I.
390
Isometsa, E.
429, 415
Israelyan, A.
471
Iwamoto, K.I.
390
Jacka, F.
133
135
Jacka, F.N.
Jacoby, A.S.
Jahanbin, I.
Jandl, M.
Jang, J.H.
Jang, J.S.
Jarassaeng, N.
Jenkins, M.M.
Jeon, H.
Jeon, H.J.
Jeong, H.G.
Jeong, H.J.
Jeong, J.
Jeong, J.H.
Jeong, K.A.
Jernberg, T.
Jhanwar, V.G.
Jhoo, J.H.
Jhung, K.
Jingping, Z.
Joeng, J.H.
Jon, D.I.
Joo, E.
Joo, Y.
Joo, Y.H.
Jou, Y.T.
Joung, Y.S.
Joyce, P.R.
Jun, C.S.J.
Jun, Y.J.J.
Jung, H.Y.
Jung, I.C.
Jung, K.Y.
Juruena, M.F.
Juul, S.
Kaczmarek, M.
Kaladjian, A.
Kamal, N.
Kamath, J.
Kamilla, M.
Kanahara, N.
Kanba, S.
Kaneda, Y.
Kang, E.S.
Kang, I.Y.
Kang, J.
Kang, J.I.
Kang, J.M.
Kang, N.
Kang, S.
Kang, S.G.
Kao, C.F.
Kapczinski, F.
Kapczinski, F.P.
Karakurt, E.
Karslioglu, E.
Karslioglu, E.H.
Kasabeh, A.
Kasahara, T.
367
349, 494
290
350
428
467
455
172
291, 356
280, 329
308, 317
462, 479, 487
292
341
337, 338
90
478
316
339
219
334
292, 334, 341
79, 363, 482
196, 432, 469
20, 52, 93, 275, 360
395
24
500
84
84
127
320
307
498
423
119
250, 435
293
377
182
248
3, 160, 401, 451
451
280
337, 338
305
294, 295, 306, 331, 342, 447
296
347
297, 319
296, 307, 308, 310
268
18, 82, 148, 178, 240, 358, 393
425
440
440
507
344
107
Kasai, K.K.
390
Kaschka, W.
350
Kathirvel, N.
407
Kato, T.
78, 94, 107, 115, 390
Kavari, S.H.
298, 299, 300, 495, 301, 378, 475
Kazmaier, J.
452
Kelley, R.G.
216
Kelsoe, J.
383
Kesebir, S.
351, 352, 353, 370, 477
Kessing, L.V. 95, 128, 231, 349, 426, 438, 492, 494
Ketter, T.
137, 406, 483, 484, 505
Khodabakhsh Pirkalani, R.
325
Kieler, H.
90
KIM, B.
302, 312, 380, 461
Kim, B.J.
428
Kim, B.N.
28
Kim, C.
151
Kim, C.Y.
69
Kim, D.
506
kim, D.H.
443
Kim, E.
304, 363, 482
Kim, E.J.
396
KIM, E.Y.
302, 188, 312, 368
Kim, H.
469
Kim, H.H.
357
KIm, H.I.
308
Kim, H.W.
23, 196, 198, 295, 306, 331, 360
Kim, H.Y.
389
Kim, J
247
Kim, J. 111, 266, 303, 309, 364, 364, 397, 397, 506
Kim, J.A.
337, 338
Kim, J.E.K.
84
Kim, J.H.
394, 468, 468
Kim, J.M.
289, 294, 501
Kim, J.S.
167, 394, 427
Kim, J.W.
443
Kim, J.Y.
329, 444, 467
kim, K.
461
Kim, K.R.
281, 501
Kim, L.
307, 308, 310
Kim, M.D.
292, 334, 341
Kim, M.K.
380, 461
Kim, N.
304, 305, 309
Kim, O.J.
337, 338
Kim, S.
80, 176, 304, 329, 380
Kim, S.H.
310, 312, 317, 368, 373, 445
Kim, S.J.
295, 306, 331, 446, 449
Kim, S.T.
296
Kim, S.W.
316
Kim, T.Y.
449
Kim, W.
484
Kim, W.J.
446, 501
Kim, Y.
51, 59, 340, 356, 422
Kim, Y.H.
387, 388
Kim, Y.K.
310
Kim, Y.S.
80, 184, 373
Kirime, E.
402, 403
Kittel-Schneider, S.
452
Klein, B.
143
136
Ko, Y.H.
Koganei, K.
Koh, M.J.
Koh, O.
Koh, O.H.
Klbk, P.
Kolbe, M.K.
Knig, B.
Konuk, N.
Koo, T.
Koo, T.H.
Kopf, J.
Koseki, M.
Kostukova, E.G.
Kramer, M.
Krawczak, E.
Kripke, D.
Kroger, H.
Kuan, Y.
Kumar, S.
Kuo, P.
Kupka, R.
Kvitland, L.
Kvitland, L.K.
Kwak, Y.S.
Kwon, J.
Kwon, Y.
Laber, E.
Lagerberg, T.V.
Landen, M.
Laszlovszky, I.
Lauder, S.
Law, S.
Le Bas, J.
Lee, B.
Lee, B.D.
Lee, B.J.
Lee, C.H.
Lee, C.K.
Lee, C.S.
Lee, C.W.
Lee, D.
Lee, D.H.
Lee, D.Y.
Lee, E.
Lee, E.H.
Lee, E.I.
Lee, H.
Lee, H.B.
Lee, H.J.
Lee, H.L.
Lee, H.M.
Lee, J.
Lee, J.G.
Lee, J.I.
Lee, J.J.
Lee, J.N.
Lee, J.S.
Lee, K.
317
472
306
379
13
497
233
414
335
506
443
452
248
416
215
362
383
409, 410, 411, 505, 506
493
63
268
32, 40, 71, 147, 149
89, 371
439
74
61
285
433
89, 371
117
405, 406
143
485
486
356
462, 479, 487
387, 388, 389
387, 388, 389
315
428
386, 447
280, 467
310
394, 422
281, 294, 305, 356, 445
468
310
277, 285, 328, 383
311, 337, 338
196, 296, 307, 308, 309, 310, 312
294
315
19, 313, 319, 408, 430
292, 334, 341, 387, 388, 389
297
462, 487
289
360
266, 363, 427, 468, 482
Lee, K.S.
Lee, M.
Lee, M.S.
Lee, N.Y.
Lee, S.
Lee, S.H.
Lee, S.J.

Lee, S.Y.
Lee, T.
Lee, Y.
Lee, Y.J.
Lee, Y.M.
Lee, Y.R.
Lee, Y.S.
Leopold, K.
Leppamaki, S.
Lesch, K.P.
Levitt, A.J.
Li, C.T.
Li, H.C.
Li, H.F.
Li, J.I.N.G.
Li, K.Q.
Li, L.J.
Li, Z.
Licht, R.
Lichtenstein, P.
Lim, M.
Lim, S.W.
Lin, J.L.
Lin, K.
Lin, S.K.
Lindahl, B.
Lindefors, N.
Lipkovich, I.
liu, C.
Liu, T.B.
Liu, Z.
Loebel, A.
Lopez Jaramillo, C.
Lopez-Larson, M.
Losy, J.
Louredo, A.C.
Lu, K.
Lu, R.
Lu, R.B.
Lu, W.
Lu, Z.
Lyoo, I.K
Ma, Y.
Maekawa, T.
Magalhaes, P.V.
Mak, K.
Malhi, G.
Malhotra, A.K.
Maneeganondh, S.
Mantere, O.
Marendaz, C.
314
200
309, 317
373
316, 354, 355, 355, 469
161, 308, 380, 444, 461
432, 385, 386, 428, 444, 445,
446, 447, 448, 449, 450, 501
428
315, 270
205
286, 309
462, 479, 487
337, 338
284
105
429, 415
384
489, 490
168
120
120
221, 271
120
120
267
99
117
316, 467
283
395
270, 272
249
90
504
433
365
222
221, 271
409, 410, 411, 505, 506
398, 502
85
119
358
405, 406
186
268
270, 272
120
84, 86
221, 271
401
201, 202, 203
166
54, 156, 214, 399, 400
181
455
415, 429
345, 346, 442
137
Marinelli, V.
Marinescu, V.
Marrufo-Melendez, O.
Martnez-Ortega, J.M.
Maruyama, A.
Masand, P.S.
Masaomi, I.
Massuda, R.
Mast, J.
Mayur, P.
Mazzola-Pomietto, P.
McCombie, W.R.
McElroy, S.
McGlade, E.M.
McGorry, P.D.
McKinney, E.
Mehdizadeh, M.
Mehta, U.M.
Melle, I.
Melle, I.M.
Melle, I.S.
Mellesdal, L.
Merinder, L.A.R.S.
Miclutia, I.
Mikawa, W.
Miklowitz, D.
Milev, R.
Miller, S.
Min, H.
Min, H.J.
Min, K.J.
Min, Y.J.
Minuzzi, L.
Mischoulon, D.
Miskowiak, K.W.
Mitchell, P.
Miura, T.
Moechars, D.
Mohamed, K.
Mok, Y.M.
Mokhber, N.
Moland, K.M.
Molin, E.
Montes, J.M.
Moon, E.
Moon, E.S.
Moon, J.H.
Moor, S.
Moreno, D.
Mosalem, F.
Mosolov, S.N.
Motta, G.
Motta, G.L.C.L.
Motta, L.S.
Munkholm, K.
Na, E.H.
Na, K.S.
Nacif, M.P.
Nagpal, R.
91
453
218
460
505
355
248
393
423
366
435
215
410
85
473
198
326
381
89
439
371
173
454
453
402, 403
201, 202, 203
123, 124, 125, 503
483, 484
340
422
292, 341
334
361
280, 291
438
170, 235, 236, 372
451
108
344
12, 185
510
174
90
65
316, 462, 487
479
308
500
206
293
416
425
358
358
349, 492
289
296
217
478
Naik, S.
Nam, Y.
Nam, Y.Y.
Namkoong, K.
Naruse, M.
Natsubori, A.
Nazari, M.
Nelson, B.N.
Newton, R.
Nguyen, T.
Nierenberg, A.

Nieto, A.
Nikaido, K.
Ning, Y.P.
Nishikawa, A.
Nissen, F.
Nolen, W.

Nourozi, K.
Oda, Y.
Oedegaard, C.H.
Oedegaard, K.J.
Oh, D.H.
Oh, H.
Oh, H.J.
Oh, J.S.
Oh, J.Y.
Oh, K.S.
Oh, S.
OLoughlin, D.
Omori, Y.
Ongur, D.
Onitsuka, T.
Ono, H.
Ospina, S.
Ospina-Duque, J.
Otto, M.
Ouyang, H.
Ozalp, E.
Ozerdem, A.
Ozyildirim, I.
Pae, C.
Paik, J.W.
Palacio, J.D.
Pallaskorpi, S.
Panizzutti, B.
Pankowski, S.V.
Park, C.I.
Park, C.S.
Park, D.
Park, E.
Park, H.
Park, H.C.
Park, H.D.
Park, H.Y.
Park, J.
Park, J.I.
Park, J.M.
407
339
295, 316
294, 306
509
81
325, 326
473
486
423
142, 150, 154, 201,
202, 203, 239, 242
463
431
120
505
454
2, 36, 38, 50, 56, 58, 71,
98, 152, 189, 193
298, 299, 301, 378, 475, 495
401
173, 174
173, 174
448, 449
468
284
317
318
180, 283, 336
278
486
229
211
164, 401, 451
402, 403, 505
502
502
201, 202, 203
270, 272
440, 507
43, 155, 158, 264, 369
456
355
317
502
429
393
504
295, 331
428
319
319, 320
488
287
280
321, 322
304, 305, 340
316
462, 479, 487
138
Park, J.Y.
Park, K.
Park, K.H.
Park, M.H.
Park, S.
Park, S.J.
Park, S.W.
Park, T.
Park, T.S.
Park, T.W.
Park, Y.C.
Park, Y.M.
Park, Y.S.
Parla, J.
Pasco, J.A.
Pearlstein, J.G.
Peckham, A.D.
Peker, S.
Perlini, C.
Permoda-Osip, A.
Perrin, A.
Peruzzolo, T.
Peruzzolo, T.L.
Peters, A.
Petznick, C.
Pfennig, A.
Phillips, D.
Pichat, C.
Pikalov, A.
Pilecki, M.
Pimpanit, V.
Pirkalani, K.
Pirooznia, M.
Polita, S.L.
Polosan, M.
Porcelli, S.
Post, R.
Potash, J.
Poulsen, H.E.
Pozzi-Mucelli, R.
Prasad Rao, G.
Quevedo, J.
Quiroz, D.
Rabbani, M.G.
Rambaldelli, G.
Ramrez-Bermdez, J.
Rascovsky, S.
Rasgon, N.
Ratheesh, A.
Raucher-Chn, D.
Ray, D.
Reckziegel, R.
Reddy, M.S.
Regeer, E.J.
Reif, A.
Reis, C.
Reiss, A.
Renes, J.W.
Renshaw, P.
281, 450
321, 322
296
359
432, 469, 488
329
387, 388, 389
266
284
21
132
308
364
215
367
359
142
507
91
118
392
425
358
142, 201, 202, 203, 474
503
105, 413
410
392
409, 410, 411, 505, 506
436, 480
455
323, 324, 325, 326
215
393
346, 392, 442
355
73
215
492
91
457
217
263
491
91
218
398
49, 157
473
250
478
393
9, 11, 375, 376, 478
71
384, 452
490
216, 396
71
83, 84, 86
Ressler, K.
423
Reus, G.
217
Reutfors, J.
412
Rhee, S.J.
312
Richards, T.
86
Riemersma - van der Lek, R.F.
193
Ringen, P.A.
89, 371
Roberts, G.
236
Rodrigues, R.
358
Roh, M.
328
Roh, S.
329
Rohde, L.A.
425
Rong, H.
222
Ruby, C.L.
344
Rybakowski, J.
118, 119, 210
Ryu, H.S.
385, 386, 444, 445, 447, 448, 449
Ryu, S.
266, 356, 427
Ryu, S.H.
284
Ryu, V.
163, 385, 386, 444, 446, 450, 501
Sadek, R.
293
Sagar, R.
246, 374
Saggar, M.
216
Saghaei, M.
326
Sahu, A.
246, 374
Saito-Tanji, Y.
505
sajith, S.
330
Sakano, Y.
509
Sakurai, D.
248
Saldarriaga-Gomez, S.
502
Salvador, M.
357
Sanches, M.
466
Sanchez de Carmona, M.
14, 15, 55, 251
Snchez Povedano, M.
424
Sachs, G.
506
Sanders, E.
396
Sanders, E.M.
359
Sarma, K.
411, 505, 506
Sassi, R.B.
348
Sauer, C.
413
Savitz, J.
191
Sayaki Grdal, S.
370
Scarpini, E.
139
Schaefer, C.A.
382
Schaffer, A.
125, 204, 207, 489, 490
Scheen, L.
412
Scholz, C.J.
384
Schulze, T.
100
Scola, G.
357
Se Joo, K.
220
Sefasi, A.
332
Sefasi, A.P.
332
Seghatoleslam, T.
333
Sehmbi, M.
348, 361, 362
Senturk Cankorur, V.
508
Seo, J.
334
Seo, J.S.
292, 341
Seo, M.K.
387, 388, 389
Seok, J.H.
287, 448
Seol, W.G.
389
139
Serretti, A.
Severus, E.
Sevil, N.
Sevincer, G.
Shafarenko, A.A.
Shaffer, H.J.
Shamsa, F.
Shen, L.
Shen, Q.J.
Shi, J.G.
Shim, S.
Shim, S.H.
Shimano, S.
Shin, E.
Shin, Y.C.
Shirakawa, O.
Shon, S.H.
Shulman, K.
Si, T.
Sidorov, A.
Silva, R.
Sim, K.
SIm, M.
Simeonova, D.I.
Simhandl, C.
Singh, M.
Singh, M.K.
Singh, R.
Sinyor, M.
Siuda, K.
Siwek, G.
Siwek, M.
Skadhede, S.
Skibinska, M.
Smith, M.
Snelgrove, N.
Snellen, M.
So, K.
So, S.J.
Soares, J.C.
Soares, Z.
Soh, M.
Sohn, J.H.
Sohn, S.Y.
Son, I.G.
Son, S.H.
Song, D.H.
Song, H.M.
Song, J.
Song, Y.
Song, Y.J.
Song, Y.Y.
Sora, I.
Sore, R.
Sourander, A.
Sowder, C.
Squarcina, L.
Stange, J.
Stange, J.P.
355
413, 433
507
335
416
315
510
382
222
120
285
292, 341
451
336
292, 334, 341
402, 403
360
126, 130
221, 237, 271
366
411, 505, 506
10
337, 311, 338
423
414
30, 216, 396
359
377
489, 490
436, 480
436
436, 437, 441, 480
496
118, 119
361
361
420
270
307, 308
114, 466
466
329
287
331
292, 334, 341
310
331
308
117
304, 305, 339
501
281, 342
451
486
421
198
91
203
142
Steiner, M.
Stevens, A.
Stevens, A.W.M.M.
Steyer, J.
Straub, R.
Streck, E.
Strejilevich, S.
Stuart, A.
Stuart, H.
Su, A.
Su, T.
Su, T.P.
Sugawara, H.
Sumiyoshi, T.
Sun, J.I.N.G.
Sun, J.Y.
Sunaga, F.S.
Sundstrm, J.
Suominen, A.
Suominen, K.
Suppes, T.
Svanborg, C.
Syan, S.K.
Sylvia, L.G.
Taboada, J.
Takaya, M.
Taketani, R.
Talaeerad, Z.
Talasman, A.
Tan, Q.R.
Tansella, M.
Tanskanen, A.
Tasdelen, R.
Tatlidil Yaylaci, E.
Taylor, M.
Teague, T.K.
Teixeira, A.L.
Terlouw, C.
Terrien, S.
Thirthalli, J.
Thorell, L.H.
Tian, H.J.
Tiihonen, J.
Tobimatsu, S.
Toker, L.
Torpy, A.
Toyomaki, A.
Tramontina, S.
Tsai, S.
Tsai, S.Y.
Tsuchimoto, R.
Tsujii, N.
Tsujimoto, E.
Tu, P.C.
Tunca, Z.
Turan, C.
Uddin, M.M.J.
Udomratn, P.
Ueda, J.U.
348
47, 145, 146, 227, 258
259
350
350
217
17, 263
367
503
330
165, 493
168
390
140
221, 271
446
390
90
421
429
411
504
361
142, 201, 202, 203
218
402, 403
505
323, 324, 325, 326
453
120
91
412
456
351, 352, 477
413
191
393
257
250, 434, 435
381
350
120
412
401
108
367
81
358, 425
129
481
401
402, 403
402, 403, 505
168
369
353
491
1, 8, 57, 245
390
140
Ueland, T.U.
Ulutin, T.
Ushkalova, A.V.
Vggemose, U.L.L.A.
Valencia-Escobar, M.
Valtonen, H.
Valtonen, H.V.
van Achterberg, T.
van de Heuvel, S.
van den Heuvel, S.C.G.H.
van Hulzen, K.
Van Meter, A.
Vanegas, A.
Vargas Castro, J.A.
Vargas, C.
Vasconcelos-Moreno, M.
Vedel Ankersen, P.I.A.
Veldic, M.
Vianna-Sulzbach, M.
Victor, T.A.
Vik Lagerberg, T.V.L.
Vinberg, M.
Vinberg, M.V.
Vitoratou, S.
Vivekanandan, S.
Volkert, J.
Vrabie, M.
Walker, M.
Walker, R.S.
Wang, G.
Wang, G.
Wang, P.W.
Wang, S.J.
Wang, X.
Wang, X.P.
Wang, Z.
Weinstock, L.
Wernlund, A.
West, A.
Williams, L.
Williams, M.
Wolfersdorf, M.
Won, E.
Won, E.K.
Won, E.S.
Won, S.
Won, S.H.
Wong, M.
Wong, M.
Wong, M.C.M.
Wong, W.C.
Woo, E.
Woo, H.
Woo, Y.S.
Wu, F.
Wu, Z.
Xiang, Y.
Xiao, J.
Xing, M.
439
391
416
497
398
429
415
257
258
257
384
103, 197, 198, 470
398
424
398, 502
393
497
347
393
191
439
179, 349, 438, 492
494
369
246, 374
452
453
234, 254, 256
291
120, 223
221, 271
483, 484
395
221, 271
120
417, 418
489
454
474
367
458
350
340
422
309
506
443
4
70
68, 269
476
488
383
292, 334, 341
433
417, 418
223
407
417, 418
Xu, G.
270, 272
Xu, X.F.
120
Xu, Y.
120
Yadollahikhales, G.
290
Yalin, N.
369
Yamanaka, Y.
81
Yanagi, M.
402, 403
Yang, H.
221, 271
Yang, H.C.
222
Yang, H.J.
308
Yang, H.Z.
222
Yang, J.I.
337, 338
Yang, P.D.
120
Yang, S.Y.
249
Yang, Y.
186
Yang, Y.K.
169
Yatham, L.
113, 121, 175, 208
Yen, Y.C.
419
Yeom, C.W.
363
Yi, J.
97, 482
Yilmazer, S.
391
Yim, S.J.
289, 311
Yong, D.S.
337, 338
Yoon, B.H.
334, 341
Yoon, D.H.
312
Yoon, H.
319, 342
Yoon, H.K.
307, 308, 310
Yoon, J.S.
122
Yoon, S.
356
Yoon, U.
432
Young, L.T.
60, 357
Youngstrom, E. 27, 33, 75, 103, 172, 195, 198, 470
Youngstrom, E.A.
196, 197
Youngstrom, J.K.
172
Yu, B.
356
Yu, B.H.
280, 288, 318
Yu, I.K.
288
Yu, J.
316
Yu, X.
120, 221
Yu, X.I.N.
271
Yuksel, M.Y.
344
Yum, S.Y.
196
Yurgelun-todd, D.A
85
Zandi, P.
215
Zandstra, T.E.
193
Zeni, C.P.
358, 425
Zhang, C.
267
Zhang, H.G.
120
Zhang, H.Y.
120
Zhang, J.
222
Zhang, K.R.
120
Zhang, Y.
221, 271
Zhang, Z.
404
Zhou, J.
365
Zokaee, M.
343
Zrazhevskaya, I.
471
RECOGNITION,
ACKNOWLEDGEMENTS
AND INDUSTRY SUPPORT
142
ACKNOWLEDGEMENTS
The Organizing Committee of the 16th Annual Conference of The International Society
for Bipolar Disorders would like to express its gratitude and acknowledge the
following companies and organizations for their generous support of the Conference.
PLATINUM SPONSORS
SILVER SPONSORS
143
INDUSTRY SYMPOSIA PROGRAM

Please note that lunch boxes will be provided to delegates attending
the industry lunchtime symposia.
TUESDAY, MARCH 18
15:30 17:30
Hall A
Industry Symposium Organised by:
SHEDDING NEW LIGHT, BUILDING INSIGHTS ON DEPRESSION

Chairperson: H. Cho (Korea)
15:30 MERGING EVIDENCE AND CLINICAL EXPERIENCE IN THE MANAGEMENT

OF BIPOLAR DEPRESSION

Y. Ahn (Korea)
16:15 AN EARLY IMPROVEMENT IN DEPRESSIVE SYMPTOMS PREDICTS

SYMPTOMATIC REMISSION OF SCHIZOPHRENIA

Y.H. Chou (Taiwan)
144
WEDNESDAY, MARCH 19
12:00 13:30
CHALLENGES IN THE MANAGEMENT OF BIPOLAR DISORDER:

FOCUS ON UNMET NEEDS
Chairperson: L. Yatham (Canada)
12:00 CHALLENGES IN THE MANAGEMENT OF BIPOLAR DISORDER

L. Yatham (Canada)
12:30 MANAGEMENT OF BIPOLAR DEPRESSION: CURRENT PRACTICE

A. Young (UK)
13:00 NOVEL TREATMENT OPTIONS FOR BIPOLAR DEPRESSION

M. Frye (USA)
Hall A
145
THURSDAY, MARCH 20
12:00 13:30
PREVENTING DEPRESSIVE EPISODES IN BIPOLAR DISORDER:

COMPLEXITIES AND IMPERATIVES
12:00 START OF SYMPOSIUM
12:15 CHAIRMANS INTRODUCTION
12:20 WHERE ARE WE NOW? DEPRESSION IN BIPOLAR DISORDER

INITIAL THERAPY AND TREATMENT STRATEGY

G. Malhi (Australia)
12:40

HOW DID WE GET HERE? METHODOLOGICAL COMPLEXITIES IN

STUDYING THERAPIES FOR THE TREATMENT OR PROVENTION OF
BIPOLAR DEPRESSION
A. Nierenberg (USA)
13:00 WHERE ARE WE GOING? PREVENTING DEPRESSIVE EPISODES IN

BIPOLAR DISORDER INTEGRATIVE MAINTENANCE THERAPY

M. Berk (Australia)
13:20 Q&A PANEL
Hall A
146
FRIDAY, MARCH 21
12:00 13:30
ENHANCING TREATMENT OUTCOMES WITH ANTIPSYCHOTICS IN

BIPOLAR DISORDER
Chairperson: Y.H. Joo (Korea)
12:10 ADDRESSING TREATMENT NEEDS OF PATIENTS WITH BIPOLAR
DISORDER

P. Udomratn (Thailand)
12:40 INTRODUCTION OF ASIAN EVIDENCE IN BIPOLAR DISORDER

Y.H. Chou (Taiwan)
Hall A
147
EXHIBITION MAP AND LIST OF EXHIBITORS

Company
Booth Number
7
4
Janssen Korea
3A
11
11
3
08
REGISTR A TION A RE A
PILL A R
07
3
06
3
05
4.5
04
03 A
3
ENTR A NCE
3
09
148
SPONSOR AND EXHIBITOR COMPANY PROFILES

AstraZeneca
18th floor, Luther building
7-20, Sincheon-dong
Songpa-gu, Seoul
Korea, 138-240
www.astrazeneca.co.kr
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.
Our mission is to make a meaningful difference to patient health through great
medicines that bring benefit for patients and add value for our stakeholders and
society. We discover, develop, manufacture and market prescription medicines for
six important areas of healthcare, which include some of the worlds most serious
illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and
respiratory and inflammation. We are active in over 100 countries and we invest over
$4 billion in R&D each year.
Bridges to Recovery
1460 San Remo Drive
Pacific Palisades, CA 90272
USA
www.Bridgestorecovery.com
Bridges to Recovery is a premier licensed residential behavioral health facility,
located in Los Angeles California, USA, designed for men and women suffering
from psychiatric disorders who are seeking an alternative to a hospital environment
for their care through a unique and effective combination of psychotherapy and
integrative therapy. We combine individual psychodynamic psychotherapy, DBT,
and SE along with milieu and group therapy in order to provide in-depth and
holistic integrated treatment. This allow out patients to be treated for complex
and persistent psychiatric disorders, by addressing their emotional, spiritual, and
physical needs. Our goal is to relieve suffering through compassionate, coordinate
care in order to empower and motivate our patients to succeed.
149
GSK
GlaxoSmithKline
980 Great West Road
Brentford, Middlesex
United Kingdom, TW8 9GS
www.gsk.com
We are a science-led global healthcare company that researches and develops a
broad range of innovative medicines and brands. Our products are used by millions
of people around the world, helping them to do more, feel better and live longer.
Handok
132 Gangnam-gu Teheran street
Seoul, 135-755
Korea
www.handok.co.kr
Handok has contributed to the advancement of the pharmaceutical industry in
Korea by working in alliance with global pharmaceutical companies including
Hoechst, Aventis, Sanofi and many others. Handok is growing into a leading
pharmaceutical company in Korea through continuous innovation based on its
ethical management policies. Handoks flagship products is Depakine.
150
Korea Otsuka Pharmaceutical Co., Ltd.

226 Yeoksam-ro
Gangnam-gu
Seoul
Korea
www.otsuka.co.kr
Korea Otsuka Pharmaceutical Co., Ltd. with the mission of a company contributing
to Koreas healthcare industry was established in 1982. We have large scale
production facilities which equip with consistent system from the composition
of materials to finished products. Our products have remained dedicated to
treat disease and improve health and well-being for people in Korea. Abilify
(aripiprazole), one of our novel products, creates a history of Korean antipsychotics
market through note only high quality of the product but also well-organized sales
force and strategic marketing activity. Our headquarter is located in 226
Yeoksam-ro, Gangnam-gu, Seoul, Korea and please visit our website,
www.otsuka.co.kr, for more information.
Pfizer Pharmaceuticals Korea Ltd
Pfizer Tower, 1-11, Hoehyun-Dong 3-Ga, Jung-Gu
Toegei- street
Seoul
Korea
www.pfizer.co.kr
Pfizer Pharmaceuticals Korea Ltd. (PPKL) is Korean subsidiary of Pfizer Inc. a
leader in the global pharmaceutical industry. Using its advanced R&D resources,
it has been providing innovative and value-added medicines used for treatment
of cardiovascular diseases, cancer, smoking, urogenital diseases, mental and
neurological disorders, and ocular disease in Korea. Pfizer Korea is committed to
providing top-quality differentiated products and services to meet our customers
needs, as well as making contributions to the public health and the local
pharmaceutical industry. Especially, it has been making meaningful contributions
to the industry, attracting global clinical trials, training clinical manpower
and sharing information. As a responsible corporate citizen, Pfizer Korea has
conducted various Corporate Social Responsible (CSR) programs to achieve its
vision of Working together for a healthier world.
151
Sunovion Pharmaceuticals, Inc.

84 Waterford Dr.
Marlborough,
MA 01752
USA
www.sunovion.com
Sunovion Pharmaceuticals Inc. (Sunovion) is a leading pharmaceutical company
dedicated to discovering, developing and commercializing therapeutic products
that advance the science of medicine in the Psychiatry, Neurology and Respiratory
disease areas and improve the lives of patients and their families. Sunovion is an
indirect wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP)
which is headquartered in Japan. More information about Sunovion is available at
www.sunovion.com.
Whain Pharmaceutical
Whanin Pharmaceuticals
Songpa-Gu Seoul-Si
117 Saemalro
Seoul 138-200
Korea
www.whanin.com
Whain Pharmaceutical is the most specialized pharmaceutical company in
psychiatry field in Korea. From antipsychotics and antidepressants to drugs for
alcohol dependence and ADHD treatment, we try to help people keep their mind
healthy and sound. For doing this better, we have built systematic research &
development capabilities and sales organization since Whanin pharmaceutical was
found in 1978. Right at this moment, we are trying to achieve our value We seek
value of life and reject pain of disease
You are cordially invited to attend an Official Satellite Symposium

of ISBD 2014 from Sunovion Pharmaceuticals Inc.
Challenges in the
Management of Bipolar Disorder
FOCUS ON UNMET NEEDS
A promotional presentation sponsored by Sunovion Pharmaceuticals Inc.
Wednesday, 19 March 2014

12:0013:30
COEX Convention Center
Grand Ballroom 103 (Hall A)
Ground Floor
Seoul, South Korea
PRESENTED BY
Mark Frye, MD
Lakshmi Yatham, MD, MBBS, FRCPC, MRCPsych
Program Chair
Allan Young, MD, PhD, FRCPsych
is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd.
2014 Sunovion Pharmaceuticals Inc. All rights reserved. 2/14
PROPERTY OF SUNOVION PHARMACEUTICALS INC.
PROPRIETARY AND NONTRANSFERABLE. NOT FOR FURTHER DISSEMINATION.
Abilify can relieve mood symptoms by stabilizing
Dopamine-Serotonin System
Schizophrenia
MDD
Bipolar
Disorder
t Schizophrenia
t Acute Treatment of Manic and Mixed Episodes
t Adjunctive Treatment of Major Depressive Disorder
t Irritability Associated with Autistic Disorder
t Tourette's Disorder
Otsuka Vision Bldg., 226, Yeoksam-ro, Gangnam-gu, Seoul 135-928, Korea
100-771 110 TEL 02-317-2114 080-022-1400 website www.pfizer.co.kr | TEL 080-210-2114 E-mail mis.korea@pfizer.com ( )
SAVE THE DATE

Book

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Book

Uploaded by

Copyright:

Available Formats

FINAL PROGRAM

Kyooseob Ha, MD, PhD

Willem Nolen, MD, PhD

VP for Education, ISBD

REGIONAL ORGANIZING COMMITTEE

INTERNATIONAL SOCIETY FOR BIPOLAR DISORDERS

LIABILITY AND INSURANCE

1-3 Rue de Chantepoulet, PO Box 1726

The 6th Conference of

The 6th Conference of the Asian Network of Bipolar Disorder

Day 1 - Tuesday 18th March

State of the Art

The Bipolar Prodrome: Can we

Diet, Exercise, and

Day 2 - Wednesday 19th March

Clinical and Therapeutic

The Potential Clinical and

Treatment Track I Clinical Manifestation

New Medical Treatments Targeting

Day 3 - Thursday 20th March

How to Manage Bipolar

Staging and Profiling

Structural, Functional and

Bipolar Disorder and

Identifying Mood Disorder

Samuel Gershon Award

Cultural Issues and Bipolar

Treatment Track I Clinical Manifestation

The Future Care of Bipolar

Day 4 - Friday 21st March

Rapid Communications III

Genetic Studies on Bipolar Disorders

Treatment Track I Clinical Manifestation

The Role of Biomarkers in Clinical Practice: Lessons from Bipolar Disorder

Neurobiological Basis of Bipolar Disorder

Novel Therapies: Translation, Validation and Implementation

SAMUEL GERSHON JUNIOR

Championing best practice in CME

Address individual needs in compliance with their Continuous Professional

ACCREDITATION STATEMENT AND CREDIT DESIGNATION

TO RECEIVE YOUR CME/CPD CERTIFICATE OF ATENDANCE

DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

INDUSTRY SUPPORT DISCLOSURE

INFORMATION AT YOUR FINGERTIPS!

CARING FOR THE ENVIRONMENT

INFORMATION FOR PRESENTERS

IMPORTANT NOTE FOR MACINTOSH USERS:

Tuesday March 18, 2014

Wednesday March 19, 2014

Poster Session II:

Thursday March 20, 2014

REGIONAL POSTER SESSION

Presentations from Asian scholars, and

Clinical Case Studies

Child and Adolescent

Child and Adolescent

VENUE FLOOR PLANS

SAVE THE DATE

SCIENTIFIC PROGRAM TUESDAY, MARCH 18, 2014

THE 6TH CONFERENCE OF THE ASIAN NETWORK OF BIPOLAR DISORDER:

THE 6TH CONFERENCE OF THE ASIAN NETWORK OF BIPOLAR DISORDER:

PATTERN OF PHARMACOTHERAPY BY EPISODE TYPE FOR

J.H. Baek (USA)

GUIDELINE CONCORDANCE OF PHARMACOLOGICAL